Role of parvovirus MVMp in generation of antitumor immune responses by Grekova, Svitlana
  
 
 
  
 
 
 
 
 
 
                                        Dissertation 
 
 
submitted to the 
Combined Faculties for the Natural Sciences and for 
Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
 
 
 
 
 
presented by 
Master of Science in Microbiology Svitlana Grekova 
born in Kiev, Ukraine 
 
 
 
     Oral examination:  
 
 
 3
 
      
 
 
 
 
 
 
 
 
 
Role of Parvovirus MVMp in generation of antitumor 
immune responses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees: Prof. Dr. Rainer Zawatzky  
      Prof. Dr. Stefan Wölfl 
Table of contents  
Table of Contents 
 
Summary…………………………………………………………………………8 
Zusammenfassung……………………………………………………………...10 
 
1. Introduction………………………………………………………………..12 
1.1. The Clinical Role of Glioma and Melanoma Tumors…………………..12 
1.1.1. Gliomas……...................................................................................12 
1.1.2. Melanoma………………………………………………………...13 
1.2. Glioma- and Melanoma-directed Therapy……………………………...15 
1.2.1. Standart Therapy………………………………………………….15 
1.2.2. Alternative Therapy………………………………………………16 
1.3. Autonomous Parvovirus Therapy as an Alternative Strategy…………..19 
1.4. Anti-tumor Immune Response………………………………………….25 
1.4.1. Innate Immune Response…………………………………………25 
1.4.2. Adaptive Immune Response……………………………………...32 
1.5. Aim of Work……………………………………………………………36 
2. Materials……………..…………………………………………………….38 
2.1. Materials for Tissue Culture…………………………………………….38 
2.2. Materials for Molecular Biology Methods……………………………...41 
2.3. Materials for FACS……………………………………………………..42 
2.4. Materials for ELISA/ELISPOT…………………………………………43 
2.5. Additional Reagents and Equipment……………………………………43 
2.6. Cell Lines……………………………………………………………….43 
2.7. Experimental Animals…………………………………………………..45 
3. Methods…………………………………………………………………….46 
3.1. Cell Culture Methods…………………………………………………..46 
3.1.1. Maintenance of Cell Lines………………………………………..46 
3.1.2. Freezing and Thaing Mammalian Cells…………………………..46
Table of contents  
 
3.1.3. Cells Viability Methods…………………………………………..47 
3.1.4. Generation of Microglia…………………………………………..48
3.1.5. Generation of Dendritic Cells from Bone Marrow……………….49 
3.1.6. Isolation of Dendritic Cells from Spleen and Lymph Nodes……..50 
3.1.7. Isolation of Splenocytes…………………………………………..51 
3.1.8. Co-culture of Dendritic Cells and Tumor Cells…………………..51 
3.1.9. Co-culture of Microglia and Glioma GL261 cells………………..52 
3.1.10. Transient Transfection for Luciferase Assay………………53 
3.2. Animal Techniques…………………………………………………….54 
3.2.1. Injection of In Vitro Infected Tumor Cells……………………….54 
3.2.2. Isolation of In Vitro Infected Tumor cells from bearing mice……55 
3.3. Molecular Biological Methods…………………………………………55 
3.3.1. Luciferase Assay………………………………………………….55 
3.3.2. Westernblot Analysis……………………………………………..55 
3.3.3. Total RNA Extraction from Cells………………………………...57 
3.3.4. Reverse Transcription of RNA……………………………………57 
3.3.5. PCR……………………………………………………………….58 
3.3.6. Southern Blot……………………………………………………..58 
3.4. Immunochemical Methods…………………………………………….59 
3.4.1. Cytokine ELISA………………………………………………….59 
3.4.2. FACS analysis……………………………………………………59 
3.4.2.1. Phenotypic Characteristic of Dendritic Cells……………...59 
3.4.2.2. Intracellular Detection of NS1…………………………….60 
3.4.2.3. TUNEL assay……………………………………………...60 
3.4.3. ELISPOT assay…………………………………………………..61 
3.4.4. Detection of caspase-3 activity…………………………………..61 
3.5. Virus production………………………………………………………62 
3.6. Statistical Analysis…………………………………………………….62
Table of contents 
 
List of Abbreviation……………………………………………………………63 
 
4. Results……………………………………………………………………...65 
4.1. Oncolytic effct of PV MVMp in tumor cell lines……………………...65 
4.1.1. Melanoma B78/H1 and glioma GL261 cell lines are both permissive 
for MVMp infection………………………………………………..65 
4.1.2. MVMp exerts a cytotoxic effect in tumor cells and inhibits cell 
proliferation…………………………………………………………68 
4.1.3. Induction of the apoptotic pathway following MVMp infection…71 
4.2. Activation of dendritic cells and microglia induced by MVMp……….75 
4.2.1. Generation of dendritic cells……………………………………...75 
4.2.2. MVMp-mediated GL261 tumor lysates activate DCs……………78 
4.2.3. Microglia activation induced by MVMp-mediated glioma GL261 
lysates……………………………………………………………….85 
4.2.4. GL261 tumor cell lysates induce NF-kB signalling via TLR3 in vitro 
in DCs…………………………………………………………….....88 
4.3. Stimulation of anti-tumor specific immune response in vivo mediated by 
MVMp…………………………………………………………………..92 
4.3.1. MVMp affects tumor growth in immunocompetent mice………..93 
4.3.2. Hematopoietic cell distribution does not change within the spleen 
upon tumor induction of MVMp-infected glioma GL261 cells…….97 
4.3.3. The T-cell memory response plays crusial role against tumor 
development………………………………………………………..100 
5. Discussion…………………………………………………………………..102 
5.1. MVMp lyse glioma GL261 cells with hight efficiency………………...102 
5.2. MVMp induced activation of DCs and microglia……………………..102 
5.3. MVMp-mediated tumor cell lysates stimulate specific antitumor immune 
response………………………………………………………………...111
 
Table of contents 
 
 7
 
List of References………………………………………………………………115 
Appendix………………………………………………………………………..131 
Acknowledgments……………………………………………………………...133
 
Summary 
 
 8
 
Summary 
Rhodent autonomous parvoviruses display a pronounced tropism for tumors and their 
infection may ultimately result in lysis of established tumors. This work evaluated the efficacy of 
Minute Virus of Mice prototype (MVMp) as a stimulus of specific antitumor immune response 
against mouse melanoma and glioblastoma tumors.  
MVMp was shown to effectively infect both melanoma B78/H1 and glioma GL261cell lines 
and induce cell death. MVMp was more effective inducing cell death in glioma GL261 cultures 
where 10% live cells were detected 96h after virus infection at multiplicity of infection (MOI) 10. In 
comparison only 40% cell death was observed in the melanoma B78/H1 cells after virus infection at 
high MOI 100. MVMp infected glioma GL261 cells displayed characteristics of apoptosis, such as 
caspase-3 activation and DNA fragmentation, which were not detected in melanoma.  
Activation of antigen presenting cells (APC) provides the initial cue for an innate and 
adaptive immune response. Therefore, we generated tumor cell lysates after MVMp-infection and 
investigated their capacity to induce activation of dendritic cells (DCs) and microglia, specific 
subtypes of APC. Whereas MVMp infected B78/H1 melanoma cells were unable to activate DCs, 
virus infected glioma cells efficiently induced DC activation. Two different DC subpopulations 
(myeloid and lymphoid) were activated after co-culture with MVMp-infected glioma GL261 cells, 
and activation was monitored by upregulation of specific activation markers such as CD80, CD86, 
and MHC class II. In addition, the release of proinflammatory cytokines such as TNF-α and IL-6 
was measured. Similarly, microglia were activated, when co-cultured with MVMp-infected glioma 
GL261 cells, measured by upregulation of activation markers and cytokine production. Taken 
together these results demonstrate that glioma GL261 cell lysates generated after MVMp infection 
can substantially activate DCs as well as microglia. 
Toll-like receptors (TLRs) expressed in DCs and microglia mediate crucial signaling 
pathways initiating effective innate and adaptive immune responses. To assess the contribution of 
TLR signaling in the context of PV-based virotherapy, stable cell lines expressing single murine 
TLRs were established. These cells lines were used as a model to correlate specific TLR activation 
with the exposure to virus induced tumor cell lysates. A direct downstream target of the TLR 
signaling cascade is the transcription factor NF-κB and thus a reporter approach was utilized to 
measure NF-κB activation. Upon culture of single TLR expressing stable cell lines with MVMp-
mediated tumor cell lysates, the cell line stably expressing TLR3 had an eight fold higher activation 
of NF-κB reporter gene expression compared to control. This finding called for a role of TLR3 
mediated signaling in the activation NF-κB and downstream target genes such as pro- and 
inflammatory cytokines.  
The in vitro findings were extended to in vivo studies and antitumoral effects mediated by 
MVMp were assessed in immunedeficient RAG2-/- and immunocompetent C57BL/6 mice. 
Summary 
 
 9
Immunocompetent mice completely (100%) rejected MVMp-infected glioma GL261 at MOI 3 and 
MOI 30 with greater efficiency than control tumor cells (17%). Eradication of tumor cells mediated 
by the oncolytic effect of MVMp at MOI 30 amounted to only 20% in immunodeficient RAG2-/- 
animals. In addition, the release of IFN-γ from splenocytes of mice, which were injected with 
MVM-infected glioma cells, in response to uninfected glioma cells was assessed ex vivo and was 
significantly higher (2.3 times more IFN-γ producing cells) compared to control splenocytes. These 
findings provide evidence of a specific immune response towards glioma GL261 cells and highlight 
the importance of a T cell mediated immune response to obtain a strong antitumor effect. 
Furthermore, it was shown in re-challenge experiments that mice were protected from tumor 
growth. This highlights the induction of a tumor specific memory response. 
In conclusion, MVMp induced GL261 tumor cell lysates stimulate activation of APC, 
initiate cytokine production via NF-κB signaling and in vivo initiate primary and secondary tumor 
specific immune responses. These findings could place PV as promising candidates to break tumor 
tolerance and treat glioma. 
Zusammenfassung 
 
Zusammenfassung 
Autonome Parvoviren zeichnen sich aus durch einen ausgeprägten in vivo Tumortropismus, 
der zur Lyse bereits etablierter Tumore führen kann. Ziel der vorliegenden Arbeit war, am Beispiel 
des autonomen Parvovirus „Minute Virus of Mice prototyp“ (MVMp) zu untersuchen, ob 
spezifische Immunreaktionen an dessen antitumoraler Wirkung beteiligt sind. 
Es zeigte sich, dass MVMp in vitro sowohl Maus-Melanomzellen der Linie B78/H1 wie auch 
Gliomzellen der Linie GL261 infizieren und in diesen Kulturen Zelltod induzieren kann, wobei die 
Effizienz in GL261 deutlich höher war. In GL261 wurden im Gegensatz zu B78/H1 nach MVMp 
Infektion zudem Apoptose-typische Veränderungen beobachtet.  
Die Aktivierung Antigenpräsentierender Zellen (APC) ist das erste Signal für die Einleitung 
einer angeborenen oder adaptiven Immunantwort. Aus diesem Grund wurde überprüft, ob 
myeloische Dendritische Zellen (DC), lymphoide DC oder Mikroglia als wichtigste Vertreter 
peripherer bzw. zentraler APC sich durch Tumorzelllysate aktivieren lassen, die nach MVMp 
Infektion generiert wurden. Es zeigte sich, dass Lysate aus MVMp infizierten GL261 Gliomzellen 
im Gegensatz zu infizierten B78/H1 Melanomzellen sehr effizient DC aktivierten gemessen an der 
Zunahme der spezifischen Aktivierungsmarker CD80, CD86 und MHC II. Darüberhinaus wurde 
eine erhöhte Menge der proinflammatorischen Zytokine TNF-α und IL-6 freigesetzt. Auch 
Mikroglia zeigten nach Inkubation mit Lysaten MVMp-infizierter Gliomzellen verstärkte 
Expression der Aktivierungsmarker CD80 und CD86 sowie TNF-α und IL-6 Sekretion. 
Zusammengefasst zeigen die Ergebnisse, dass sowohl DC als auch Microglia durch Lysate aus 
MVMp infizierten Gliomazellen aktiviert werden können. 
“Toll-like” Rezeptoren (TLR) sind wichtige Erkennungsstrukturen für pathogene 
Mikroorganismen, die von DC oder Mikroglia exprimiert werden und wichtige Signale 
übermitteln, die angeborene oder adaptive Immunantworten auslösen. Im Rahmen dieser Arbeit 
wurde untersucht, ob Lysate MVMp-infizierter GL261 Zellen auch TLR aktivieren können. Dazu 
wurden Zelllinien erzeugt, die einzelne Maus TLR stabil exprimieren. Die Aktivierung des 
Transkriptionsfaktors NF-κB, die in vivo eine unmittelbare Reaktion auf eine TLR-Aktivierung 
darstellt wurde in diesem Model indirekt über eine Reportergenaktivität gemessen. Nachdem die 
verschiedenen stabilen TLR-exprimierenden Zelllinien mit MVMp-induzierten Tumorzelllysaten 
inkubiert wurden, ergab sich nur in der Zelllinie, die TLR 3 exprimierte eine - verglichen mit der 
der Kontrolle - achtfach erhöhte Reportergenaktivität. 
Die in vitro gewonnenen Befunde wurden in in vivo Mausmodellen weiter untersucht. Dabei 
wurden die Tumor-inhibierenden Eigenschaften von MVMp in immundefizienten RAG2-/- und in 
immunkompetenten C57BL/6 Mäusen verglichen. Immunkompetente Mäuse bildeten keine 
Tumoren, nach Injektion von GL261 Gliomzellen, die mit MVMp bei einer MOI von 3 oder 30 
infiziert worden waren während 83% der Mäuse nach Gabe nicht infizierter Tumorzellen Tumore 
bildeten. In 80% der RAG2-/- Mäuse traten Tumore trotz vorheriger MVMp Infektion mit MOI 30 
Zusammenfassung 
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auf. Darüber hinaus zeigten Milzzellen aus Tieren von MVMp-infizierten Gliomzellen eine 2,3-fach 
höheren Anteil an IFN-γ produzierenden Leukozyten gegenüber solchen aus Tieren mit nicht-
infizierten Tumorzellen. Die erneute Injektion nicht-infizierter Gliomzellen führte zu keinem 
Tumorwachstum in immunen C57BL/6 Mäusen. Zusammen deuten diese Ergebnisse auf einen 
MVMp-induzierten spezifischen antitumoralen Effekt unter Beteiligung von T-Zellen hin. 
 
 
 
Introduction 
 
1. Introduction.  
 
1.1. The Clinical Role of Glioma and Melanoma Tumors.  
 
1.1.1. Gliomas.  
 
Gliomas are primary central nervous system (CNS) tumors that arise from 
astrocytes, oligodendrocytes or their precursors (reviewed by Buckner J.C. et. 
al., 2007). As the normal development of the CNS ceases, neurons become post-
mitotic with the exception of stem cells in a small compartment. However, glial 
cells (astrocytes, microglia, oligodendrocytes) keep their ability to proliferate 
throughout life. Thus, it might be not too surprising that most neurological 
tumours in adults are of glial origin. 
Malignant gliomas are characterised by biological features that make them 
intractable diseases. These include uncontrolled tumor cell proliferation, 
invasion into normal brain parenchyma, induction of tumor angiogenesis, 
inhibition of apoptosis and suppression of the immune system (Okada H. et al. 
2001; Louis D.N., 2006). Invasion of the tumor might be accomplished by 
various proteases, such as serine, cysteine and metalloproteinases (Mohanam S. 
et. al. 1999; Forsyth P.A. et. al. 1999; Sawaya R.E. et. al. 1996). These proteases 
might enable tumour cells to digest the extracellular matrix (ECM), to penetrate 
connective-tissue barriers, to induce vascular remodeling and to destroy normal 
brain tissue. 
The World Health Organization (WHO) established a grading system 
(Grade I through IV) to classify gliomas, based on the degree of their 
malignancy: grade I gliomas being the least aggressive tumour mostly with a 
benign phenotype and grade IV are the most malignant ones. These criteria were 
determined by histopathological analysis. Grade IV gliomas are usually 
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infiltrating astrocytic neoplasms, and are known as the glioblastoma multiforme 
(GBM) one of the most aggressive human cancers.  
Gliomas are refractory to most standard therapies, including surgical 
resection, radiation therapy and chemotherapy (Fischer U., Meese E., 2007). 
From the time of diagnosis with glioblastoma, the mean survival time ranges 
from 17 weeks without treatment to 30 weeks with surgery and radiation. The 
median survival time of less than one year has not changed a lot over the past 
two decades (Maher E.A. et. al., 2001; Holland E.C., 2001). Despite established 
treatments these tumors will recur and cause neurological deterioration and 
death (Dai C. et. al., 2001). Glioma patients are often immunosuppressed. 
Molecules like transforming growth factor-β (TGF-β), IL-10 and prostaglandin 
E2 are reported to be involved in down-regulation of the cellular immune 
response in glioma patients. It can be manifested by induction of growth arrest 
and apoptosis in immune cells, suppression of MHC class II expression and by 
inhibition of the development cytotoxic T lymphocytes (Castro M.G. et. al. 
2003). 
Traditional therapeutic modalities have been shown to be very ineffective 
in curing tumors of the CNS, due to the radioresistance of glioma cells and the 
difficulty of achieving complete tumor resection as gliomas usually have 
diffuse, infiltrative growth patterns (Aoki T. et. al., 2007).  The tremendous 
complexity of the brain as a highly seclusive organ makes it even more difficult 
to treat these tumors with chemotherapy. Thus, alternative therapies have 
become more and more attractive in the treatment of gliomas. 
  
1.1.2. Melanoma. 
 
There are several types of skin cancer, which include melanoma, basal 
cell carcinoma (BCC) and squamous cell carcinoma (SCC). BCC develops from 
basal cells, and SCC develops from keratinocytes. BCC and SCC usually occur 
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in older people. Most cases of non-melanoma skin cancer are easily treated and 
cured. 
Melanoma is a malignant tumor of melanocytes which are found 
predominantly in the skin but also in the intestine and the eye. Around 160,000 
new cases of melanoma are diagnosed worldwide each year, and it is more 
frequent in males and caucasians. According to the WHO Report about 48,000 
melanoma related deaths occur worldwide per annum (Lucas, R. 2006). 
Mortality rates for cutaneous malignant melanoma depend on stage at diagnosis; 
thus, efforts are aimed at early detection and identification of risk factors for 
melanoma to distinguish those individuals requiring close surveillance 
(Gerstenblith MR, et. al. 2007).  
There are five stages of melanoma (Balch C. et. al., 2001): 
- Stage 0: Melanoma in Situ, 100% Survival,  
- Stage I/II: Invasive Melanoma, 85-95% Survival,  
- Stage II: High Risk Melanoma, 40-85% Survival,  
- Stage III: Regional Metastasis, 25-60% Survival 
- Stage IV: Distant Metastasis, 9-15% Survival. 
Features that affect prognosis are tumor thickness in millimeters, type of 
melanoma, presence of lymphatic/perineural invasion, presence of tumor 
infiltrating lymphocytes (if present, prognosis is better), location of lesion, 
presence of satellite lesions, and presence of regional or distant metastasis 
(Homsi J., et.al., 2005). When melanomas have spread to the lymph nodes, one 
of the most important factors is the number of nodes with malignancy. Extent of 
malignancy within a node is also important; micrometastases in which 
malignancy is only microscopic have a more favorable prognosis than 
macrometastases. Once distant metastasis have occurred, the cancer is generally 
considered incurable. The five year survival rate is less than 10% (Balch C. et. 
al., 2001). The median survival is 6 to 12 months. Metastases to skin and lungs 
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have a better prognosis. Metastases to the brain, bone and liver are associated 
with a worse prognosis. 
Despite many years of intensive laboratory and clinical research, surgery 
is the first choice therapy for localized cutaneous melanoma. Treatment of 
advanced malignant melanoma is performed from a multidisciplinary approach 
(adjuvant treatment; chemo- and immunotherapy, or radiation therapy).  
 
1.2. Glioma- and Melanoma- directed Therapy.  
 
1.2.1. Standart Therapy. 
 
Currently, the standard of care for the treatment of patients with high-
grade malignant glioma and melanoma is resection followed by focal 
radiotherapy. For patients in whom surgical resection is possible, total resection 
should be the goal; the extent of tumor resection may be a decisive prognostic 
factor. However, complete resection is not possible in the majority of patients 
due to the lack of a defined tumor edge or localization in the critical areas of the 
brain (for gliomas). The biopsies of inoperable tumors provide information for 
possible implementation of other therapies (Castro M.G. et. al., 2003).  
Adjuvant therapy (radio- and chemotherapy) increases survival in patients 
with high-grade malignant glioma and melanoma. It has become the standard 
adjuvant treatment for these patients (Brandes A.A., 2003; Aoki T. et. al., 2007). 
Patients treated with radiotherapy plus adjuvant chemotherapy had a survival 
advantage. Nevertheless, chemotherapy of brain tumors is not curative and the 
goals of the treatment are mainly to control the growth of the tumor and to 
maintain good performance and quality of life for the patient for as long as 
possible (Castro M.G. et al., 2003). 
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1.2.2. Alternative Therapy. 
 
Other strategies have been pursued to efficiently treat tumors. New 
alternative approaches are used as adjuvant strategies complementing current 
strategies (surgery, radiation, chemotherapy). Although considerable preclinical 
data have been accumulated, promising results for therapy of human glioma 
have only recently appeared (Cavaliere R. et. al., 2007). The resistance of brain 
tumors and melanomas to the attempts at conventional therapy have made them 
particularly attractive for gene therapy trials (King G.D. et. al.,  2005 ; de Groot 
J.F., Gilbert M.R., 2007; Lassman A.B., Holland E.C., 2007). “Gene therapy” 
can be defined as the transfer of genetic material into a patient’s cells for 
therapeutic purposes. Such a definition includes a variety of therapeutic 
approaches. Using the broad definition, gene therapy approaches fall into several 
categories: 
 - gene transfer-based immunotherapy,  
 - enzyme/prodrug therapy,  
 - transfer of the therapeutic transgenes into cells,  
 - antisense strategies, 
 - viral vectors.  
Over the last 10 years, more than 300 protocols for cancer and genetic 
diseases have been initiated worldwide (Bansal K. et. al., 2000). Genetic 
material can be introduced through direct delivery into the target organ (in vivo 
technique). The therapeutic agent is applied at the time of tumor resection or by 
means of stereotactic injections. Another method of genetic material delivery is 
ex vivo technique, where the cells are initially outside of the host and then 
implanted into affected area. 
Attempts at gene therapy for boosting the activity of the immune system 
against cancer cells have often focused on activating cell-mediated immunity. 
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These attempts have been actually utilized mouse, rat, human in vitro models, 
and clinical tials. They include:  
- induction of increased immunogenicity of tumor cells by enhancement 
of the immune response using cytokines, for example by inducing the 
production of IL-2, IL-4, IL-13 or GM-CSF within the tumor (Okada H. et al., 
1999; Glick R.P. et. al., 2000; Shimamura T., 2006),  
- reversal of tumor derived immunosuppression by enhancement of T cell 
activation (by upregulation MHC I on the tumor cell surface, upregulation of 
tumor antigenes, upregulation of B7 costimulatory antigens) (Parney I.F. et al., 
1997; Okada H. et. al., 2004; Mitchell D.A, et. al. 2003; Abad J.D., Wrzensinski 
C., et. al., 2008),  
- ex vivo manipulation of effector cells, for example, manipulation of 
dendritic cells as tool for cancer immunotherapy by stimulating them with 
specific antigens or promoting their maturation (Aoki H. et al., 2001; Hiasa A., 
Hirayama M., et. al., 2008),  
- antibodies-coupled compounds delivery, for example anti-CD44 directed 
antibodies conjugated with isotopes or immunotoxines (Breyer R. et al., 2000), 
- local application of activated tumor-infiltrating lymphocytes or NK cells 
(Ishikawa E. et al., 2004).  
Viral vectors can be used as effective carriers for transferring foreign 
genes into the cells in the approaches boosting the activity of the immune 
system, in the enzyme/prodrug therapy and in the transfer of therapeutic 
transgenes. Very often they are also used as direct oncolytic factors.  
Gene therapy using viral vectors for the treatment of tumors has proven to 
be a promising novel treatment modality (Aghi M., Chiocca E.A., 2006), for 
example such as a murine melanoma model B16F10 using Sendai virus vectors 
with IFN-beta pulsed DC (Yonemitsu Y. et. al., 2008). The quantity of 
replication-competent viruses could potentially increase after inoculation; this 
benefit is not offered by any existing cancer treatments. Any viral-based gene 
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therapy vectors to be useful in patients must be safe, potent against tumors and 
complement or ever synergize with existing standard therapies (Shah A.C.et al. 
2003).  
The most studied viruses proposed for the use in the tumor gene therapy 
include Herpes simplex virus-1 (HSV-1) (Markert J.M. et. al., 2006), Newcastle 
disease virus (NDV), Reovirus (Errington F., White C.L., et. al., 2008), 
Poliovirus-derived viruses, and Vaccinia virus. 
A considerable number of clinical trials have been initiated based on these 
approaches. Although most therapeutic strategies proved safe, clinical responses 
fell short of expectations raised by preclinical results. This, to a large extent, has 
to be attributed to a lag in the development of efficient vector systems. Although 
much effort has been put into this area of research, oncologists are still in await 
of a vector system allowing for selective and efficient tumor cell transduction. 
This has led to increased interest in distinct but related strategies, e.g. oncolytic 
viruses or direct intra-tumoral delivery of anti-sense oligonucleotides. 
Especially the approach using onocolytic viruses has gained much 
attention (HSV for glioma model - Todo T., 2008; adenovirus for glioma model 
- Sonabend A.M. et. al., 2006). On one hand, viruses can serve as vectors 
delivering genes exerting anti-tumoral effects. On the other hand, these viruses 
themselves have oncolytic or even oncosuppressive properties. 
 A well defined oncolytic as well as oncosuppressive virus is the family of 
autonomous parvoviruses (PV). Some of these autonomous PV, for example the 
murine minute virus of mice prototype (MVMp) and rat H1 PV, have been 
shown to infect and lyse tumor cells with great efficiency (Wollmann G., 2005; 
Moehler M., 2001).  
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1.3. Autonomous Parvovirus Therapy as an Alternative Strategy.  
The autonomous PV is a small (18 to 26 nm), non-enveloped, nuclear-
replicating DNA virus, which belongs to the Parvoviridae family. It infects a 
broad variety of species from insects to humans. Members of the Parvoviridae 
family, which are able to infect vertebrates, can be placed into one of three 
genera: the genus Dependoviruses comprises the adeno-associated parvoviruses 
(AAV) which cannot replicate efficiently without the help of some tumor 
viruses, while the erythrovirus as well as the parvovirus are self-sufficient in 
regard to their replication capacities (Cornelis J.J. 2004).  
The first parvoviral isolates were derived from tumors and tumor cell lines 
(Kilham L. et. al., 1959). These facts initially brought PV into the class of 
oncogenic viruses, but this was not confirmed since PV infections did not 
correlate with higher tumor incidence. On the contrary, later investigations 
revealed that PVs could prevent the formation of tumors in animal models 
(Dupressoir T. et al. 1989; Rommelaere J. et al. 1991).  
Only one member of the PV family - B19 is known to be pathogenic to 
humans. Acute infection causes fifth disease in children, polyarthropathy 
syndromes in adults or chronic anemia due to persistent infection in 
immunocompromised patients (Cassinotti P. et al. 1994). Autonomous PVs 
cause infectious pathology in some animal species but none of them has been 
associated with human diseases (Rommelaere J. et al. 2001).  
PVs do not possess an envelope and consist of an icosahedral capsid in 
which a single-stranded DNA genome of around 5000 nuclotides is packaged. 
The three-dimensional structures of several PVs have been determined using X-
ray crystallography (Fig. 1).  
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The 5’- and 3’-end of the parvoviral genome consists of palindromic 
sequences which can form hairpin structures. These hairpin structures serve as 
self-priming origins of DNA replication. The genome of PV usually includes 
two large open reading frames (ORFs) and two promoters. The ORFs code for 
the two non-structural (NS) polypeptides and viral capsid proteins (VPs) 
(Cornelis J.J. 2004)). 
NS1 is an 83 kDa multifunctional nuclear protein. It is relatively stable 
with a half-life of approximately 6 hours (Miller C.L. et al., 1995). Minute virus 
of mice (MVM) NS1 protein is a multifunctional phosphoprotein endowed with 
a variety of enzymatic and regulatory activities necessary for progeny virus 
particle production. NS1 is the only viral DNA protein being essential for DNA 
replication in all cell types tested.  
A productive PV infection may be associated with cell death, for which 
NS1 is considered to play a major role (Vanacker J.M. et al. 1995). H1 has been 
reported to induce apoptotic cell death in rat glioblastoma cells (Ohshima T. et. 
al., 1998) and human leukemic U-937 cells. In the last system induction of 
apoptosis can be assigned to the cytotoxic NS proteins (Rayet B. et al. 1998).  
To regulate all of its different functions in the course of a viral infection, 
NS1 has been proposed to be modulated by posttranslational modifications, in 
particular, phosphorylation. NS1 is a target for protein kinase C (PKC) lambda 
phosphorylation in vivo and that this modification is essential for the helicase 
activity (Nuesch J.P. et al. 2003).  
Fig. 1. The Capsid of MVM. Depth-cued 
representation of a whole MVM particle. The 
particle surface shading is based on distance 
from the viral center: the lighter regions 
represent residues that are at the greatest radial 
distance and the darkest regions represent 
residues at the shortest radial distance. The 
icosahedral fivefold, threefold and twofold 
axes for one viral asymmetric unit are 
indicated. Agbandje-McKenna (1998), 
Structure 6(11): 1369-81.  
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NS2 is a small protein with a molecular weight of 23-25kDa. In contrast 
to NS1, NS2 has a predominantly cytoplasmic localisation. In vitro and in vivo 
experiments point to the fact that NS2 of MVMp is essential for a productive 
viral infection in mouse (the natural host) cells (Naeger L.K. et al. 1993). It was 
also shown that the NS2 proteins of MVMp are required for efficient nuclear 
egress of progeny virions in mouse cells (Eichwald V. et al. 2002).  
The capsids consist of three structural proteins VP1 (83-86 kDa), VP2 
(64-66 kDa) and VP3 (60-62kDa) with VP2 being the most prominent (80%). 
VP3, a cleavage product of VP2, is present in small, varying amounts in DNA-
containing virions (Agbandje-McKenna M. et al. 1998). The VP1/VP2 ratio is 
about 1:5, and this is the proportion in which they appear in the capsid. The role 
of the VP proteins is first to assemble into empty capsids (Willwand K. et al. 
1991). VP2 is necessary for the accumulation and encapsidation of virus 
progeny single-stranded DNA. VP1 is dispensable for these functions but is 
required to produce an infectious virion. Virus that lacks VP1 binds to cells as 
efficiently as wild-type MVM but fails to initiate a productive infection (Tullis 
G.E. et al. 1993).  
The two promoters upstream of each of the two large ORFs at map units 4 
and 38 are named P4 and P38, respectively. Two P4 transcripts, R1 (4.8kb) and 
R2 (3.3kb), are generated upon splicing and encode the two nonstructural 
proteins NS1 and NS2 (L, Y, R isoforms). The P38 transcript R3 (3.0kb) 
produces the VP-1 and VP-2 proteins after differential splicing (Morgan W.R. et 
al. 1986).  
 
The Life Cycle of Parvoviruses. The life cycle of MVM starts with the 
binding of the virus to N-acetylneuraminic acid containing glycoproteins, which 
are located on the cell surface. The PV enters the cell via endocytosis. It was 
shown for the canine PV that the virus enters the cells by dynamin-promoted, 
clathrin-coated vesicles (Suikkanen S. et. al., 2002). The viral particles are 
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transported via late endosomes to the perinuclear vesicular compartments. It is 
very probable that the DNA of PV is released from the lysosomal compartment 
to the cytoplasm to be then transported to the nucleus. The microtubulus 
network might play an important role in the whole transport process of PV in the 
host cell as it is actively protected during MVM infection in contrast to other 
cytoskeleton elements such as actin filaments (Neusch J.P. et.al., 2005).  
The single-stranded genome of PV is converted into a duplex replication 
form in the nucleus. This conversion reaction is strictly S-phase dependent as 
early S-phase specific cyclin A and/or its kinases are required for this reaction 
(Cornelis J.J. 2004). Thus, PV cannot replicate in cells, which do not enter S-
phase. The duplex intermediate form is amplified via multimeric forms and is 
also used as a template for the synthesis of mRNA. The amplification is 
performed by a rolling circle-like mechanism, which is extraordinary for viruses. 
Progeny single-stranded negative DNA is packaged into empty capsids 
(Cotmore S.F. et. al. 2005).  
PV replication in permissive cells leads to the release of newly 
synthesized virions, which is usually associated with cell death. Cell death can 
either occur by apoptosis or by necrosis and might be dependent on the infected 
cell system (Moehler M. et. al. 2001; Ran Z. et. al. 1999). The NS1 protein, as it 
is accumulated in infected cells upon viral replication, seems to be the main 
cytopathic effector of autonomous PV although the mechanism, by which the 
cell killing is induced, is not fully understood. Studies have shown that NS1 
protein blocks cellular DNA replication, that it causes nicks in cell chromatin, 
arrests cells in S-phase and that it is related to changes in the synthesis and 
phosphorylation of cell proteins (Op de Beeck A. et. al., 1997; Anouja F. et. al., 
1997). 
Among the oncolytic viruses that have been proposed as vectors for the 
gene therapy of cancer are the autonomous PVs H1 and MVMp (prototype) 
(Blechacz, B., 2004). Vectors derived from MVMp are well expressed in 
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oncogene-transformed cells of different types but not in equivalent non-
transformed cells (Cornelis J.J. 2004). The mechanisms underlying oncospecific 
gene expression of MVMp are still not known. Clearly, PV replication and gene 
expression take advantage of perturbations of the cell cycle, in particular the S-
phase, a hallmark of tumor cells (Cornelis J. J. 2004).  
 
Oncosuppressive and oncolytic properties of PV. Although PVs infect 
a wide variety of species, their replication is restricted to tissues with high 
proliferation index. Therefore, rodent PV infection can have severe pathogenic 
effects in fetuses and neonates. For instance, in neonate hamsters, infection with 
the rat PV H1 led to high incidence of dwarfed and deformed animals with 
mongoloid traits (Toolan, H. W. 1960).  Interestingly, these animals were found 
to have a 20-fold lower incidence of spontaneous tumors than non-infected 
animals, indicating that PV infection led to an oncosuppressive phenotype of 
these animals (Toolan, H. W. 1967). Persistent or latent infections with PVs may 
significantly protect against spontaneous tumorigenesis. When PVs were used to 
infect tumor cells, which were subsequently implanted into rodents or dogs, 
inhibition of tumor development was observed in the recipient animals (Toolan 
H.W et al. 1967).  
Besides their oncosuppressive impacts, PV was reported in a number of 
research papers to have oncolytic properties. Many human and murine cell lines 
of in vitro transformed cells of fibroblastic and epithelial origin were shown to 
be much more sensitive to viral infection than the normal cells from which they 
derive. Transformation by physical and chemical carcinogenes, as well as viral 
oncogenes (such as large T antigen of SV40, middle T antigen of polyomavirus, 
v-src, Ha-ras), correlates with an increased cytopathic effect of PVs 
(Rommelaere J. et al. 1991). Conversely, the functional inactivation of the tumor 
suppressor gene product p53 was shown to correlate with a sensitisation of rat 
cells to H-1 virus infection (Telerman A. et al. 1993). It seems that the cell 
transformation coincided with the stimulation of an intracellular step(s) in the 
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parvoviral life cycle, in particular viral DNA amplification and/or viral gene 
expression.  
Similarly to the in vitro transformed cells, many human and rodent cell 
lines established from various tumors (fibrosarcoma, epidermoid and mammary 
carcinomas, gastric cancer, hepatoma and lymphoma) are more susceptible to 
killing by MVMp or H1 virus than the corresponding normal cells (Cornelis J.J. 
et al. 2001; Ohshima T. et al. 1998; Herrero Y.C.M. et. al. 2004). Humans are 
hosts for a number of PVs such as the autonomous B19 as well as AAV-2, 
AAV-3 and AAV-5. This gives hope of including some of these viruses or their 
components, in the arsenal of anticancer therapeutic agents. It should be stated 
however that tumors might arise in autonomous PV-infected organisms (as 
shown, for instance by the isolation of PVs from human tumor material 
implanted in animals). The antitumor response could be limited by the initial 
quantity of virus present at the site, by inefficient local production of new 
particles or by the host’s immune response.  
H1 was already tested in clinical trials in patients with advanced 
disseminated cancer as feasibility studies (Le Cesne A. et. al., 1993).  No 
pathological side effects were observed although it was not yet possible to 
investigate the spreading of injected H-1 virus into the central nervous system, 
nor was it possible to rule out possible long-term side effects.  
It seems that PV does not have any severe side effects in adult organisms 
and so far, there is no evidence that PV integrates into the host genome. As a 
consequence, PV MVMp and H1 might be an effective, non-dangerous 
therapeutic tool which could be of great use in future cancer treatments.  
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1.4. Anti-tumor immune response. 
 
1.4.1. Innate immune response. 
 
The immune system has been shown to play a crucial role in the 
recognition and elimination of tumor cells. As highlighted above, gene therapy 
focuses mainly on the activation of cell-mediated activity of the immune system. 
Oncolytic viruses are able to initiate the two major components of the immune 
system – innate as well as adaptive – efficiently.  
The innate immune system comprises the cells and mechanisms that 
defend the host from foreign antigen, in a non-specific manner. One of its main 
features is the pro-inflammatory response, which is induced by antigen-
presenting cells (APC), such as macrophages, dendritic cells (DC) and 
microglial (MG) cells, which are particularly located in the brain.  
The major functions of the innate immune system include: 
1) recruiting immune cells to sites of infection and inflammation, through 
the production of cytokines and chemokines.  
2) activation of the complement cascade to identify bacteria, activate cells 
and to promote clearance of dead cells (phagocytosis) or antibody complexes.  
3) activation of the adaptive immune system through a process known as 
antigen presentation.  
Increasing experimental evidence suggests that organisms distinguish 
invading microorganisms by recognizing pathogen-associated molecular 
patterns (PAMPs). They include molecules such as lipopolysaccharide (LPS) 
associated with the outer membrane of Gram-negative bacteria, mannose, 
fucose, and other sugar residues; techoid acid (associated with the peptidoglycan 
cell wall of Gram-positive bacteria), N-formyl peptides, unmethylated CpG 
motives in bacterial DNA, double-stranded RNA in RNA viruses and mannans 
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in yeast cell walls (Ulevitch R.J. et. al. 1995; Medzhitov, R. 1997). Specific 
protein families have been identified to recognize PAMPs: C-type lectin, the 
scavenger receptors, the pentraxins, which are components of the acute phase 
reaction that are synthesized in the liver and released into the plasma in response 
to pathogens (Emsley J. et al. 1994), lipid transferases, which can bind LPS 
(Schumann R.R. et al. 1990), integrins, complement control proteins and the 
most prominent of PAMP receptors, the so-called Toll-like receptors (TLRs), 
which play a central role in pattern recognition and induction of immune 
responses.   
Binding of PAMPs to their receptor on the host cells usually results 
mainly in the activation of transcription factors such as NF-κB and interferon 
regulatory factor 3 (IRF3), which provide the inflammatory context for the rapid 
activation of host defenses. The cells which appear first in the site of 
inflammation and recognize foreign antigens are monocytes.  As a consequence 
of the inflammatory microenvironment, monocytes that infiltrate this site can 
differentiate into macrophages and dendritic cells.  
 
Dendritic cells (DCs) are recognized as one of the most important cell 
types for initiating the priming of naive CD4+ T helper cells and for inducing 
CD8+ T cell differentiation into killer cells. Immature DCs are found at strategic 
anatomical sites throughout the body, thereby allowing them to respond rapidly 
to microbial invasion. Immature DCs, on sensing potentially dangerous 
microbial signals through their pattern recognition receptors (PRRs), undergo 
maturation and subsequent migration to secondary lymphoid organs to prime 
naive T cells. At least three different subsets of DCs (myeloid, lymphoid and 
Langerhans cells) have been described based on their origins and phenotypic 
characteristics (including expression of distinct TLR repertoires). Hence, 
activation of different DCs has the potential to induce qualitatively distinct 
immune responses. Activation of lymphoid DCs, because of their preponderance 
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to secrete IL-12, may be important for priming Th1-like responses, whereas 
early activation of myeloid dendritic cells may lead to Th2- or Th0-like 
responses. TLR signaling also has an important role in determining the quality 
of these helper T cell responses. DCs may also exert indirect effects through, for 
example, the blockade of negative regulators of immune activation. It has been 
suggested that the production of IL-6 by DCs may be responsible for inhibiting 
the suppressor activity of CD4+CD25+ regulatory T cells. (reviewed by Pashine 
A. et. al., 2005). 
 
Macrophages are cells within the tissues that originate from monocytes.  
Monocytes and macrophages are phagocytes, acting in both innate immunity as 
well as cell-mediated immunity. Their role is to engulf and then digest cellular 
debris and patogens, and to stimulate lymphocytes and other immune cells to 
respond to these pathogens. Macrophages provide yet another line of defense 
against tumor cells and body cells infected with fungus or parasites.  
 
Microglia belongs to the mononuclear phagocyte lineage related to other 
organ specific macrophage populations (Vilhardt F., 2005). The old dogma 
states, that the brain is an immuno-privileged site. This might be true in regard 
of adaptive immunity, since hardly any or only weak adaptive immunity is 
exhibited in response to injury, infection, or tumor formation. However, the 
brain does exhibit a robust innate immune response carried out by microglia, 
which represent the major resident immuno-competent cell in the CNS and are 
capable of mounting macrophage-typical innate defence actions. Their functions 
include cell proliferation, migration, phagocytosis, enhanced antigen-presenting 
capabilities upon activation, up-regulation of innate immune cell surface 
receptors, secretion of pro-inflammatory mediators and reactive oxygen species 
(ROS). Infectious agents, such as bacteria, viruses, molecules in abnormal 
concentrations and other unidentified signals and conditions, which are related 
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to disturbed CNS functions and tissue destruction, trigger the transformation of 
resting microglia to an alerted, activated and fully reactive states.  
In almost every CNS disease, accumulation of microglia can be observed, 
which could be a result of migration mediated by chemokines. Such 
accumulation of microglia is also the case in brain tumors although the exact 
role of these glia cells in the biology of glioma is still unknown. There is 
evidence for anti-tumor as well as pro-tumor activity of microglia in brain 
tumors (Badie B. et. al., 2001).  
 
Activation of macrophages, as well as microglia, can occur by different 
stimuli and by recognition through different receptors, and results mainly in the 
activation of transcription factors such as NF-κB and interferon regulatory factor 
3 (IRF3). The NF-κB pathway controls the expression of proinflammatory 
cytokines such as IL-1β and tumor necrosis factor (TNF), whereas the IRF3 
pathway leads to the production of antiviral type I interferons (IFN-α, IFN-β). 
 Microbial stimuli, which are mainly recognized by PRRs, mediate the 
innate activation, which is followed by the production of type I IFNs, ROS and 
nitric oxide (NO). Along with these cytokines, various chemokines (such as IL-
8, monocyte chemoattractant proteins, macrophage inflammatory proteins and 
RANTES) are released and their receptors are expressed on the surface of 
activated cells. As a result, vascular endothelial cells may alter surface 
expression of selectins and intercellular cell adhesion molecules, leading to the 
extravasation and selective retention of some leukocytes at the inflamed site. 
This cellular infiltrate consists of activated monocytes, neutrophils, basophils, 
eosinophils and NK cells, many of which also express TLRs and may 
subsequently become activated by the presence of their respective ligands. 
Enhanced expression of co-stimulatory surface molecules (for example 
CD80, CD86) favors antigen presentation. Scavenger receptor-A and mannose 
receptor promote phagocytosis and endocytosis of host, as well as exogenous 
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ligands. The classical activation, on the other hand, is mediated by the priming 
stimulus IFNg, followed by microbial trigger, such as LPS. Activation results in 
secretion of pro-inflammatory cytokines, NO, oxidative burst, leading to tissue 
damage and cellular immunity. Activation of macrophages and microglia is 
quite complicated since they express further cytokine receptors (besides IFNγ 
receptors) for TNF, IL-1, IL-4, IL-10, IL-12, IL-13, IL-15, IL-18 and TGF-β; as 
well as complement receptors, prostaglandin receptors, chemokine receptors, 
Fc-receptors and Toll-like receptors (Aloisi F. 2001).  
 
Toll-like Receptors (TLRs) are mammalian homologues of the Toll 
protein, which was first discovered as an essential molecule for the 
establishment of the dorsoventral axis in the Drosophila embryo (Akira S., 
2004). So far, 11 TLRs have been discovered and described for mice and 
altogether 12 members of the TLR-family were identified in mammals. 
Members of the TLR-family share characteristic extracellular and cytoplasmic 
domains. They belong to a larger superfamily, which also includes the IL-1 
receptors (IL-1R). The extracellular domain contains multiple leucine-rich 
repeats, whereas the cytoplasmic domain is strikingly similar to the IL-1R, 
commonly known as the Toll/IL-1R homologous regions (TIR domains) (Slack 
J.L. et.al., 2000). TLRs detect multiple PAMPs, a brief summary is given in 
Table 1.  
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Table 1. Toll-like receptors and their ligands. 
Pattern-recognition 
receptors 
Ligands 
TLR1 Bacterial lipoproteins from Mycobacteria, Neisseria 
TLR2 Zymosan yeast particles, peptidoglycan, 
lipoproteins,glycolipids, lipopolysaccharide 
TLR3 Viral double-stranded RNA, poly:IC 
TLR4 Bacterial LPS, plant product taxol, Hsp60 
TLR5 Bacterial flagellins 
TLR6 Yeast zymosan particles, lipotechoic acid, lipopeptides 
from mycoplasma 
TLR7 Single-stranded RNA 
TLR8 Single-stranded RNA 
TLR9 CpG oligonucleotides 
TLR10 Unknown 
TLR11 Bacterial components from uropathogenic bacteria 
 
Recent research indicates that, under certain conditions, such as deficient 
clearance of apoptotic cells, the host-derived nucleic acids (often in complex 
with DNA-or RNA-binding proteins) may become available for activating 
TLRs, which may break tolerance and lead to autoimmunity (Leadbetter E.A. et 
al., 2002). Since TLRs play crucial role in the recognition of foreign antigens, 
their activation and modulation might enhance specific immune response, 
particularly anti-tumor immune response.  
Most of the TLRs are well described. TLR4 was the first characterized 
mammalian TLR. It recognizes LPS, and requires several accessory molecules. 
LPS is first bound to a serum protein, which transfers LPS to CD14. CD14 is a 
high-affinity LPS receptor, which can be expressed as a glycophosphoinositol 
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(GPI)-linked protein on the surface of macrophages, besides the possibility to be 
secreted in the serum. Another protein, which is associated with the recognition 
of LPS by TLR4, is MD-2. MD-2 is a small protein without a transmembrane 
domain and is expressed on the cell surface in association with the extra-cellular 
portion of TLR4. Despite the fact, that MD-2 function is not well understood, it 
increases the efficiency of LPS interaction with TLR4 as CD14 does.  
TLR2 can recognize a broad range of microbial products, including 
peptidoglycan from Gram-positive bacteria, bacterial lipoproteins, 
mycobacterial cell-wall lipoarabinomannan, glycosylphosphatidylinositol lipid 
from Trypanosoma Cruzi, cell walls from yeast and LPS, which is structurally 
different from Gram-negative LPS. The fact that TLR2 can cooperate with 
TLR1 and TLR6 by formation of heterodimers, might be an explanation for the 
broad range of ligands recognized. In such a way, hetero-dimerization between 
TLR2 and either TLR1 or TLR6 dictates the specificity of ligand recognition 
(Ozinsky A. 2000). The full repertoire of possible TLR heterodimers is not yet 
known. Some TLRs, such as TLR4, TLR5 as well as TLR2 are likely to function 
as homodimers.  
TLR3 functions as a receptor for double-stranded RNA (dsRNA), which 
is a molecular pattern produced by most viruses at some point of their infection 
cycle. Cells, which were deficient for TLR3 were shown to have a profound 
defect in their responsiveness to polyinosine-polycytosine (polyIC), the 
synthetic analogue to dsRNA (Alexopoulou L. et al. 2001). Therefore, TLR3 
contributes to the antiviral defense of the host as its specific ability to recognize 
dsRNA broadens the range of pathogens that can be detected by the TLRs.  
The TLRs dimerize and undergo conformational changes after ligand 
binding, which are required for the recruitment of a number of downstream 
factors in the TLR signaling. The signaling pathways of TLRs can be divided in 
two groups: the MyD88 dependent pathway and the MyD88 independent 
pathway. All TLRs can activate a common MyD88 dependent pathway that 
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culminates in the activation of NF-κB transcription factors, as well as the 
mitogen-activated protein kinases (MAPKs) such as the extracellular signal-
regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK). NF-κB is 
released and translocated into the nucleus, where it activates NF-κB-dependent 
genes (Fig. 2). 
 
 
 
Fig. 2. Activation of NF-kB, MAPKs, and IRF3 upon TLRs-TLRs ligand  
recognition. Modified from Re F,, Strominger J., 2004. 
 
A vast amount of proteins is regulated by NF-κB, including TNF, IL-1, 
IL-2, IL-6, IL-8, IL-12, various chemokines, such as monocyte chemoattractant 
protein-1, RANTES, and many other factors and proteins (Varney, M.L. et. al. 
2002).  
 
 
1.4.2. Adaptive immune response. 
 
TLRs activation in APCs can lead to abundant production of pro-
inflammatory cytokines, such as IL-1β, IL-6, IL-12, TNF and type-I IFN, 
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expression of co-stimulatory molecules and chemokines (Iwasaki A. 2004). The 
secretion of cytokines in turn can either activate APCs themselves by autocrine 
and paracrine mechanisms or attract and stimulate other cells (for instance 
leukocytes) for surveillance, attack and containment of invading pathogens. The 
products of TLR signaling can shape the adaptive immune response (Akira S. et 
al. 2001). TLR induced pro-inflammatory cytokines are important mediators for 
the activation and regulation of the adaptive immune response.  
 
Tumour necrosis factor (TNF) is a major proinflammatory cytokine, 
produced mainly by activated monocytes and macrophages. However, at certain 
conditions, almost all the cells, with the exception of erythrocytes, are able to 
synthesise TNF (Nagata S. 1997). TNF mediates both physiological and 
pathological effects. It plays a role in normal physiological processes like: 
embryogenesis, haematopoiesis, inflammation, and protection against infections. 
Pathological effects mediated by TNF appear upon stress, which generally 
increases TNF production. Well known is TNF contribution to the induction of 
sepsis, arthritis, pancreas inflammation and ischemia (Reimold A.M. 2003). 
TNF affects cellular growth, differentiation and metabolism. TNF is cytotoxic 
for many transformed cell lines and may cause hemorrhagic necrosis of the 
tumors in vivo (Lans T.E. et al. 2004). Depending on the target cell and 
metabolic inhibitors TNF can induce apoptotic or necrotic call death. Due to the 
potential use in the cancer therapy, antitumor properties (tumor growth 
suppression) of TNF are being intensively studied now. TNFα-mediated 
antitumor effect is often depending on the dose, however, high doses of this 
cytokine result with systemic toxicity. For many cell lines TNF is only 
cytostatic, but not cytolytic and many lines are totally resistant to its cytotoxic 
activity. Some tumors undergo regression upon combined treatment (TNF 
applied with IFNg or with cytostatic drugs).  
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TNF is widely studied in different antitumor approaches: as direct 
antitumor agent or as immunostimulatory molecule (enhancer of DCs 
maturation or TIL (tumor infiltrating lymphocytes) – mediated cytotoxicity) 
(Zhang W. et al. 2002; Itoh Y. et al. 1995).  
 
Interleukin 6 (IL-6) is a pleiotropic cytokine with many different 
functions. It is involved in the acute phase response, B cell maturation, and 
macrophage differentiation. IL-6 is an essential molecule for antiviral humoral 
responses, as well as for the induction of the acute phase reaction (Kopf M. et al. 
1994). Secreted IL-6 from fibroblasts in contact with monocytes, up-regulates 
M-CSF receptors on monocytes. Up-regulation of M-CSF receptors allows 
monocytes to be activated by their own M-CSF, which in turn promotes 
moncyte differentiation to macrophages rather than DCs (Chomarat, P. 2000).   
 
The type I interferon family consists of IFN-α, IFN-β, IFN-ω and IFN-λ, 
whereas IFNg is predominant in the type II IFN family. The IFN-α gene family 
consists of many members. In contrast, there is a single gene encoding IFN-β. 
Stimulation of certain cell types (mainly DCs, macrophages and other cells of 
hemotopoietic origin) with viruses, bacteria or TLR ligands, such as polyIC, 
LPS, CpG and imiquimod, resulted in the production of IFN-β and IFN-α4. 
Thus, it was shown that type I IFNs are produced in response to TLR3, TLR4, 
TLR7 and TLR9 activation, which makes these IFNs to important TLR response 
genes (Hertzog P. J. et al. 2003). IFNs were first discovered because of their 
ability to confer an antiviral state on cells. Any stage in the replication cycle of 
viruses appears to offer the possibility for inhibition by IFNs, including entry 
and/or uncoating, transcription, initiation of translation, maturation and 
assembly and release (Stark G.R. et. al. 1998; Muller U. et al. 1994). Besides 
their antiviral properties, type I IFNs were reported to promote the proliferation 
of memory T cells and prevent T cell apoptosis, by activating STAT4 directly 
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and inducing IFN-γ secretion from CD8+ T cells in mice and CD4+ T cells in 
humans (Nguyen K.B. et. al. 2002; Rogge L. et al. 1998).   
The innate immune response is usually followed by an adaptive immune 
response, which is mediated by the clonal selection of lymphocytes and leads to 
long-term immune protection. The exquisite specificity of antigen recognition 
by the T cell arm of the immune response provides an important basis for cancer 
immunotherapy. The ability to discriminate tumor cells from normal tissues is 
critical for enabling effective tumor destruction while minimizing toxicity. 
Indeed, the isolation of tumor-specific T cells from cancer patients has fueled 
the search for tumor-associated antigens. Given that most non-hematopoietic 
tumors express MHC class I molecules, which serve as the restricting element 
for CD8+ T cell recognition, but do not express MHC class II molecules, which 
are required for CD4+ T cell recognition, it has been assumed that the 
predominant tumoricidal effectors mechanism is killing by CD8+ CTL. The 
requirement for CD4+ T cells in these responses has been attributed to providing 
help during priming to achieve full activation and effectors function of tumor-
specific CTL. However, several lines of evidence suggest a broader role for 
CD4+ T cells in mediating other significant antitumor effectors functions. 
Depletion of either CD4+ T cells or NK cells, but not CD8+ T cells, resulted in 
the inability to reject the MHC class I negative variant, suggesting that CD4+ T 
cells may provide help as well as a measure of antigen specificity to effector 
cells of the immune response that do not themselves have the capacity for 
antigen-specific recognition (El Andaloussi, A., et. al. 2006; Sonabend, A.M., 
2008).    
It is well known that cell-mediated immunity is suppressed in patients 
with neoplastic diseases. One critical determinant of host immunity is the 
cytokine/chemokine milieu in the tumor microenvironment. A critical 
component therefore is likely to be the cytokine IL-10, which has been shown to 
hinder a number of immune functions, i.e. T lymphocyte proliferation, Th1 type 
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cytokine production, antigen presentation, and lymphokine-activated killer cell 
cytotoxicity. High plasma level of IL-10 correlates with bad prognosis for 
patients with melanomas, haematological malignancies, nasopharyngeal 
carcinoma and other solid tumors (Fortis C. et al. 1996). TGFβ is also well 
established as a multifunctional immunosuppressive cytokine. Produced by 
tumors, significantly reduces the potency of DC/tumor fusion vaccines. TGF 
beta stimulates in an autocrine as well as and paracrine way the production of 
VEGF at the transcriptional level, contributing to the malignant phenotype. 
Circulating IL-6 is associated with worse survival in patients with metastatic 
breast cancer and is correlated with the extent of the disease (Müller L. et al. 
2003). 
 
It is known that the anticancer activity of certain oncolytic viruses, 
notably the Newcastle disease virus (NDV), is not only mediated by their direct 
killing effect on cancer cells, but also involves an adjuvant effect of the virus on 
the immune system (Schirrmacher V. et al. 2000; Schirrmacher V. et. al. 2005). 
Besides ‘exposing’ tumor-associated antigens, oncolytic viruses can provide 
danger signals and/or modulate the production of immunoregulating molecules, 
resulting in the activation of the immune system and the breakage of tolerance 
towards the tumor. Therefore, this work was focused on the investigation of 
immunostimulating properties of MVMp-mediated tumor lysates.   
       
1.5. Aim of work.  
Malignant gliomas and melanomas are refractory to most standard 
therapies, including resection, radiation therapy and chemotherapy. A variety of 
different alternative approaches were performed within the last decades. PV 
represent one of the promising approaches due to their oncolytic and 
oncosupressive properties.  
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In this study, we hypothesized that MVMp-infected glioma GL261 and 
B78/H1 melanoma tumor cells possess the ability to induce a specific immune 
response leading to tumor eradication. 
In vitro experiments have been performed to evaluate the efficacy of 
MVMp to infect and lyse tumor cell lines; to investigate the activation of DC 
and microglia upon co-culture with PV-infected tumor cells. Additionaly, the 
possible role of TLRs in induction of immune response was investigated.    
In vivo studies consisted of the evaluation of a tumor specific immune 
response induced by MVMp in murine models.  
  
 
Materials 
  
 
 
 
2. Materials 
 
2.1. Materials for Tissue Culture. 
 
Plastic. All plastic materials for tissue culture (tubes, dishes, plates, 
pipets, tips ets.) were purchased from Greiner Bio-One, Sarstedt, NUNC and 
FALCON.  
 
Mediums, buffers and solutions 
1M HEPES – 238.31g of HEPES were dissolved in ddH2O to a volume 
1L. pH was titrated to 7.0 - 7.2 with 1M NaOH. Solution was filtered through a 
0.2μm nitrocellulose filter.  
2.5M CaCl2 – 183.7g CaCl2*2H2O were dissolved in ddH2O to a volume 
500mL. Solution was filtered through a 0.2μm nitrocellulose filter and stored in 
working aliquots.  
2xHBSS - buffer saline pH 7.05 – 0.267g of Na2HPO4*2H2O, 0.746g of 
KCl, 16.36g of NaCl, 2.162g of (D)-Glucose and 11.91g Hepes were solved in 
800mL ddH2O. pH was titrated to 7.05 with 10M NaOH. H2O was added to 1L. 
2xHBSS was sterilized by filtering through a 0.2μm nitrocellulose filter.  
cDMEM – DMEM plus 10% FCS, L-glutamine (100x), non-essential 
aminoacids (100x), 25mM HEPES, Na-pyruvate (100x), β-mercaptoethanol 
(1000x). 
cDMEM with antibiotics – cDMEM plus Penicillin/Streptomycin (100x) 
Gey´s solution - 20 parts Stock A; 5 parts Stock B, 5 parts Stock C; 70 
parts sterile ddH2O. 
  Stock A: 35.0 g NH4Cl; 1.85 g KCl; 1.13 g Na2HPO4• 7H2O; 0.12 g 
KH2PO4; 5.0 g glucose bring to 1 L with ddH2O and autoclave.  
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Stock B: 0.42 g MgCl2•6H2O; 0.14 g MgSO4•7H2O; 0.34 g CaCl2 
Bring to 100 ml with ddH2O and autoclave.  
Stock C: 2.25 g NaHCO3 bring to 100 ml with ddH2O and autoclave.  
Magic Medium (MM) – Iscove´s medium plus 10% FCS, L-glutamine 
(100x), non-essential aminoacids (100x), 25mM HEPES, Na-pyruvate (100x), β-
mercaptoethanol (1000x), Penicillin/Streptomycin (100x), Gentamicin (1000x) 
RIPA buffer  -  10mM Tris pH7.5, 150mM NaCl, 1mM EDTA pH 8.0, 
1% NP-40, 0.5% Na-Deoxycholate, 0.1% SDS 
SM (staining medium) – HBSS plus 2% FCS, 25mM HEPES 
 
Na-pyruvate (Gibco 11360-039), Non-essential aminoacids (Gibco, 
11140-035), PBS-EDTA 1.5 mM (0,22μm sterile filtered), HBSS (Invitrogen 
14175-053), Iscove´s medium (Sigma I3390), L-glutamine (Gibco 25030-24), 
Tissue culture (TC) double distilled H2O, DMEM (Sigma D5796), FCS 
(Biochrom AG S0115), Trypsin-EDTA 1x (Gibco 25300-054), β-
Mercaptoethanol (Gibco, 31350-010) 
                    
Chemicals 
0.4 % Trypan Blue (Sigma, T-8154) 
Collagenase A (Roche, 10103578001) 
DMSO 
DNAse I (Roche, 11284932001) 
Propidium Iodide (Sigma, P4170) 
Poly-L-Lysine 
MTT (Sigma, M5655) 
 
Antibiotics  
Blasticidin S (InvivoGen, ant-bl) 
Geneticin G418 (Sigma, A1720, Gibco, 11811) 
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Gentamycin (Invitrogen 04390311 A) 
Penicillin/Streptomycin (Gibco 15140-122) 
 
Cytokines and growth factors 
Recombinant human TNF (Peprotech, 300-01) 
Recombinant murine FLT-3 Ligand (Peprotech, 250-31) 
Recombinant murine GM-CSF (Peprotech, 315-03) 
Recombinant murine IL-4 (Peprotech, 214-14) 
Recombinant murine Stem Cell Factor (Peprotech, 250-03) 
Recombinant murine TNF (Peprotech, 315-01) 
 
TLRs ligands, mitogens 
Concanavalin A (Sigma, C5275) 
Lectin from Phaseolus vulgaris, Phytohemagglutinin (Sigma, L8902) 
Lectin from Phytolacca Americana (pokeweed) (Sigma, L8777) 
LPS from Escherihia coli 011:B4 (InvivoGen, tlrl-elps)) 
LPS from Escherihia coli 026:B6 (Sigma-Aldrich L2654) 
ODN1826 (InvivoGen, tlrl-modn) 
ODN1826 Control (InvivoGen, tlrl-modnc) 
Peptidoglycan from Staphylococcus aureus (InvivoGen, tlrl-pgnsa) 
Zymozan (InvivoGen, tlrl-zyn) 
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2.2. Materials for Molecular Biology Methods  
List of primers for PCR.  
Gene Primer type Sequence 
β-actin Sense 5´-3´ TGG GTC AGA AGG ACT CCT ATG 
 Antisense 3´-5´ CAG GCA GCT CAT AGC TCT TCT 
IFN-β Sense 5´-3´ CCC TAT GGA GAT GAC GGA GA 
 Antisense 3´-5´ CTG TCT GCT GGT GGA GTT CA 
IL-1β Sense 5´-3´ CAG GCA GGC AGT ATC ACT CA 
 Antisense 3´-5´ TCC ATT GAG GTG GAG AGC TT 
IL-6 Sense 5´-3´ AAT TTC CTC TGG TCT TCT GGA 
 Antisense 3´-5´ GCC ACT CCT TCT GTG ACT CC 
NS-1 Sense 5´-3´ GTT TTG GGA GCA ACC AAC TG 
 Antisense 3´-5´ TCC AGC CAG AGT CAC TGC TA 
mTLR1 Sense 5´-3´ CAA TGT GGA AAC AAC GTG GA 
 Antisense 3´-5´ TGT AAC TTT GGG GGA AGC TG 
mTLR2 Sense 5´-3´ CAG ACG TAG TGA GCG AGC TG 
 Antisense 3´-5´ GGC ATC GGA TGA AAA GTG TT 
mTLR3 Sense 5´-3´ GAG GGC TGG AGG ATC TCT TT 
 Antisense 3´-5´ TGC CTC AAT AGC TTG CTG AA 
mTLR4 Sense 5´-3´ GCT TTC ACC TCT GCC TTC AC 
 Antisense 3´-5´ CGA GGC TTT TCC ATC CAA TA 
mTLR5 Sense 5´-3´ GCT TTG TTT TCT TCG CTT CG 
 Antisense 3´-5´ ACA CCA GCT TCT GGA TGG TC 
mTLR6 Sense 5´-3´ GCA ACA TGA GCC AAG ACA GA 
 Antisense 3´-5´ GTT TTG CAA CCG ATT GTG TG 
mTLR7 Sense 5´-3´ ATT CAG AGG CTC CTG GAT GA 
 Antisense 3´-5´ AGG GAT GTC CTA GGT GGT GA 
mTLR8 Sense 5´-3´ TCC TGG GGA TCA AAA ATC AA 
 Antisense 3´-5´ AAG GTC GTA GCG CAG TTC AT 
mTLR9 Sense 5´-3´ ACC CTG GTG TGG AAC ATC AT 
 Antisense 3´-5´ GTT GGA CAG GTG GAC GAA GT 
 
Chloroform, Ethanol, Isopropanol and Methanol were purchased from 
Fluka. 
Materials 
 
 42
 
Luciferase Assay Reagent (Promega, E1483)  
Luciferase Cell Culture Lysis Reagent (Promega, E1531) 
Roti-Aqua-Phenol (Carl Roth GmbH A9803) 
Trizol (Invitrogen, 15596-018) 
UltraPure DNAse/RNAse-Free Distilled Water (Invitrogen 10977-015) 
Luciferase Assay Reagent (Promega F1483) 
Luciferase Cell Culture Lysis Reagent (Promega E1531) 
LIA-Plate 96 well (Greiner Bio-One 764075) 
 
2.3. Materials for FACS. 
List of antibodies for FACS. 
specificity clone Conjugates Source 
B220 RA3-6B2 FITC, PE, biotin Pharmingen 
CD117 (c-kit)  APC eBioscience 
CD11b M1/70 PE, biotin Pharmingen 
CD11b M1/70 FITC, biotin eBioscince 
CD11c HL3 FITC, PE, biotin Pharmingen 
CD11c N418 APC Caltag 
CD25 7D4 FITC, biotin Pharmingen 
CD4 RM4-5 FITC, PE, biotin Pharmingen 
CD40 HM40-3 Biotin eBioscience 
CD40 HM40-3 FITC  Pharmingen 
CD69 H1.2F3 FITC, biotin Pharmingen 
CD69 H1.2F3 Biotin eBioscience 
CD8 53-6.7 FITC, PE Pharmingen 
CD80 (B7-1) 16-10A1 FITC, biotin Pharmingen 
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CD86 GL1 Biotin Pharmingen 
CD86 GL1 Biotin eBiosciense 
Goat-anti Rat IgG  PE Caltag 
MHC II 25-9-17 FITC, biotin Pharmingen 
NK1.1 PK136 Biotin  Pharmingen 
Sca-1 (Ly-6A/E) D7 FITC, biotin Caltag 
Sca-1 (Ly-6A/E) D7 PE.Cy5, biotin Caltag 
Sheep anti-Rat IgG polyclonal  DynalBiotech 
TCR H57-597 FITC, biotin eBioscience 
TCR H57-597 FITC Pharmingen 
 
Monensin (NatuTec, 00-4505-51) 
 
2.4. Materials for ELISA/ELISPOT 
TMB Substrate Reagent Set (BD, BD OptEIA 555214) 
Mouse IL-6 ELISA set (BD, BD OptEIA 555240) 
Mouse TNF ELISA set (BD, BD OptEIA 558874) 
 
2.5. Additional Reagents and Equipment 
Freezing box (Nalgene) 
Kimwipes Lite 200 (Kimberla Clark) 
Neubauer Zählkammer 
Nitex (Sefar, 03-85/34) 
Pasteur pipets 
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2.6. Cell Lines  
293 FT 
The 293FT cell line was originally generated from human epithelial 
kidney cells. The cells were originally purchased from Invitrogen and were 
obtained from Dr. Matteo Di Piazza (ATV) in the forth passages. The 293FT 
cells were maintained in cDMEM and were selected periodically in Geneticin 
(500 mg/mL). 
HEK293 
The HEK293 cells were also generated from human epithelial kidney 
cells. The cell line was obtained from Dr. Cerwenka (DKFZ). The cells were 
maintained in cDMEM. 
 GL261 
The GL261 mouse glioma tumor was originally induced intracerebral 
injection of the chemical carcinogen methylcholantrene into C57/BL6 mice and 
maintened in its syngenic host by alternating intracranial and subcutaneous 
implantation of small tumor pieces. Safrany et. al. (Szatmari T. et. al., 2006) 
have established the permanent GL261 cell line from the tumor. The cells were 
maintained in cDMEM. 
B78/H1 
The mouse B16 melanoma subclone B78/H1 was obtained from Dr. Jan 
Cornelis (ATV). The cells were maintained in cDMEM. 
B16F10/GM-CSF and B16F10/FLT3L 
Both of the cell lines were originally obtained in lab. Dr. G. Dranoff 
(Dranoff G. et. al., 2003 ; Mach N. et. al. 2000). The cells were maintained in 
cDMEM. 
Stably transfected cells /TLRs 
Stably transfected HEK293 and 293FT cell lines with single mouse TLR2 
or mouse TLR4 were generated in the laboratory by Dr. Ute Koch and H. Hong. 
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Stable clones were selected with 25μg/mL Blasticidin. The cells were 
maintained in cDMEM. 
Cell lines 293 stably expressed mouse TLR3, mouse TLR2/TLR6, mouse 
TLR4/MD2/CD14 were purshared from Invivogen. The cells were maintained in 
cDMEM with 10μg/mL of Blasticidin. 
The 293.2 mTLR9 NFkB Promoter cells were obtained from the lab of 
Dr. S.  Bauer (Bauer S. et. al., 2001). Stable clones expressing mTLR9 with a 6-
fold NF-kB luciferase reporter plasmid were selected with 0.7 mg/ml G418.  
 
2.7. Experimental Animals 
Experimental mice were obtained from Charles River Wiga company 
(Sulzburg, Germany). Mice represented strains C57/Bl6. 5-6 week old male 
were grouped up to 5 animals per cage. The cages were placed in the isolator at 
21-240C, 40-60% humidity. All animals were housed under the same pathogen-
free conditions (food and water, 12h dark-light). Animals were killed by cervical 
dislocation.  The Referat Vaterinärwesen at the Regierungspräsidium, Karlsruhe, 
Germany approved the animal studies. 
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3. METHODS. 
 
3.1. Cell Culture Methods. 
 
3.1.1. Maintenance of Cell Lines.  
The cells were maintained as monolayer cultured - all used cell lines were 
adherent. Cells were usually cultured in cDMEM without antibiotics and 
propagated in T75 flasks at 370C, 5% CO2 and 90% humidity. Dependently on 
the cell growth rate the cells were splited one or two times a week. Confluent 
flasks were washed once with HBSS. Cells were trypsinated with Trypsin-
EDTA for 5-8 min. When a single cell suspension has been obtained, the 
cDMEM was added to the cells. An aliquot of cell suspension was diluted with 
Trypan-Blue. Cells were counted with the Neubauer Zahlkammer and split as 
desired. Maximum passage number of cells was ten.  
Microglia was cultured in cDMEM with antibiotics, as the danger of 
contamination was significantly higher when working with cells derived from 
primary culture. Dendritic cells and splenocytes were cultured in MM. 
  
3.1.2. Freezing and Thawing Mammalian Cells. 
For freezing, the cells from the confluent culture were collected using 
trypsin, centrifuged and resuspended in FCS containing 10% w/v DMSO. The 
cell suspension was transferred into cryovials and frozen in a cell freezing box at 
-800C.  
For thawing, a criovial was kept at 370C until the content was melt. The 
cell suspension was transferred into a 15mL tube containing 10mL of proper 
medium. Cells were centrifuged at 1500rpm for 10 min. The supernatant was 
removed, cells resuspended in 10mL fresh medium and placed in a cell cultured 
flask. 
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3.1.3. Cells Viability Methods. 
 
MTT activity assay. For the determination of cell viability, the metabolic 
activity of mitochondrial dehydrogenases was measured through the ability of 
these enzymes to produce a formazan dye through reduction of 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). 
Glioma GL261 and melanoma B78/H1 cells were plated in 96-well plates 
(2x103cells/well) in cDMEM. After 18h medium was removed and cells were 
infected in 50μL of DMEM without supplements with MVMp at different 
MOIs.  Plates were incubated at 370C for 1.5 hours. During infection, plates 
were rocked every 15min. 150 μL of cDMEM was added to the cells after 1.5h. 
After infection time (24h, 48h, 72h, 96h p.i.) 50µl of medium was removed, and 
MTT was added (final concentration 0.5mg/mL) to the cultures, and incubation 
was continued for 4h at 37°C. After centrifugation of the plate, the supernatant 
was removed, and the cells were dried for 30min at 37°C before lysis by addition 
of 100µl isopropanol. The absorbance of the formazan dye was measured at 
595nm using an ELISA plate reader. The viability of infected cells was 
expressed as the ratio of the corresponding absorbance to that of noninfected 
cells taken arbitrarily as 100%. 
Trypan Blue Dye Exclusion Method. Trypan blue is the most common 
stain used to distinguish viable cells from non-viable cells; only non-viable cells 
absorb the dye and appear blue and may appear asymetrical. Conversely, live, 
healthy cells appear round and refractive without absorbing the blue-coloured 
dye. The use of this stain, however, is time-sensitive. Viable cells absorb Trypan 
blue over time, and can affect counting and viability results. A 10 μL aliquot of 
cell suspension was placed in appropriate tube and 90μL of 0.4% Trypan blue 
was added, and gently mixed. 10μl of stained cells were placed in a 
hemocytometer and the number of viable (unstained) and dead (stained) cells 
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was counted. The total number of viable cells was determined according to the 
following calculation: 
 
cells/mL = # of cells counted in a square x 104 x dilution factor  
total cells = cells/mL x volume of original cell suspension 
 
3.1.4. Generation of Microglia. 
Brains from the newborn C57/BL6 mice were used for the preparation of 
Microglia. The heads were cut off from the mice using scissors. The skullcap 
was opened medially with a spiky pair of tweezers. The brain was carefully 
removed and transferred into a tube with 1x HBSS.  Meninges were removed 
under a stereoscope. Mice brains were then transferred on ice into 50mL poly-
propylene tubes with 10mL cDMEM. The brains were trypsinised with trypsin-
EDTA in the presence of DNAse (0.05%) for 20 min. The cells were spun at 
1000 rpm for 10 min and supernatant sucked off. The cell pellet was 
resuspended in cDMEM with antibiotics and plated in T75 flasks precoated with 
poly-L-Lysine (20μg/mL) in a final 10mL volume and then incubated at 370C, 
5%CO2. The medium was changed once per day following 2 days, and on day 7 
post-plaiting. At day 14, adherent cells were confluent and consisted of a 
mixture of astrocytes and microglia. At this time, the medium was sucked off, 
and Trypsin-EDTA was added for 5 min at 370C. The Trypsin-EDTA was 
sucked off and cDMEM plus DNAse (0.05%) was added. The cells were easily 
detached using Pasteur pipette, spun as before, and the pellet replated on 6 cm 
dishes at 370C, 5%CO2 to enable microglia to adhere while astrocytes remained 
in suspension. After 1h of incubation, the supernatant was transferred to cell 
culture graded dishes to develop astrocyte cultures. Subsequently, medium was 
changed once every week and astrocytes used at 14 days whereas microglia was 
ready for use at 21 days following replating. 
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3.1.5. Generation of Dendritic Cells from Bone Marrow 
To enrich the HSC population in BM and deplete actively cycling cells, 5-
fluorouracil was given intravenously as a single dose of 150 mg/kg body weight 
5 days prior the cells isolation. BM was extracted from the tibia and femur with 
SM using a 2mL syringe and 25-gauge needle. This single cell suspension was 
the centrifuged at 1200 rpm 5min at 40C and the pellet resuspended in a 5mL of 
Gey´s solution for 5min to lyse erythrocytes. The single cell suspension was 
collected, washed two times with SM, and counted. Desired amount of cells 
were resuspended in proper amount of SM. To deplete non-HSC the pellet was 
incubated with supernatant from the following cell culture (see Table.1), for 
45min on ice. 
Table 1. Staining for lineage markers. 
Antibody Source Number Number of 
hybridoma 
Dilution 
Anti-CD4 TCSN YTS 191.1  A170 1:100 
Anti-CD8 TCSN YTS 169.4 A150 1:100 
AntiCD19 TCSN Id 3 A200 1:100 
Anti CD3 TCSN YCD 3ε A110 1:8 
Anti CD3 TCSN Thy1.2/3OH10 A690 1:50 
Anti TER 119 TCSN TER 119 A330 1:100 
 
The cells were collected and washed in SM. Aftrewards, the pellet was 
labelled with Sheep anti-Rat IgG coupled to the magnetic beads for 20min at 
40C on the rotor.  Beads-coupled cells were eliminated on the Magnetic column 
and HSC-containing suspension was spun down at 1200rpm, 5min, 40C. The 
procedure with magnetic beads was repeated twice more. 
The remaining cells were cultured in MM in 6 well plates 
(0.5x106cells/well) with supplement of SCF for the first 24h, and GM-CSF, 
FLT3L, combination of GM-CSF and FLT3L for 9 days.  Medium with fresh 
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cytokine cocktail was added every 3 days. The morphological changes of cells 
were observed under the microscope. After 9 days DCs were used in follow 
experimental settings (see 3.1.8). 
       
3.1.6. Isolation of Dendritic Cells from Spleen and Lymph Nodes.  
C57/BL6 mice were injected s.c. with B16F10/GM-CSF or 
B16F10/FLT3L (1x106cells/mouse in 100μL PBS) 14 days prior DCs isolation. 
LN and Spleen were isolated from each single mouse. The organs were chopped 
with scissors and were gently pressed through the metal sieve using a rubber 
plunger in a syringe, all the while gently applying fresh media on the spleen to 
keep the cells moist and add transfer through the sieve. The pellet was 
resuspended in a 5mL of Gey´s solution for 5min to lyse erythrocytes. The 
single cell suspension was collected, washed two times with SM and counted. 
Desired amount of cells were resuspended in proper amount of SM. To deplete 
non-CDs the pellet was incubated with supernatant from the following cell 
culture (see Table 2.), for 45min on ice. 
 Table 2. Staining for lineage markers. 
Antibody Source Number Number of 
hybridoma 
Dilution 
Anti-CD4 TCSN YTS 191.1  A170 1:100 
Anti-CD8 TCSN YTS 169.4 A150 1:100 
Anti B220 TCSN RA3 6B2 A120 1:100 
AntiCD19 TCSN Id 3 A200 1:100 
Anti CD3 TCSN YCD 3ε A110 1:8 
Anti CD3 TCSN Thy 1.2 3OH10 A690 1:50 
Anti MAC1 TCSN M1/70 A100 1:100 
Anti GR1 TCSN RB6-8C5 A130 1:100 
Anti TER 119 TCSN TER 119 A330 1:100 
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The cells were collected and washed with SM. Aftrewards, the pellet was 
labelled with Sheep anti-Rat IgG coupled to the magnetic beads for 20min at 
40C on the rotor. Beads-coupled cells were eliminated on the Magnetic column 
and cells-containing suspension was spun down at 1200rpm, 5min, 40C. The 
procedure with magnetic beads was repeated twice more. After that DCs were 
used in follow experimental settings (see 3.1.8). 
 
3.1.7. Isolation of Splenocytes  
Spleens were isolated from each single mouse. The organs were chopped 
with scissors and were gently pressed through the metal sieve using a rubber 
plunger in a syringe, all the while gently applying fresh media on the spleen to 
keep the cells moist and add transfer through the sieve. The pellet resuspended 
in a 5mL of Gey´s solution for 5min to lyse erythrocytes. The single cell 
suspension was collected and washed with SM. Afterthat splenocytes were used 
in follow experimental settings. 
 
3.1.8. Co-culture of Dendritic Cells and Tumor Cells 
On day 0 glioma GL261 or melanoma B78/H1 cells were plated in 6-well 
plates, at 5x105 cells per well. On day 1 the cells were washed once with 
DMEM and were infected in 0.5mL of DMEM without supplement using 
MVMp (see 3.5.) at MOI10 for glioma GL261 and MOI100 for melanoma 
B78/H1. Plates were incubated at 370C for 1.5hours. During infection, plates 
were rocked every 15min. 2.5mL of cDMEM was added to the cells after 
1.5hours. 
On day 3, after 48h p.i., when a fraction of infected tumor cells was lysed 
(see 4.1.2.), DCs (1x106) were added into the wells with tumor lysates. In 
addition, DCs were added to MOCK-infected tumor cells and to lysates from 
tumour cells after 4 cycles of freezing and thawing. As a positive control, DCs 
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were stimulated with 5μg/mL of LPS. In addition, DCs were incubated alone or 
were infected with MVMp at MOI100.  
On day 5, after 48h of co-culture, DCs were harvested from the culture 
wells. Supernatants were collected and frozen at -200C for ELISA assay (see 
Methods 2.4.1.). Cells of the 6 well plates were processed for 2 different 
procedures: 
- for FACS analysis of  expression activation markers (see 3.4.2.1), 
- for RNA extraction (see 3.3.3.). 
 
 3.1.9. Co-culture of Microglia and Glioma GL261 cells 
On day 0 glioma GL261 cells were plated in 10cm dishes, at 5x105 cells 
per well. On day 1, tumor cells were washed once with DMEM and were 
infected in 1mL of DMEM without supplement using MVMp (see 3.5.) at 
MOI10. Plates were incubated at 370C for 1.5 hours. During infection, plates 
were rocked every 15 min. 7mL of cDMEM was added to the cells after 1.5 
hours. 
On day 2 microglia was harvested and plated. Briefly, the supernatant 
from the microglia (see 3.1.4.) was discarded. To detach microglia from the 
dishes, the cells were incubated with 10mL of PBS/EDTA for 15min at RT. 
Cells were harvested using Pasteur pipette while carefully sprinking the plate in 
order to detach cells which were still adherent. Microglia was transferred into 
sterile 50mL FALCON tubes, already containing 10mL cDMEM. Cells were 
collected and washes with SM. Pellet was resuspended in appropriate amount of 
cDMEM and counted. 1x106 microglia were plated into 10cm dishes.  
At day 3, supernatant from microglia was sucked off and discarded. After 
48h p.i., when a fraction of infected tumor cells was lysed (see 4.1.2.), glioma 
GL261 cells were scraped and cell suspension/lysate was transferred to the 
dishes with microglia. In addition, microglia was co-cultered with MOCK-
infected glioma GL261 cells and lysates from tumour cells after 4 cycles of 
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freezing and thawing. As a positive control, microglia was stimulated with 
5μg/mL of LPS/ 30 ng/mL IFNg. In addition, microglia was incubated alone or 
was infected with MVMp at MOI100.  
On day 5, 48h after co-culture, microglia was harvested from the culture 
dishes. Supernatants were collected and frozen at -200C for ELISA assay (see 
3.4.1.). Cells from the 10cm dishes were processes for 2 different procedures: 
- for FACS analysis of  expression activation markers (see 3.4.2.1), 
- for RNA extraction (see 3.3.3.). 
 
3.1.10. Transient Transfection for Luciferase Assay  
The 293FT or HEK293 cells stably transfected with single TLRs (0.6x105 
cells/well) were plated into 6-well tissue culture plates 3mL cDMEM and were 
incubated at 370C 5%CO2 overnight. Cells should be at 80-90% of confluence 
next day.  
After 16h, 14μg of DNA (Translucent Reporter Vector pNFkB-Luc 
(Panomics LR0051) or Translucent Control Vector (see Appendix); (stock 
concentration 1μg/mL) were diluted in 616μl of sterile ddH2Oto a final volume 
630μl. Then 70μl of sterile filtered 2.5M CaCl2 was added to the DNA mixture. 
Afterwards, 700μl of 2xHBSS (pH7.05) was added. Immediately, a mechanical 
pipettor attached to a plugged pipette was used to mix the suspension of 
2xHBSS and DNA/CaCl2 by feeding in air bubbles for 15sec. Mixture was 
vortexed for 5sec right away and incubated at RT for 10 min so that precipitates 
could form.  
During the incubation time, medium from the dishes with adherent cells 
was removed carefully. Cells were washed once with 1xHBSS (3mL per well) 
and 3mL cDMEM was added to the tissue culture dish. 200μl of the precipitate 
were distributed over each well of the 6-well tissue culture plate. Cells were 
incubated for 48h at 370C with 5%CO2.  
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Highest expression of Luciferase was detected between 24h and 48 hours. 
Thus, around 40 hours post transfection, cells were stimulated with human TNF 
(50 ng/mL), LPS (5 μg/mL), and specific ligands for TLRs, were infected with 
MVMp, or were co-cultured with MVMp-infected glioma GL261 or melanoma 
B78/H1 cells. 
8h later, growth medium from the cells was removed. 400μl Trypsin-
EDTA per well was added and incubated at 370C for 10min. Then 3ml of ice-
cold cDMEM was added. From this time on, cells were kept on ice. Cells were 
suspended and transferred into 4.5 mL tubes for centrifugation at 40C, 1200rpm 
for 5min. After removal of the supernatant, the cells were lysed by resuspending 
the pellet in Luciferase Cell Culture Lysis Reagent. The lysates were 
centrifugated once more at 40C, 1200rpm for 10min and the supernatants were 
transferred into 1.5mL tubes and stored at -800C, until luciferase assays were 
performed (see 2.3.1). 
    
3.2. Animal Techniques. 
 
3.2.1. Injection of In Vitro Infected Tumor Cells 
The glioma GL261 cells were seeded in 10cm in cDMEM dishes one day 
before infection (1x106 cells/dish). On the day of infection medium was 
removed and cells were infected with indicated MOIs in 1mL of DMEM without 
supplements. The dishes were placed at 5% CO2, 370C, for 1.5h and gently 
rocked every 15min. After 1.5h the cells were supplied with cDMEM and placed 
in the incubator. Four hours after infection the cells were trypsinized, collected, 
washed two times with PBS and counted. Desired amount of cells were 
resuspended in proper amount of PBS. 100μl of cell suspension (1x106 cells) 
were injected subcutaneously in the right flank of each animal. Growing tumors 
were examined and measured every 2-3 days. For the evaluation of tumor´s 
volume length, breadth and height were measured every 3 days with the 
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assistance of a calliper. Tumor volume was calculated for an ellipsoids 
according to the formula V=π/6*L*B*H.  
 
3.2.2. Isolation of In Vitro Infected Tumor Cells 
Tumors were isolated from each single mouse and were digested in the 
presence of DNAse (0.05%) and collagenase for 20 min. Afterthat, the tumors 
were gently pressed through the metal sieve using a rubber plunger in a syringe, 
all the while gently applying fresh media on the tissue to keep the cells moist 
and add transfer through the sieve. The single cell suspension was collected, 
resuspended in a 5mL of Gey´s solution for 5min to lyse erythrocytes, and 
washed with SM. After that single cell suspension was used in follow 
experimental settings. 
 
3.3. Molecular Biological Methods 
 
3.3.1. Luciferase assay 
Luciferase Assay Reagent was thawed and maintained into a water bath at 
room temperature for at least 30min to ensure temperature equilibrium. Samples, 
which had been lysed in the Luciferase Cell Culture Lysis Reagent, were thawed 
on ice.  
The luminometer was programmed for 2sec delay time and 10sec reading 
time. 10μL of cell lysate were applied per well in a LIA-plate. Plate with 
samples was plated into luminometer. The injector of the luminometer added 
50μL of Luciferase Assay Reagent per well, the well was then read immediatly.  
  
3.3.2. Westernblot analysis 
 
Protein isolation from the Mammalian Cells. For the detection of NS1, 
LC3, and caspase-3 active form proteins upon MVMp infection a protein extract 
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from 1x106 cells cultures in 10cm dishes was prepared. The medium was 
removed, cells were washed with PBS and subsequently lysed with RIPA buffer. 
The lysates were collected, transferred into a 1.5mL tubes and placed on ice for 
20 min. After that the samples were centrifuged for 10 min at 14000rpm at 40C. 
The supernatant was transferred into a fresh tube and stored at -200C.   
 
Western Blot analysis. The proteins were separated of using SDS-
polyacrylamide gel electrophoresis. A desired amount of protein extract 
(containing 20 μg, 40 μg of total proteins) was mixed 1:1 with loading buffer, 
denaturated 5 min. at 95°C and placed on ice. After loading on a gel, 
electrophoresis was performed over night at 70V, 100mA. A nitrocellulose 
membrane (Protran; Schleicher & Schuell, Relliehausen, Germany) was placed 
on the gel and, by using of a semidry blotting apparatus (Bio-Rad Laboratories, 
Munich, Germany the negatively charged protein bands were driven onto the 
nitrocellulose membrane. This gave a nitrocellulose membrane that is imprinted 
with the same protein bands as the gel. The membrane was blocked with 
blocking buffer at RT for 1h. The primary antibodies used for immunostaining 
were directed against LC3, caspase-3 active form, cathepsin B, β-tubulin 
(Sigma), NS1 (rabbit antiserum αSP8). Incubation with primary Abs was 
overnight at 40C. The membrane was washed 3x 10 min. with washing buffer. 
The membrane was incubated 1 h at RT with a secondary antibody (an antibody-
enzyme conjugate). The washing 3x 10 min. with washing buffer was 
performed. Peroxidase-conjugated secondary antibodies were all purchased from 
Santa Cruz. Immunodetection was performed with Western Lightning 
Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, Rodgau-
Jügesheim, Germany). The membrane was exposed of to an x-ray film (Kodak).  
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3.3.3. Total RNA Extraction from Cells 
For the isolation of total RNA cells were transferred into the Eppendorf 
1.5mL, treated with 1 mL of Trizol, and frozen at -800C. Subsequently, per 1 
mL Trizol, 0.2mL of chlorophorm was added, mixed and the sample was placed 
at RT for 2-3 min. Afterwards, the sample was centrifugated for 15 min at 14000 
rpm at 40C. The upper aqueous phase, containing RNA, was collected in another 
tube, the same amount of acid phenol and 1/10 of chlorophorm was added in 
order to remove remaining DNA/protein contamination and purified RNA. The 
sample was centrifugated at 14000 rpm for 5 min at 40C. Afterwards, RNA from 
aqueous phase was precipitated by mixing with equal volume of cold isopropyl 
alcohol. The sample was incubated overnight at -200C. RNA formed a gel-like 
pellet and was spun down by centrifugation at 14000 rpm for 15 min at 40C. The 
pellet was washed once with 1mL of cold 80% ethanol, spun down by 
centrifugation at 9600 rpm for 10 min at 40C, air-dried for 10 min, resuspended 
in DNA, RNA-free water and stored frozen at -800C.  
 
3.3.4. RT-PCR (Reverse Transcription-Polymerase Reaction) of RNA 
RT-PCR (Reverse Transcription-Polymerase Reaction) is the most 
sensitive technique for mRNA detection and quantification currently available. 
It allows detecting the expression of a gene of interest. In this method, RNA is 
first transcribed into complementary cDNA and then DNA is multiplied.  
As a first step 1 μg RNA was mixed with 1μL Random Primers 
(Invitrogen). Total sample volume was 10 μl (adjusted with sterile dH2O). The 
probe was incubated 10min. at 70°C, 10 min at 25°C,  and placed on ice. After 
that MasterMix was added   
Reaction mix 5,0 μl 10x RT enzyme buffer (Promega)  
1,0 μl RT enzyme M-MLV (Promega)  
1,0 μl 40U Rnasin (Promega)  
2,0 μl 5 mM dNTP mix (Sigma)  
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Reaction conditions: 50 min. at 42°C, 15 min. at 70°C, kept at 4°C.  
During the step of reverse transcription RNA was transcribed into cDNA. 
Ready cDNA sample was diluted 1: 10 with H2O and stored at -20°C.  
 
3.3.5. PCR 
The polymerase chain reaction (PCR) is a method for oligonucleotide 
primer directed enzymatic amplification of a specific DNA sequence. This 
technique is capable of amplifying the sequence of interest from nanogram 
amount of template DNA within a large background of irrelevant sequences 
(e.g. from total genomic DNA).  
The PCR product was amplified from cDNA templates using a heat-stable 
DNA polymerase from Thermus aquaticus (Taq DNA polymerase) in an 
automated thermal cycler through repeated cycles of denaturing, annealing of 
primers, and polymerization steps. After amplification, the DNA products were 
separated by agarose gel electrophoresis and vizualized after staining with 
ethidium bromide.  
 
3.3.6. Southern Blot 
For analyses of the viral DNA intermediates produced after infection, 
cells were infected at various MOI, trypsinised, washed in PBS, processed for 
low-molecular weight DNA in a mixture (1:1) of vTE buffer and 2x Hirt buffer 
(20 mM Tris [pH 7.4], 20 mM EDTA, 1.2% SDS) and then digested with 
proteinase K (400 µg/ml) for 18 h at 46°C. After cellular genomic DNA was 
sheared by several passages through 0.5- and 0.4-µm needles, DNA samples (2 
µg) were fractionated through 0.8% agarose gel electrophoresis. After DNA 
denaturation and transfer onto Hybond-N nylon membranes (Amersham 
Pharmacia Biotech), the viral intermediates were identified by hybridization 
with a 32P-labeled DNA probe corresponding to the EcoRV (nt 385)-EcoRI (nt 
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1084) fragment of MVMp NS gene. Membranes were exposed to BioMax MS 
Film (Kodak, 8294985) for 18hrs at -200C.  
 
3.4. Immunochemical methods 
 
3.4.1. Cytokine ELISA 
Level of TNF and IL-6 was measured in the supernatants from stimulated 
DCs and microglia (see 3.1.7 and 3.1.8) by using Mouse IL-6 ELISA set and  
Mouse TNF ELISA set.  
 
3.4.2. FACS analysis 
 
3.4.2.1. Phenotypic characteristic of Dendritic Cells and Microglia  
All cellular preparations were performed at 40C, except where indicated. 
Cells from various preparations (see above) to be analysed were first blocked 
from non-specific binding for 30min. Then, they were washed once with 3mL of 
SM, and labelled with Abs against surface markers. After that, the cells were 
washed with 3mL of SM and spun down at 1200rpm, 5min. If it was nescssary 
cells were labelled with secondary Abs for 35 min on ice and were washed once 
again with 3mL of SM. 10-50x106 cells per sample were analysed. Prior to 
anylysis, propidium iodide (PI) was added to the sample (1μg/mL) to label dead 
cells for subsequent dead cell exclusion. To exclude non-DCs and non-
Microglia contamination during analysis, double staining CD11c/CD11b was 
performed for each single sample. 
FACS was performed at FACSCalibur (Beckton Dickinson) using a 
CellQuest computer software. Data were processed by using the CellQuest or 
FlowJo software packages. 
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3.4.2.2. Intracellular detection of NS1  
Glioma GL261 or melanoma B78/H1 cells were plated in 6-well plates, at 
5x105 cells/well. Next day the cells were washed once with DMEM and were 
infected in 0.5mL of DMEM without supplement using MVMp (see 3.5.) at 
MOI10 for glioma GL261 and MOI100 for melanoma B78/H1. Plates were 
incubated at 370C for 1.5hours. During infection, plates were rocked every 
15min. 2.5mL of cDMEM was added to the cells after 1.5hours, and cells were 
incubated at 370C, 5% CO2. After indicated time of infection, cells were 
collected by trypsinisation, fixed in 1% cold PFA for 15 min at 40C, washed in 
ice-cold PBS-BSA (0.1%), resuspended in 80% ice-cold methanol and incubated 
overnight at −20°C (1×106 cells for each sample). Following removal of fixative 
by washes in ice-cold PBS, cells were washed once with ice-cold PBS-BSA 
(0.1%) and permeabilised by two washes with PBAT at 40C. Blocking was 
performed for 30min at 4°C in PBS-40% rat serum followed by incubation with 
the NS1-specific antibodies (clones 2C9 and 3D9 mixed at a 1:10 final dilution 
each) for 45 min (4°C), three washes in PBAT and incubation with the 
secondary Cy2-conjugated rat anti-mouse antibody for 60min at 4°C. After two 
washes in PBAT, cells were filtered through Nitex and analysed by flow 
cytometry.  
 
3.4.2.3. TUNEL assay. 
One of the later steps in apoptosis is DNA fragmentation, a process which 
results from the activation of endonucleases during the apoptotic program. 
These nucleases degrade the higher order chromatin structure into fragments of 
~300kb and subsequently into smaller DNA pises of about bp lengh. A method 
which is often used to detect fragmented DNA utilizes a reaction catalyzed by 
exogeneous TdT, often referred to TUNEL (terminal 
deoxynucleotidyltransferase dUTP nick end labelling). The DNA fragments 
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were labelled with APO-BRDU Kit (BD Pharmingen, 556405) and measured by 
FACS.  
 
2.4.3. ELISPOT assay 
For assessing IFNg secretion by individual cells, MultiScreen-IP plates 
(PVDF membranes, Millipore, Bedford, MA) were coated overnight at 4°C with 
100 μg/well of anti-mouse IFNγ antibodies (BD Pharmingen, 551216) diluted at 
1 mg/ml in carbonate/bicarbonate buffer (0.05 M, pH 9.6). After overnight 
incubation, plates were washed with PBS and saturated with MM for 2h at RT 
prior to use. Splenocytes (1×105/well in 200 μl) were added to triplicate wells 
and stimulated by mitogen or by glioma GL261 cells (5×104/well). After 
incubation overnight at 37°C, supernatants were discarded and 200 μl of cold 
pure water was added for 10 min to osmotically shock the cells. Plates were 
washed with PBS + 0.05% (v/v) Tween 20 (PBS-T) and 100 μl of biotinylated 
rabbit anti-mouse IFNγ detecting antibody (BD Pharmingen, 554410) diluted to 
0.25 μg/ml in PBS-T was added. After 2hrs incubation at 4°C, plates were 
washed with PBS-T, and streptavidin-alkaline phosphatase enzyme conjugate 
was added. After 30 min incubation at room temperature, plates were washed 
with PBS-T and the spots were visualised with BCIP/NBT Liquid Substrate 
system (Sigma, B1911) according to the manufacturer's instructions. 
  
3.4.4. Detection of caspase-3 activity. 
One of the commonly used ways to detect caspases activities is tu 
incubate synthetic substrates such as pepetides conjugated to a fluorochrome 
with lysates of cells and measure their cleavage. Substrate processing gives rise 
to increased fluorescence intensity, whose signal is proportional to the amount 
of cleaved substrate, which in turn is dependent on caspase activity and is 
related to the percentage of apoptotic cells in a cell population (Kohler et. al., 
2002). Caspases activities was determined by adding 25μl of whole-cell extract 
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to caspase buffer (Hepes 50mM pH 7.4, NaCl 150mM, 0.1% CHAPS, 0.1% 
Triton X-100, EDTA 1mM, 10% Glycerol, DTT 10 mM) supplemented with 
caspase 3 (Ac-Asp-Glu-Val-Asp-AFC) substrate (1 mM, Calbiochem). The 
reaction was monitored for 1 hour on a Fluoroskan (Termolabsystem) measuring 
the emission at 510 nm wavelength with the excitation wavelength set at 390 
nm. 
 
3.5. Virus production 
MVMp was produced by “Virus production unit” INSERM U701. Briefly, 
MVMp virus was produced in A9 cells and  purified with Iodixanol Density 
Gradient. The titer of virus was determined by Plaque Assay and Hybridisation 
Assay.  
 
3.6. Statistical analysis 
Statistical differences were determined using the Student´s t test. A 
P<0.05 was considered significant.  
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List of Abbreviation 
 
(m)RNA (messenger) - Ribonucleic acid 
AAV - adeno-associated virus  
APC - antigen presenting cell 
BM - bone marrow  
BSA - bovine serum albumin  
CNS - central nervous system  
CTL - cytotoxic T lymphocyte  
DC - dendritic cell  
DMEM - Dulbecco´s modified Eagle medium 
DMSO - Dimethyl Sulfoxide 
DNA - Deoxyribonucleic acid 
ds DNA - double stranded DNA 
ECM - extra cellular matrix 
EDTA - ethylendiamintetraacetic acid  
EGFP - enhanced green fluorescent protein  
ELISA - enzyme-linked immunosorbent assay  
EtBr - ethidiumbromide  
FACS - fluorescence activated cell sorter  
FCS - foetal calf serum  
FITC - fluorescein isothiocyanate  
GM-CSF - granulocyte-macrophage colony stimulating factor  
HBSS - Hank’s buffered salt solution  
HSC - hemaetopoietic stem cells 
HSV - herpes simplex virus  
IL - interleukin  
INFg - interferon gamma  
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Kb - kilobases  
kD - kilodalton  
LPS - lipopolysaccharide  
MHC - major histocompatibility complex  
MOI - multiplicity of infection  
MVMp - minute virus of mice prototype strain  
NDV - Newcastle disease virus  
NK - natural killer cells  
NS1 - parvoviral non-structural protein 1 
OD - optical density  
ODNs - oligodeoxynucleotides  
PBS - phosphate-buffered saline 
PFU - plaque forming unit  
PV - parvovirus 
RT - room temperature 
s.c. - subcutaneous 
TNF - tumor necrosis factor 
TGF - transforming growth factor 
WHO - World Health Organisation 
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4. Results.  
 
4.1. Oncolytic effect of PV MVMp in tumor cell lines.  
 
Previously, circumstantial evidence was provided that the oncolytic PV 
MVMp has the potential to elicit a tumor specific immune response (Moehler 
et.al., 2003; Guetta et. al., 1986). The main goal of the study presented here was 
to investigate the detailed mechanism by which PV MVMp is mediating a 
tumor-specific immune response in murine tumor models. A murine melanoma 
cell line, B78/H1, and glioma cell line, GL261, were used to analyze the 
induction of PV mediated oncolysis leading to a tumor-specific immune 
response in vitro and in vivo. MVMp vectors delivering immunostimulatory 
chemokines and cytokines have been evaluated to induce anti-tumor effects in 
the above-mentioned tumor models (Wetzel K. et. al. 2007; Lang S.I. et. al., 
2006; Dinsart C. et. al. unpublished). However, the mechanisms involved, 
especially the contribution of the innate as well as adaptive immune response 
remains to be elucidated. A series of studies was conducted to verify the validity 
of both tumor models to assess their potential in the framework of this study 
inducing tumor-specific immune responses.  
 
4.1.1. Melanoma B78/H1 and glioma GL261 cell lines are both 
permissive for MVMp infection. 
 
A sequence of experiments was performed to assess whether the murine 
melanoma B78/H1 and glioma GL261 cell lines are sensitive to PV MVMp 
infection. First of all the replication of MVMp in these two cell lines was 
investigated. It is known, that the single-stranded genome of PV is converted 
into a monomeric replication form in the nucleus. This monomeric intermediate 
form is amplified via multimeric forms and is also used as a template for the 
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synthesis of mRNA. This process can be monitored by SouthernBlot according 
to the replicative forms described. 
 For this assay cells were left either uninfected or were infected with 
different MOI (1, 10, 100 for melanoma B78/H1 and 5 for glioma GL261). The 
amount of cell-associated viral single-stranded (ss) DNA was evaluated by 
Southern blotting analysis of low-molecular–weight DNA extracted 6hrs after 
virus infection. As shown in Fig.1, signals for the input of ssDNA could be 
detected in both melanoma B78/H1 and glioma GL261 cells (6hrs post 
infection), confirming the competence of these cell lines for MVMp uptake. 
Next, the formation and amplification of double-stranded  (ds) DNA replicative 
forms (RF) of monomeric (mRF) and dimeric (dRF) size were analyzed at later 
time point after infection (48hrs post infection (p.i.)).  Both replicative forms 
occurred in the two cell lines assessed (Fig.1). The glioma GL261 cell line 
showed a drastic increase in the ssDNA signal indicative for the production of 
viral progeny genomes, since the same amount of DNA was loaded. Together 
these data are the first indication that both cell lines are sensitive to PV MVMp 
infection and that MVMp can replicate in both cell lines albeit to a different 
extent with the GL261 cell line being the more susceptible one.  
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Fig.1. Southern blotting analysis of viral DNA intermediates. Glioma GL261 and 
melanoma B78/H1 cell lines were infected with different MOI (1, 5, 10, 100) of MVMp. 
Cells were harvested at the indicated times (6hrs and 48hrs post infection (p.i.)) and processed 
for the analysis of virus replication. 2μg of DNA were loaded.  mRF, monomer replicative 
form; dRF, dimer replicative form; ssDNA, single-stranded genomic DNA; M – molecular 
weight marker.  
 
Since the accumulation of viral genomes is coupled with their 
encapsidation (Cotmore, 1987), the expression of NS1 protein was investigated 
in both cell lines using flow cytometry. MOI 100 and MOI 10 were chosen as 
the optimal for melanoma B78/H1 and glioma GL261, respectively (data not 
shown).  NS1 expression steadily increased in a time-dependent manner with the 
peak of expression at 96 hrs p.i. for the melanoma tumor cell line and at 72hrs 
p.i. for the glioma tumor cell lines (Fig. 2). Due to massive cell death upon 
MVMp infection, the glioma GL261 cell line shows less NS1 expression at 96 
hrs p.i. Since NS1 plays a crucial role in the cytotoxic activity of PV, the cell 
survival might be affected due to MVMp infection. 
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Fig.2. Expression of NS1 protein in cell lines upon MVMp infection. A. - 
Melanoma B78/H1, B. - glioma GL261 at 48hrs, 72hrs, 96hrs p.i. Red  line histograms 
represents the MOCK-infected control samples, green line histograms depict MVMp-infected 
samples (melanoma B78/H1 cell line infected with MOI 100, glioma GL261 cell line infected 
with MOI 10). One representative experiment out of three is shown. Percentage of positively 
staining cells each indicated in the histograms.  
 
4.1.2. MVMp exerts a cytotoxic effect in tumor cells and inhibits cell 
proliferation. 
 
Autonomous PV are endowed with cytotoxic and oncolytic activities 
(Rommelaere J. 2001; Geletneky K. 2005; Wildner O. 2001). In order to 
establish whether PV MVMp infection was associated with the induction of cell 
48hrs p.i.  72hrs p.i. 96hrs p.i. 
A. 
B. 
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death in these tumor cell lines, the MTT assay was applied to verify cytotoxicity 
and the trypan blue dye exclusion method was used to assess the absolute 
number of live cells.  
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Fig.3. Cell survival upon MVMp infection.  One million cells were infected with 
MVMp at A) MOI 100 for the melanoma B78/H1 cell line, or B) MOI 10 for the glioma 
GL261 cell line. The number of live cells was determined using the trypan blue exclusion 
method. Data represent the mean of three independent experiments. * - p < 0.05 (t-test) 
compared to MOCK infected samples. 
 
Figure 3 shows the absolute cell numbers, which indicate the proliferation 
over time of the B78/H1 and GL261 tumor cell lines infected with different 
MOIs in comparison to non-infected control cells (MOCK). The two cell lines 
revealed a striking difference in their sensitivity to viral infection. Normal 
proliferation and increase in cell number in both uninfected cell lines was 
observed. Upon MVMp infection cell viability was partially reduced in the 
melanoma B78/H1 cells and dramatically in the glioma GL261 cells.  
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Fig.4. Cytotoxic effect of MVMp on tumor cell lines. A. Melanoma B78/H1 and B. 
glioma GL261 cells (2x103) were infected with different MOIs (B78/H1 – MOI 10, MOI 100: 
GL261 – MOI 1, MOI 5, MOI 10). The cytotoxic effect of MVMp was measured using the 
MTT assay after 24hrs, 48hrs, 72hrs and 96hrs p.i. Data represent the mean of three 
independent experiments. * - p < 0.05 (t-test) compared to MOCK infected samples. 
 
Although the virus is able to replicate in the B78/H1 cell line and cell 
death is initially visible 2 days post infection, there are still about 30% living 
cells at day 4 using a MOI of 100. This might be due to the continuous 
proliferation of a population of possibly virus resistant cells (Fig.4). These cells 
were considered resistant since re-infection of cultures at the same MOI had no 
effect neither on survival nor proliferation (data not shown). The glioma GL261 
cell line revealed high sensitivity to MVMp infection. The greatest cytotoxic 
effect of MVMp was observed at day 3 and day 4 post infection. Almost 90% of 
cells had died at day 4 upon MVMp infection with a MOI 10. Even though both 
the melanoma and glioma tumor cell lines are permissive for MVMp infection, 
glioma GL261 cells are more susceptible for the infection and more sensitive to 
the cytotoxic effect of the virus. Due to the high cytotoxic effect of MVMp on 
the glioma GL261 cell line, the mode of cell death was investigated. 
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4.1.3. Induction of the apoptotic pathway following MVMp infection. 
 
Rodent PV infection can induce either necrosis or apoptosis, depending on 
the tumor model considered (Moehler M. et. al. 2001; Rayet et.al. 1998; Ran et. 
al. 1999). The question arises whether PV MVMp would trigger the apoptotic 
death pathway or necrosis in either the melanoma B78/H1 or glioma GL261 cell 
line. There were no indications of necrosis in these cells upon MVMp infection 
in previous studies (Lang S. et. al., 2005). Therefore, the possible induction of 
the apoptotic death pathway was investigated in more detail. 
Apoptosis is mediated by sequential activation of caspases, which are 
constitutively present in most cells as inactive proenzymes. Caspases operate in 
an intracellular cascade leading to the activation of downstream effectors 
caspases-3, -6 and -7 (Adams J.M. 2003; Green D.R. et al. 1998). 
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Fig.5. Caspase-3 activation induced by MVMp infection in A. melanoma B78/H1 
and B. glioma GL261 cells. One million cells were plated and infected with different MOIs. 
At different incubation times (24hrs, 48hrs, 72hrs, 96hrs p.i.) 1x106 cells were collected, lysed 
and caspase-3 activity was assessed in a fluorescence assay with synthetic substrates. 
Caspase-3 activity is expressed in relative fluorescence units (RFU) per minute. Data 
represent the mean of four independent experiments. * - p < 0.05 (t-test) compared to MOCK 
infected samples. 
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It is known that caspase-3 is a key mediator of nuclease activation, which 
results in DNA degradation during apoptosis. Therefore, we analyzed whether 
MVMp induced caspase-3 in infected cells. The presence of the active form 
caspase-3 was observed by flow cytometry in both cell lines investigated (data 
not shown). A fluorescence assay based on the enzymatic activity of caspase-3 
was performed to verify at which time point caspase-3 activity was at its 
maximum upon MVMp infection. As depicted in Fig. 5, non-infected cells 
(MOCK) of both tumor cell lines showed constant caspase-3 activity within the 
first three days (24-72hrs). Upon MVMp infection caspase-3 activity in the 
melanoma B78/H1 was not significantly increased at either 72hrs p.i. (2-times 
fold increase compared to MOCK-infected cells) or 96hrs p.i. (1.5-times fold 
increase compared to MOCK-infected cells), which is in accordance with low 
replication potency of MVMp in these cells and viral cytotoxic effect. The 
outgrowth of MVMp resistant cells resulted in enhanced proliferation and 
reduced cell death of melanoma B78/H1. However, caspase-3 activity was 
significantly increased in infected glioma GL261 cells compared to MOCK.  
The highest activity was observed at 48hrs (5-times increase) and 72hrs p.i. (4-
times increase) and this correspondes to massive cell death.  
 
The final step of the apoptotic pathway is characterized by the breakdown 
of genomic DNA by endonucleases resulting in DNA fragmentation 
(Zhivotosky B. et. al. 2001). The terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) method was used to assay the endonuclease 
cleavage products by enzymatical end-labelling of the DNA strand breaks. To 
investigate whether DNA fragmentation as the final step in the apoptotic cell 
death pathway occurs upon MVMp infection, TUNEL labeling was assessed by 
flow cytometry. No considerable increase in DNA fragmentation was observed 
in the melanoma B78/H1 cell line after 72hrs (23%) or 96hrs (21%) p.i. (Fig. 6). 
In contrast, the glioma GL261 cells showed significantly increased DNA 
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fragmentation at 72hrs (58%) p.i. due to the higher sensitivity to PV MVMp 
infection (Fig. 6).   
 
    
                       
       
  Fig.6. DNA fragmentation upon MVMp infection in A. melanoma B78/H1 and B. 
glioma GL261 cells. Cells were seeded at 0.5x106 and infected with MVMp at MOI 10 for 
glioma GL261 and MOI 100 for melanoma B78/H1. Cells were labelled with FITC-BrdU and 
analysed by FACS at either 72hrs or 96hrs p.i.. Red  line histograms represents the MOCK-
infected control samples, green line histograms depict MVMp-infected samples. One 
representative experiment out of three is shown.  
 
Taking all the data together we can conclude that both melanoma B78/H1 
and glioma GL261 tumor cells are permissive to PV MVMp infection. Upon 
MVMp infection glioma GL261 showed higher sensitivity to the cytotoxic effect 
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of the virus and apoptotic features of cell death. These essential studies 
confirmed the usefulness of both tumor cell lines as models for the following 
investigations for the induction specific immune responses by MVMp albeit 
with the certain limitations. Due to the heterogeneity of the melanoma B78/H1 
cell line and due to the resistance of a subpopulation of it to MVMp, this tumor 
cell line might only be useful for in vitro and in vivo assays within a very narrow 
window of time and at high MOIs. However, the melanoma cells B78/H1 
provide a better model for in vivo studies due to the physiological relevance of 
the route of tumor transplantation subcutaneously. The glioma GL261 cells are 
more applicable for robust and reliable in vitro studies and can be used in in vivo 
models with the certain restrictions.  The subcutaneous (s.c.) route of tumor 
transplantation does not mimick the physiological appearance of gliomas, 
however, a direct comparison between MOCK-infected and MVMp-infected 
cells, which are injected s.c., is still feasible and allows to test specific 
experimental parameters, such as innate and adoptive immune cells activation.  
Due to the oncolytic activity of PV, MVMp-initiated tumor lysates are 
being generated in both tumor models. If this process takes place in vivo, lysed 
tumor particles might elicit the immune response. The first event of interaction 
between immune system and tumor cell lysates is antigen processing and 
presentation by APC, such as DCs or microglia in CNS.  
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4.2. Activation of dendritic cells and microglia induced by MVMp. 
 
We have clearly shown that both tumor cell lines (melanoma B78/H1 and 
glioma GL261) are permissive for MVMp infection. There are some strong 
differences between two tumor cell lines. The main difference is the sensitivity 
to the oncolytic activity of PV MVMp leading to apoptosis. We initially 
hypothesized that oncolysis of the tumor cells would initiate a tumor specific 
immune response and commenced on a detailed study in the generation of a 
specific immune response mediated by MVMp. It is well established that 
activated dendritic cells (DCs) provide the first line of defense in tumor cell 
recognition. It is also known, that there are two main subsets of DCs – the 
myeloid DCs and the lymphoid DCs. Both of these populations can be 
discriminated according to their phenotype (expressing specific cell surface 
receptors) and their functions. Myeloid DCs express the CD11c+CD11b+CD8- 
cell surface receptor combination and lymphoid DCs are CD11c+CD11bintCD8+. 
These two DC subsets have different antigen-presenting capacities. Whereas 
myeloid DCs initiate Th1 immune responses, lymphoid DCs regulate Th2 
responses (Georgelas A., Schibler K. 2000). Whether MVMp infection and/or 
MVMp-mediated tumor cell lysates are responsible for the activation of DCs 
mediated specifically through either one of these populations, two basic 
approaches were established to generate either myeloid or lymphoid DCs. 
 
 4.2.1. Generation of dendritic cells. 
 
The first approach is referred to as in vitro hematopoietic stem cell (HSC) 
-derived DCs and the other as in vivo generated DCs of either the myeloid or 
lymphoid phenotype. In vitro HSC-derived DCs were obtained using highly 
purified HSC from bone marrow (BM) cells of C57/Bl6 mice that were treated 
for 5 days with 5-fluorouracil (5FU). A single injection of the pyrimidine analog 
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5FU kills cycling hematopoietic cells, bringing the spared quiescent HSCs into 
cycle to repopulate the depleted bone marrow (Harrison and Lerner 1991; 
Randall and Weissman 1997). HSCs are cells isolated from BM which have self 
renewing potential and are omnipotent (H. Nakauchi, 1998). HSCs are defined 
through a combination of specific cell surface receptors namely c-kit (CD117) 
and Sca-1 and are negative for antigens of differentiated cells CD2, CD3, CD4, 
CD5, CD8, NK1.1, B220, TER-119, Gr-1 (Lin− cells) (W.H.B.M. Levering, et 
al., 2004). Negative selection for and sorting of Lin-/c-kit+/Sca-1+ BM cells was 
performed (Fig.7.). HSCs were differentiated into either myeloid or lymphoid 
DCs using specific cytokine cocktails (SCF (100ng/mL), GM-CSF (20ng/mL) 
for myeloid DCs, and Flt3L (200ng/mL) or combination of GM-CSF and Flt3L 
for lymphoid DCs) for 9 days.  
These cells were further assayed for their cell surface marker profile 
indicative of the specific DCs-subpopulation (data not shown). A 200-fold 
increase in absolute cell number was achieved for cells differentiated into the 
myeloid DC phenotype (CD11c+CD11b+CD8-) and a 30-50-fold increase was 
obtained for the lymphoid DCs (CD11c+CD11bintCD8+).  
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 77
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7. Generation of DC progenitor populations prior culture with cytokine 
cocktail. A. Selection of cells by size prior depletion (blue gate shows live cells (PI 
negative)). B. Selection of cells by granularity prior depletion (blue gate shows homogeneous 
size and granularity of cells). C. Lin- cells before depletion. D. Lin- cells after depletion. E. 
HSC before depletion (red gate) – 0.05%. E. HSC after depletion (red gate) – enriched to 
68%. 
 
Ex vivo generated DCs were obtained using a tumor cell model described 
by G. Dranoff (Dranoff G. 1993). Myeloid DCs as well as lymphoid DCs were 
generated using stably transfected B16F10 melanoma cells expressing either 
GM-CSF or Flt3L which were subcutaneously injected into C57/Bl6 mice. The 
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injected mice developed readily visible tumor burden and at the same time DCs 
accumulated in the spleen and lymph nodes of the mice. Myeloid DCs 
accumulated preferentially in the spleen of the B16F10/GM-CSF injected mice 
whereas lymphoid DCs massively infiltrated in the lymph nodes of the 
B16F10/Flt3L injected mice, respectively. DCs were isolated and enriched from 
mice injected with either one of the stably transfected melanoma cell lines and 
assayed for their surface marker profile (data not shown). Myeloid DCs revealed 
the CD11c+CD11b+CD8- cell surface receptor phenotype and lymphoid DCs 
expressed the markers CD11c+CD11bintCD8+. The purity of myeloid or 
lymphoid subpopulations was greater than 95%. These two different subsets of 
DCs were used in further assays to evaluate the MVMp-mediated activation of 
DCs cells. 
 
4.2.2. MVMp-mediated GL261 tumor lysates activate DCs. 
   
Since we had highly proliferative populations of cells upon DCs 
differentiation, an additional experimental parameter to establish was the level 
of viral replication in the various DCs populations. This parameter is essential 
for further clinical applications of PV as a potent oncolytic agent. It is known, 
that PV replicates preferentially in cells undergoing S phase and that replication 
of virus in DCs would be detrimental if the virus would also actually kill the 
DCs. Southern blot analysis was performed on highly enriched DC 
subpopulations infected with MVMp.  
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Fig.8. Southern blotting analysis of viral DNA intermediates. Mieloyd DCs, 
generated ex vivo and glioma GL261 cells (positive control) were infected with two different 
MOIs (10, 100) of MVMp. Cells were harvested at the indicated time points (6hrs and 48hrs 
p.i.) and processed for the analysis of virus replication. mRF, monomer replicative form; dRF, 
dimer replicative form; ssDNA, single-stranded genomic DNA.  
 
Viral input as well as viral replication was assayed at specific time points 
with different MOIs. Viral entry into the cells was observed, however, viral  
replication could not be detected (Fig. 8). The successful establishment of the 
experimental conditions to generate DCs as well as the deficiency of MVMp PV 
to replicate in DCs allows for a suitable experimental approach to further 
analyze the mechanisms of DC activation. The fact, that MVMp can infect DCs, 
although it does not replicate in these cells, could point that virus potentially 
initates other signaling pathways to induce cytokine production and further 
activation of DCs.   
 
Co-culture assay systems were established using PV-induced tumor cell 
lysates stimulating the different DC subpopulations to assess the potential of 
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initiating an innate as well as an adaptive immune response. Induction of an 
innate immune response can be monitored through the activation status of DCs 
via the release of proinflammatory cytokines, expression of activation markers 
and TLRs. The generation of a specific immune response can be verified by the 
release of IFNg from T cells in response to tumor cells in vivo and in vitro. 
In detail, DCs were employed in co-culture assays using B78/H1 or 
GL261 MVMp-induced tumor cell lysates. Forty-eight hour co-culture assays 
were performed, subsequently assaying the DC subpopulations for the 
expression of specific cell surface markers (CD80, CD86, CD40) and the release 
of proinflammatory cytokines (TNF, IL-6) indicating activation. Since the 
percent of CD80-, CD86-, CD40-positive DCs was quite high (80-98%) even 
without additional activation (Table 2), the mean fluorescence intensity (MFI) 
was measured for all of the activation markers. Such high percent of CD80-, 
CD86-, CD40-posivite DCs was observed since DCs were generated in tumor-
bearing mice (B16F10/GM-SCF or B16F10/FLT3L).  
Thorough analysis of the expression levels of these activation markers 
revealed a significant increase in the MFI of CD80, CD86, CD40 on the myeloid 
and lymphoid DCs co-cultured with MVMp-induced GL261 tumor cell lysates, 
whereas myeloid and lymphoid DCs did not depict this increase in activation 
markers after co-culture with the B78/H1 tumor cell lysates. The induction was 
specific since the appropriate control samples did not reveal any noteworthy 
increase in the above-mentioned activation markers (Table 2, Table 3). 
It was not clear why infected B78/H1 melanoma cells failed to stimulate 
DCs, although one possibility could have been the outgrowth of virus resistant 
melanoma cells within the short time window of four days. This would lead to 
an inefficient generation of tumor cell lysate able to activate DCs. On the other 
hand, B78/H1 cells infected with high MOI should induce significant cells lysis 
and viral replication at 72h post infection. Therefore, additional studies were 
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carried out to assess whether under these conditions considerable DC activation 
could be detected. 
Co-culture assays of naïve and mature DCs with MVMp were performed 
to investigate whether high amount of virus alone can either stimulate DCs or 
induce a suppressive effect. No effect on naïve DCs was observed. Since MVMp 
did not induce the expression of activation markers (CD80, CD86, CD40) on the 
naïve myeloid and lymphoid DCs upon the infection (Table 2, Table 3). 
However, MVMp induces increased expression of CD80, CD86 and CD40 
markers on the mature myeloid (Table 2) and lymphoid DCs (maturation with 
LPS treatment (Table 3).                                    .                     
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Table.2. Expression of activation markers on myeloid DCs upon co-culture with MVMp. %-percent of positive cells, MFI – mean 
fluorescent intensity of positive cells. * - p<0.05 (t-test) compared to DCs alone. ND- not defined.  
 CD80 CD86 CD40 
 % MFI % MFI % MFI 
DCs alone 93,2±3,6 824±241,3 75,1±12,0 860±416,8 58,5±16,1 182±63,0 
DCs+B78/H1 
MOCK  
85,7±4,1 954±106,1 44,5±1,9* 558±115,1 ND ND 
DCs+B78/H1 
infected  
90,4±2,4 1163±215,7 45,8±0,5* 561±0,5 ND ND 
DCs+B78/H1 F/T 
lysates 
88,1±10,3 988±37,0 65,5±20,9 1426±1293,2 ND ND 
DCs+GL261 
MOCK  
91,2±10,5 992±40,1 67,3±10,3 986±195,3 35,0±35,9 86±23,0 
DCs+GL261 
infected  
94,7±5,4 1513±142,4* 87,0±4,3* 1321±122,4* 52,0±47,7 109±25,6 
DCs+GL261 F/T 
lysates 
92,7±8,9 962±154,3 86,7±2,6* 1123±152,3 50,0±23,4 118±9,4 
DCs+MVMp 83,4±18,9 769±283,2 86,7±8,9 714±288,9 51,0±13,8 219±4,8 
DCs+LPS 95,2±4,6 2152±371,2* 70,0±12,6 1748±588,5* 73,7±20,6* 276±134,5 
DCs+LPS+MVMp 93,3±7,3 2123±361,2* 77,8±11,8 2139±269,3* 75,8±17,4 371±111,6 
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 CD80 CD86 CD40 
 % MFI % MFI % MFI 
DCs alone 56,5±29,1 516±143,3 60,7±23,0 924±608,3 20,4±14,9 78±68,0 
DCs+B78/H1 
MOCK  
71,0±26,5 959±151,9* 81,9±16,2 556±350,8 ND ND 
DCs+B78/H1 
infected  
66,6±12,0 876±22,2* 68,7±3,8 452±208,1 ND ND 
DCs+B78/H1 F/T 
lysates 
59,0±24,5 817±283,1 90,8±4,1* 416±193,6 ND ND 
DCs+GL261 
MOCK  
78,2±3,4 1034±101,6* 70,8±5,9 1026±134,5 50,5±11,1 49±2,0 
DCs+GL261 
infected  
88,7±3,2* 1547±266,8* 85,7±2,6* 1682±194,4* 78,0±13,8* 80±23,6 
DCs+GL261 F/T 
lysates 
87,3±3,3* 1092±135,0* 62,9±3,7 1387±379,0 75,8±6,4* 54±3,5 
DCs+MVMp 51,4±36,3 522±114,4 73,4±19,3 1167±987,2 26,5±14,9 124±6,7 
DCs+LPS 89,6±5,9* 2632±1113,1* 90,6±6,4* 1874±847,1 77,4±9,0* 224±52,1 
DCs+LPS+MVMp 89,8±8,8* 3499±1185,7* 86,9±5,3* 2446±1020,1 78,8±10,7* 248±73,8 
 
Table. 3. Expression of activation markers on lymphoid DCs upon co-culture with MVMp. %-percent of positive cells, MFI – mean 
fluorescent intensity of positive cells. * - p<0.05 (t-test) compared to DCs alone. ND- not defined.  
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Release of proinflammytory cytokines TNF, IL-6 is an additional 
indicator of DC activation. An increase of proinflammatory cytokine (TNF, IL-
6) release was observed in culture supernatants from lymphoid DCs co-cultured 
with MVMp-mediated glioma GL261 lysates (Fig. 9). This was indicative for 
the activation of DCs and provided an additional signal for DC maturation. The 
supernatants from myeloid DCs co-cultured with MVMp-infected glioma 
GL261 cells did not show significant differences compared to unstimulated 
myeloid DCs.  
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Fig.9. Release of proinflammatory cytokines from myeloid and lymphoid 
dendritic cells. DCs were cultured alone, or in the presence of MOCK-infected glioma 
GL261, MVMp-infected glioma GL261 cells (MOI 10), freeze/thaw lysates from glioma 
GL261cells, or were infected with MVMp (MOI 100). Forty-eight hour co-culture assays 
were performed, supernatants were collected and the absolute amount of cytokines produced 
was measured by ELISA. Data represent the mean of three independent experiments. 
 
Concomitantly, MVMp does not stimulate the release of proinflammatory 
cytokines (TNF, IL-6) from naive myeloid and lymphoid DCs (Fig. 9). 
However, MVMp significantly increases the release of these proinflammatory 
cytokines from mature myeloid and lymphoid DCs (data not shown).  
Since, as mentioned above, MVMp alone was also inefficient in 
stimulating DCs, we tentatively conclude that the release of apoptotic bodies (or 
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other components) from glioma GL261 cells in comparison to B78/H1 
melanoma upon MVMp infection may stimulate DCs. 
 
4.2.3. Microglia activation induced by MVMp-mediated glioma 
GL261 lysates. 
 
Under physiological conditions gliomas in the CNS interact within the 
microenvironment of a specialized form of antigen presenting cells namely the 
microglia. These cells resemble certain features of the DCs used in the above 
studies but might, however, at the same time provide a specialized signaling 
environment. Microglia have antigen-presenting and phagocytic capacities, they 
can secret cytokines and chemokines (Aloisi F. 2001). 
In order to examine the activation potential of microglia a similar co-
culture assay as above was performed with MVMp-infected GL261 cells. It was 
previously shown that MVMp could infect but not replicate in microglia 
(Abschuetz A. et. al. 2006). It is well established that the expression levels of 
activation markers on microglia is lower than on other APCs, for instance DCs. 
In accordance with these findings, only a slight upregulation of CD86, CD80 
and MHC class I surface markers compared to untreated microglia was observed 
upon the co-culture conditions with MVMp-induced glioma GL261 cell lysates 
(Fig. 10). The positive control (microglia stimulated with LPS (5μg/mL)/IFNg 
(30ng/mL) showed an up-regulation of the all markers (CD80, CD86, CD40, 
MHC class II, MHC class I), and the negative controls (microglia incubated with 
MOCK-treated glioma GL261 cells, and microglia incubated with freeze-thaw 
lysates from the glioma GL261 cells) showed no significant up-regulation of the 
same markers (data not shown for CD40, MHC class II).  
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Fig.10. Microglia activation profile after 48h co-culture assay with MVMp-
infected glioma GL261 cells.  A. Microglia alone. B. Microglia co-cultured for 48hrs with 
MVMp-infected (MOI 10) glioma GL261 cells. C. Microglia activated by LPS 
(5μg/mL)/IFNγ (30ng/mL). Green histograms represent specific staining with antibodies 
against CD80, CD86, MHC class I, respectively. Red histograms represent the appropriate 
isotype controls. One representative experiment out of three is shown.  
 
Since proinflammatory cytokines play a crucial role in microglia-tumor 
cell interaction, the levels of TNF and IL-6 produced were measured. Microglia 
co-cultured with MVMp-infected glioma GL261, showed a significant increase 
in the release of TNF and IL-6 (Fig.11). As a positive control, microglia were 
stimulated with LPS and IFNg and showed the highest level of proinflammatory 
cytokines released (more than 5ng/ml) (data not shown).  
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The data correspond with a similar finding, that microglia express 
increased amounts of IL-1, IFNβ and IL-6 upon co-culture with MVMp-infected 
GL261 cells (H.Hong, unpublished data). 
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Fig.11. Release of TNF and IL-6 upon microglia activation after 48hrs. Microglia 
were cultured alone, or in the presence of MOCK-infected glioma GL261, MVMp-infected 
glioma GL261 cells (MOI 10), freeze/thaw lysates from glioma GL261cells infected with 
MVMp (MOI 100), respectively. Forty-eight hour co-culture assays were performed, 
supernatants were collected and the absolute amount of cytokines produced was measured by 
ELISA. Data represent the mean of three independent experiments. 
 
Taken together, these data showed the potency of MVMp-mediated 
glioma GL261 lysates to stimulate the activation of microglia, which represent 
the physiological interacting cellular environment for gliomas. This stimulation 
might lead to increased phagocytosis of already lysed glioma GL261 and 
provide an additional stimulus for tumor antigen presentation by microglia. 
Since this stimulation leads to the production of proinflammatory cytokines, a 
crucial signaling pathway initiating the induction of transcription of the genes 
for these cytokines is the NFκB signaling pathway. We therefore investigated 
whether NFkB signaling is induced and specifically whether the signal induction 
is mediated through TLR receptor signaling. 
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4.2.4. GL261 tumor cell lysates induce NFκB signaling via TLR3 in 
vitro in DCs 
 
DCs are known to express a broad pattern of TLRs which efficiently bind 
pathogen-associated–molecular-patterns (PAMP) and initiate an activating 
signaling cascade. One hallmark of this activation is the cytoplasmic to nuclear 
translocation of NFkB.  
In view of the stimulatory capacity of MVMp-infected GL261 cell lysates 
towards DCs, it was hypothesized that DC activation is mediated through TLR 
signaling and would lead to specific upregulation of certain TLRs. Since the 
GL261 glioma cells express several TLRs the analysis of DCs derived from the 
coculture system was not feasible (H. Hong, unpublished data). The TLR 
expression profile was examined on the mRNA level in DCs infected with 
MVMp alone. Expression of TLR2, 3, 4 and 9 on myeloid DCs and TLR2, 6 and 
9 on lymphoid DCs was increased upon virus infection (data not shown). The 
importance of this finding is still unclear since at the same time no increased 
expression of activation markers was detectable (Table 2, Table 3). Also, it is 
known, that the TLRs activation and upregulation of their expression might lead 
to upregulation of activation markers on different DCs (El Shikh, M.E., et. al. 
2007; Hellman, P. et. al. 2007).  
Unfortunately, the limited amount of DCs in these experiments did not 
allow for analysis of TLR signal transduction in cellular extracts from these 
cells. Therefore, heterologous expression of different TLRs was established in a 
tissue culture cell line HEK293 to study activation following contact with 
MVMp – infected glioma or melanoma tumor cells or with virus alone as a 
control. The main candidates selected were TLR2, TLR3, TLR4, TLR6, TLR9, 
since their mRNA expression was up-regulated on myeloid and lymphoid DCs 
upon MVMp infection. 
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Single candidate TLR expressing stable cell lines were generated to 
dissect the impact of specific receptors on downstream signaling pathways and 
the induction of proinflammatory cytokines. Specific TLR signaling upon 
stimulation with PV MVMp-induced tumor cell lysates was measured in 
cotransfection assays using a NF-κB luciferase reporter gene system. An in vitro 
culture assay system using stably transfected HEK cells allows for a much more 
precise analysis and will reflect the physiological situation within the DCs on a 
single receptor based analysis. 
The data showed, that TLR2 and 6 (Fig. 12), as well as TLR4, 
TL4/MD2/CD14 and TLR9 (data not shown) are not involved in the activation 
of NFB upon co-culture with MVMp–induced tumor cell lysates (melanoma 
B78/H1 and glioma GL261). However, untreated tumor cells showed significant 
influence on the activation of either TLR2 or TLR2/TLR6. Probably, some 
cellular proteins could directly activate these TLRs. 
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Fig. 12. Activation of NFB signalling through TLRs. A. TLR2 B. TLR2/TLR6 C. 
TLR3 D. TLR3 in the absence of positive Poly I:C control. HEK293T expressing TLRs and 
transfected with NFκB-driven firefly luciferase reporter gene were seeded in 6 well plates at 
2x105 cells per well and stimulated for 6 hrs with MOCK infected melanoma B78/H1 cells 
(B78 MOCK); MVMp infected (MOI 100) melanoma B78/H1 cells (B78 inf); freeze/thaw 
lysates from non-infected melanoma B78/H1 cells (B78 F/T); MOCK infected glioma GL261 
cells (GL261 MOCK); MVMp infected (MOI 10) glioma GL261 cells (GL261 inf); 
freeze/thaw lysates from non-infected glioma GL261 cells (GL261 F/T); MVMp MOI 100 
(MVM). LPS (5µg/ml); TNF (10ng/ml), Poly I:C (10µg/ml), and Peptidoglycan from 
Staphylococcus aureus (10µg/ml) served as positive controls. Activation of NFκB was 
assessed by measuring firefly luciferase activity in cell lysates. Values shown represent the 
fold induction compared to control vector devoid of NFκB binding sites (control vector 
contains a minimal promoter). The results of one out of three similar independent experiments 
are shown.  
 
TLR3 is involved in the DC activation by MVMp-mediated tumor cell 
lysates. Only MVMp-mediated tumor cell lysates showed a significant effect on 
A. 
C. 
B. 
D. 
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the activation of TLR3 compared to MOCK-infected cells and freeze/thaw 
lysates (Fig. 12). It is possible that dsRNA, which forms during the replicative 
cycle of virus, acts as a ligand for TLR3 in this case. However, MVMp alone 
does not affect the TLR3-mediated intracellular signaling.   
 
Taken together, the in vitro results demonstrate significant activation of 
DCs and microglia upon co-culture with MVMp infected GL261 glioma cells.  
TLR3 was dissected as an important receptor initiating NF-kB signaling leading 
to the induction of proinflammatiry cytokines. There is no specific activation 
observed in case of co-culture of these APC with MVMp-infected melanoma 
B78/H1.  
 These data gave a background for subsequent in vivo experiments. 
Significant activation of DCs and microglia might lead to a tumorspecific 
adaptive immune response, which is characterized by T-cell recruitment and 
functional activity at the site of the tumor.   
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4.3. Stimulation of anti-tumor specific immune response in vivo 
mediated by MVMp.  
 
 We were able to show a significant increase of activation markers in DCs 
upon co-culture with MVMp-infected glioma GL261 cells and the induction of 
proinflammatory cytokines. Therefore, it is essential to assess the physiological 
relevance of the in vitro observations in an in vivo model.  
We demonstrated that brain derived microglia, myeloid as well as 
lymphoid DCs displayed a comparable activation pattern of costimulatory 
surface markers. A study was initiated to monitor in vivo T-cell activation 
following s.c. administration of glioma GL261 cells into C57BL/6 mice, since 
this route is known to result in massive T-cell infiltration into the tumor tissue 
whereas too few T-cells would be recovered from the brain after intracranial 
application of glioma cell.  
An in vivo model utilizing s.c. injection of GL261 glioma cells into 
C57BL/6 was established by Marta Enderlin, PhD (unpublished data) and 
modified to optimally assess innate as well as adaptive immune responses. The 
s.c. injection of MOCK-infected 1x106 cells led to the moderate tumor 
development.  
In our experiment, glioma GL261 cells were either MOCK infected, or 
infected with MVMp at various MOIs (MOI 0.3, 3, 30). The cells were 
subsequently injected into recipient mice 4 hours after infection (Tab. 4). This 
exerperimental approach allows to monitor not only a direct oncolytic effect, but 
also the activation of cells of the immune system. The same experimental 
approach was used for RAG2-/- mice (Tab. 4).  
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Treatment C57BL/6 RAG2-/- 
MOCK-infected glioma 
GL261 cells 
16 16 
MVMp-infected glioma 
GL261 cells (MOI 0.3) 
16 16 
MVMp-infected glioma 
GL261 cells (MOI 3) 
16 16 
MVMp-infected glioma 
GL261 cells (MOI 30) 
16 16 
       
Table 4. Experimental setup for in vivo experiment. Number of mice injected per 
group is shown.  
 
Mutations in the recombination-activating gene 2 (RAG2) result in an 
almost complete arrest of lymphocyte development due to the failure to properly 
rearrange the antigen receptor genes. Mice with genetically engineered 
mutations in the recombination-activating gene completely lack both mature T-
cells and B-cells (Shinkai Y., et al. 1992).  Therefore, it is possible to investigate 
also the impact of the innate immune response alone in these mice, but not 
acquired immune response. 
 
4.3.1. MVMp affects tumor growth in immunocompetent mice.  
 
The GL261 glioma cells were infected in vitro with MVMp at MOI 0.3, 3, 
30 or left uninfected. The cells, 4hrs p.i., were injected s.c. into 
immunocompetent C57/BL6J mice or into RAG2-/- mice. First signs of tumor 
development were observed at day 5 post injection (p.i.) in B6 and RAG2 -/- 
mice. After that the tumor size was measured at day 9, 14, 18, and 21 p.i.. The 
immunocompetent B6 mice that were injected with glioma GL261 cells at a high 
infection dose (MOI 3 or MOI 30) did not develop any tumor at all (Tab. 5). 
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Almost all of the RAG2-/- immunodeficient mice had measureable tumors 
developed by day 21 p.i. All of the RAG2-/- animals injected with MVMp-
infected GL261 cells eventually developed tumors by day 35 p.i. In addition, the 
RAG2-/- showed tumor onset earlier and tumor growth at a faster rate compared 
to the C57BL/6 mice (Tab. 5). Furthermore, the C57BL/6 mice injected with 
GL261 cells infected at MOI 3 or MOI 30, revealed long-term survival 
monitored over 6 months with no obvious tumor burden developing (data not 
shown).  
  
Days p.i. Group s.c. injection 
of MOCK-
infected 
glioma 
GL261 cells  
s.c. injection 
of MVMp-
infected 
(MOI 0.3) 
glioma 
GL261 cells  
s.c. injection 
of MVMp-
infected 
(MOI 3) 
glioma 
GL261 cells  
s.c. injection 
of MVMp-
infected 
(MOI 30) 
glioma 
GL261 cells  
C57/BL6 90% 37.5% 0% 0% 9  
RAG2-/- 100% 57.1% 0% 0% 
C57/BL6 90% 30.8% 0% 0% 14  
RAG-/- 100% 100% 100% 77,8% 
C57/BL6 90% 38.5% 0% 0% 18  
RAG-/- 100% 100% 100% 60% 
C57/BL6 83% 61.5% 0% 0% 21  
RAG-/- 100% 100% 100% 80% 
 
Table.5. Percent of mice developing tumors in each group. The total number of 
animals per group was set to 100%, and mice, which developed tumors were calculated as a 
positive percentage.  
 
Tumors, which developed in the RAG2-/- recipient mice, showed at least a 
10-fold increase in size in comparison to the immunocompetent C57BL/6 mice 
(Fig. 14). This was observed at all multiplicities of infection used. These results 
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point to the involvement of a specific immune response (most likely the T cell 
branch of the immune system) mediating the rejection of MVMp-infected 
tumors.  
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Fig.14. Tumor growth following subcutaneous injection of glioma GL261 cells 
infected with MVMp. One million glioma GL261 cells, infected 4hrs prior with MVMp 
(MOI 0.3, 3, 30) or left uninfected, were injected s.c. into the right flank of the recipients. 
Tumor volumes were measured at the indicated time points in A. C57BL/6 recipient mice B. 
RAG2-/- recipient mice. 
 
Especially within the RAG2-/- recipients the MVMp-infected GL261 cells 
were not rejected and developed into sizeable tumors. We assessed the 
sensitivity of glioma GL261 cells, which escaped from rejection, to MVMp-
reinfection in vitro. For this purpose tumors were isolated from the recipient 
mice and single tumor cell suspensions were reinfected in vitro with MVMp at 
MOI 10. Furthermore, tumor cell suspensions were cultured for 30 days under 
normal tissue culture conditions in the absence of viral infection. Subsequently, 
the sensitivity of these cells to MVMp infection was verified. As shown in 
Figure 15, neither any of the primary isolated GL261 tumor cells nor the cells 
cultured for prolonged periods of time showed a significant response to the 
cytotoxic effect of MVMp, which shows heterogeneity of glioma GL261 cells.  
A  B  
Results 
 
 96
     
0
20
40
60
80
100
120
140
160
BL6
MOCK
BL6 MOI
0,3
RAG
MOCK
RAG MOI
0,3
RAG MOI
3
RAG MOI
30
GL261
tumor derived GL261
liv
e 
ce
lls
, %
after isolation 
after 30d in culture
 
Fig.15. Cytotoxic effect of MVMp on tumor isolated GL261 cells. Tumor isolated 
GL261 cells (2x103) were infected with MVMp at MOI 10. Cytotoxic effect of MVMp was 
measured with the MTT assay after 72h. Data represent the mean of two independent 
experiments, 8 different tumors samples in each group. GL261 represents the sensitivity of 
glioma in vitro. 
 
This result would support the initial hypothesis that virus induced tumor 
cell lysates elicit a tumor-virus specific immune response in vivo leading to the 
rejection of the tumor cells. The response is not solely mediated through natural 
killer cells, macrophages or DCs since these cell populations are present in 
RAG2-/- mice and the tumor cells were not rejected in these recipient mice. The 
in vivo experiments reveal that the adaptive immune response is initiated by 
MVMp-induced tumor cell lysates, since MOCK-infected tumor cells in 
immunocompetent C57BL/6 mice formed tumors. Most likely, some 
intracellular components are being recognized through the immune system that 
will call for the adaptive immune response and the rejection process. 
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4.3.2. Hematopoietic cell distribution does not change within the 
spleen upon tumor induction of MVMp-infected glioma GL261 cells. 
 
To assess possible changes in the immune cell compartment of the spleen 
after s.c. injection of MVMp-infected and non-infected glioma GL261 cells, 
populations of cells in spleen were analyzed by flow cytometry. The cells 
populations were assayed at day 7 and day 14 post injection. No significant 
differences were observed in the relative percentages of T, B, and NK cells as 
well as DCs, nor was the absolute cell number of any of these populations 
significantly affected. Additionally, the tumor infiltrating immune cell 
populations were analysed in immunocompetent mice. The massive leukocytes 
infiltration was also observed in MOCK-infected tumors.  No significant 
differences were observed in the relative percentages or absolute numbers of 
imuune cell populations in MVMp-infected tumors compared to MOCK-
infected tumors (data not shown). 
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Day p.i. Group DCs, % B cells 
(%) 
T cells 
(%) 
NK 
(%) 
CD4 
(%) 
CD8 
(%) 
Absolute Cell 
Number 
(x106) 
MOCK 
(n=7) 
0,74±0,38 48,9±3,57 32,59±6,02 3,65±0,59 21,55±6,65 15,19±2,85 67,5±32,32 7days 
MOI 3 
(n=8) 
0,73±0,52 44,1±4,97 30,04±4,71 3,69±0,83 17,09±2,79 13,73±2,07 53,13±20,81 
MOCK 
(n=9) 
1,08±0,29 44,69±6,53 22,10±8,63 2,49±0,65 15,11±5,43 11,59±2,84 49,28±17,65  14days 
MOI 3 
(n=9) 
1,14±0,29 37,41±14,02 20,14±11,43 2,86±0,39 11,27±7,05 9,29±5,10 62,83±27,24 
 
Table. 4. Ex vivo analysis of splenocyte subpopulations after s.c. injection of MVMp-infected and non-infected glioma GL261 cells. 
One million glioma GL261 cells were injected s.c. into the right flank of recipient mice. Four hours prior cells were infected with MVMp at MOI 3 
or left uninfected. The immune cell populations were stained with specific mAbs and measured by flow cytometry at day 7 and day 14 p.i. 
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 Since we did not observe any changes within the overall composition of the 
subpopulations analyzed in the spleen, it is possible that only a minute fraction of 
circulating CD8 and CD4 cells are in the spleen. However, upon restimulation those 
cells could mount a substantial IFNγ response. 
In order to verify the specific immune response towards tumor cells, the release 
of IFN from splenocytes was measured. It is known, that specific cytotoxic T-cells 
release IFNγ upon stimulation. We assessed the potential of a specific immune 
response towards the GL261 tumor cells by monitoring IFNγ release of total 
splenocytes isolated from tumor bearing animals. The splenocytes were isolated 14 
days post injection from mice bearing GL216 tumors. Two main groups of animals 
were assessed. One group, which was injected with MOCK-infected cells, and a 
second group, which was infected with MVMp at MOI 3, were used for the ex vivo 
analysis of IFNγ production. Splenocytes were incubated in presence of non-infected 
glioma GL261 cells, and the release of IFNγ was measured by ELISPOT.   
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Fig.16. Release of IFN from splenocytes in response to uninfected glioma GL261 cells. 
Splenocytes (1x106) were specifically restimulated in vitro with irradiated glioma GL261 cells 
(5x105). The release of IFN was assessed as the number of cells-producing IFN per 1x106 of 
splenocytes.  
Figure 16 depicts the median values of IFNγ released. The cells isolated from 
spleens of mice, which were injected with MVM-infected glioma cells, is 
significantly higher compared to the cells derived from mice, which were injected 
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with MOCK-infected glioma cells. This result is indicative of a specific immune 
response in animals, which were injected with MVM-treated tumor cells.   
 
4.3.3. The T-cell memory response plays a crucial role against tumor 
development.   
In order to verify, if surviving animals developed immunity against tumor 
cells, a challenge experiment was performed. There were 3 groups of mice, which 
previously received s.c. glioma GL261 cells infected with MVMp at MOI 0.3, 3 and 
MOI 30 (8 animals per group). None of the animals injected with glioma GL261 cells 
infected with MVMp at MOI 3 and MOI 30 developed tumors at day 35p.i. (0 out of 
8 per group). At the same time point, some mice, which were injected with glioma 
GL261 cells infected with MVMp at MOI 0.3 developed tumors (5 out of 8).  All 
tumor-free animals from these groups were challenged with 1x106 GL261 tumor cells 
60 days post primary challenge. After the challenge all mice survived and did not 
develop any visible tumors, with a survival range of 5 month after challenge (Fig. 
17).  
 
Fig. 17. Survival rate of C57BL/6 mice after rechallenge. C57BL/6 mice were injected 
s.c. with 1x106 glioma GL261 cells, either MOCK-infected or MVMp-infected at MOI 0.3, 3 or 30. 
Mice were rechallenged with MOCK-infected glioma GL261 tumor cells (1x106 cells/mouse) at 
day 60. All mice survived after second challenge and non of them developed tumor at day 230 . 
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This experiment demonstrated that a specific memory immune response 
mediated by MVMp-induced tumor cell lysates plays a crucial role in rejection of 
tumor. Most likely the rejection reaction is mediated by memory T cells, since 
complete rejection of the tumor cells was observed in a secondary challenge 
experiment took place at 60-230 days after the first tumor challenge.  
 
 
Taken together, the in vivo results demonstrate the activation of a T cell 
response upon s.c. injection of MVMp-infected glioma GL261 cells in 
immunocompetent C57BL/6 mice. This response is characterized by specific T-cell 
activation and T-cell memory formation towards tumor cells. Thus, we could 
conclude, that MVMp mediated a specific anti-tumor immune response against 
glioma GL261 in immunocompetent mice. 
Discussion 
  
 
 
5. Discussion. 
 
It was shown that due to the oncolytic activity of PV MVMp, formation of 
tumor lysates is possible in both of the described tumor models (glioma GL261 and 
melanoma B78/H1). Since the lysed tumor particles might elicit an immune response 
in vivo, the activation of APC, such as DCs or microglia in CNS, was investigated. 
The in vitro results demonstrated significant activation of DCs and microglia upon 
co-culture with MVMp infected GL261 glioma cells. There was no specific 
activation observed in case of co-culture of these APC with MVMp-infected 
melanoma B78/H1. These data gave a background for further in vivo experiments, 
which demonstrated the activation of T cell response upon s.c. injection of MVMp-
infected glioma GL261 cells in immunocompetent C57BL/6 mice. This response is 
characterized by specific T-cell activation and T-cell memory formation towards 
tumor cells. Thus, we could conclude, that MVMp mediated a specific anti-tumor 
immune response against glioma GL261 in immunocompetent mice. 
 
5.1. MVMp lyse glioma GL261 cells with high efficiency.  
 
Autonomous rodent PV and recombinant derivatives provide promising and 
novel approaches for cancer treatment (Cornelis J. 2004.). However, the sensitivity of 
tumors towards PVs varies greatly and depends on tumor origin and the proliferative 
capacity of cells (Herrero et al. 2004). The analysis of genomic viral DNA in MVMp-
infected glioma GL261 and melanoma B78/H1 cells clearly indicated that PV 
infected and replicated efficiently in both tumor cell lines. However, the two cell 
lines revealed a striking difference in their sensitivity to viral infection. Two to three 
days post infection it was observed that most of the glioma GL261 cells had rounded 
up, lost their adherent phenotype and started to die. Experimentally, cell cycle arrest 
and lysis of the glioma cells were assessed (data not shown) indicating that PV 
MVMp progressed through its life cycle within these cells exerting an 
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oncosuppressive effect. In addition, cell viability methods were performed to analyse 
the cell proliferation rate (cell growth) of glioma GL261 and melanoma B78/H1 cells 
upon MVMp infection.  
These combined data strongly indicated that the glioma cell line was indeed 
very sensitive and permissive to PV infection. The melanoma B78/H1 showed less 
sensitivity to the oncolytic effect of MVMp. The growth of the melanoma cell line 
might be limited only partially by the cytotoxic effect of MVMp PV, and non-
infected resistant cells continued to proliferate.   
It seems that MVMp infection activates different death pathways in different 
cell lines. We had strong indications for the autophagy process leading to the 
induction of the death pathway in B78/H1 melanoma cells upon MVMp infection 
(data not shown). At the same time, caspase-3 activation in glioma GL261 upon PV 
MVMp infection pointed clearly to the apoptotic pathway of death in these cells.  
Thus, evidence was provided that the both glioma GL261 and melanoma 
B78/H1 cells are useful models to study PV MVMp as a tool in future cancer 
treatment, but both models have certain limitations. The melanoma cells B78/H1 
provide a better model for in vivo studies due to the physiological relevance of the 
route of tumor transplantation s.c. Due to the heterogeneity of the melanoma B78/H1 
cell line and due to the resistance of a subpopulation to MVMp infection, this tumor 
cell line might only be useful for in vitro and in vivo assays within very narrow 
window of time and at high MOIs.  
The glioma GL261 cells can be used in in vivo models with the certain 
limitations as well. The s.c. route of transplantation does not place the tumor cells at 
the physiological site for the glioma to develop, however, it proved very informative 
for the involvement of the innate and adaptive branches of the immune system and 
served successfully as a proof of principle model system.  
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5.2. MVMp induces activation of DCs and microglia.  
 
Originally, we had hypothesized, that MVMp-infected tumor cells would 
induce an immune response. Most likely, apoptotic bodies or cellular components are 
involved in this process. It is known, that DCs provide the first line of defense in 
tumor cell recognition. DCs are a heterogenous cell population of the haematopoietic 
lineage. Many DC subsets of different tissues have distinct cell surface receptor 
expression profiles. However, the ability to stimulate antigen specific naïve T cell 
activation and proliferation appears to be shared between these DC subsets. 
Although, the origin and lineage of many of these cells remain poorly understood, it 
was shown that lymphoid DCs are derived from common-lymphoid progenitor and 
myeloid DCs are derived from common myeloid progenitor cells. At the same time 
several studies suggest that plasmocytoid DCs develop from both lymphoid and 
myeloid sources (Shigematsu H.  et al. 2004, Karsunky H. et.al. 2003; Karsunky H. 
et. al. 2005). However, all progenitor cells initially transform into immature DCs. 
These cells are characterized by high endocytic activity and low T-cell activation 
potential. Immature DCs uptake, process and present pathogens at their cell surface 
using MHC molecules. Simultaneously, they upregulate cell-surface receptors that act 
as co-receptors in T-cell activation such as CD80, CD86, and CD40 greatly 
enhancing their ability to activate T-cells (reviewed in Mellman and Steinman, 2001).  
Depending on the co-stimulatory environment and signals, DCs can induce T 
activation, T cell anergy or tolerance (Steinman et al., 2000; Banchereau et al., 2003). 
Myeloid DCs are one of the promising tools in immunotherapy of tumors. In animal 
models and human clinical trials adoptively transferred myeloid DCs expressing 
tumor antigens mediate substantial antitumor immunity (Nestle F.O. et.al. 2001).  
 In terms to analyze whether MVMp infection and/or MVMp-mediated tumor 
cell lysates are responsible for the activation of DCs, two basic approaches were 
established to generate myeloid and lymphoid DCs. The first approach was referred 
to as in vitro hematopoietic stem cell (HSC) -derived DCs and the other as in vivo 
generated DCs of either the myeloid or lymphoid phenotype.  
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 The generation of DCs from HSC is more correlated with clinical application 
approaches, when human DCs are generated from patient monocytes upon 
stimulation with GM-CSF and IL-4. From another point of view, generation DCs in 
vivo (upon secretion of GM-CSF and FLT3L from stably transfected tumor cell lines) 
shows normal physiological activation of DCs towards foreign (tumor) antigens.  
Both approaches were used to compare the effect of tumor cell lysates on the DCs 
activation. 
As a prerequisite, it was necessary to analyse whether MVMp infected and 
replicated in DCs or not. It was shown that MVMp infected DCs, but the virus did 
not replicate in these cells. Also DCs were infected with either low or high MOI, the 
virus, even at high concentration did not replicate and it was independent from DCs 
S-phase entry. Normally DCs have low proliferative potential, unless pushed through 
a challenge. This is crucial, since the oncolytic effect of PV is not excerted within the 
cells that are essential to mount a good activation of T cells.  
 Subsequently we investigated whether MVMp alone could stimulate DCs. 
Activation of DCs was assessed on the level of expression of specific activation 
markers (CD80, CD86, CD40) by flow cytometry and on the protein level of specific 
cytokines analyzed by ELISA. Infection at high MOI of naïve or mature, LPS-
stimulated, DCs with MVMp was performed to investigate whether high MOI of the 
virus alone could either stimulate or suppress DC activation. No effect on naïve DCs 
was observed. MVMp did not stimulate the expression of the activation markers 
MHC class II, CD80, CD86 or CD40 on naïve myeloid and lymphoid DC and no 
production of TNF or IL-6 could be demonstrated. However, MVMp was able to 
increase further the enhanced expression levels of CD80 and CD40 markers on LPS-
stimulated myeloid DCs, and CD80 and CD86 on LPS-stimulated mature lymphoid 
DCs and also to enhance the release of TNF and IL-6 from mature cells. This is a 
important finding, since PV MVMp could provide an additional activation signal to 
already mature DCs, which will ultimately lead to better antigen-presenting capacities 
and further more more efficient stimulation of the T-cell response.  
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Subsequently, we investigated the activation profile of DCs upon co-culture 
with MVMp-infected tumor cells. When MVMp-infected B78/H1 melanoma cells 
were co-cultured for 48hrs with myeloid or lymphoid DCs derived from syngenic 
C57/BL6 mice, there was no increase in the expression of activation markers on DCs, 
whereas a marked increase was observed in DCs stimulated with LPS as a positive 
control. Similarly, we also failed to detect any significant release of proinflammatory 
cytokines such as TNF and IL-6 in DCs co-cultured with infected B78/H1 cells. This 
finding strongly corresponds to the observation of partial resistance of melanoma 
B78/H1 cells to PV MVMp. Since we could not observe efficient lysis of these cells, 
we did not detect any significant stimulation of DCs with the MVMp-induced 
melanoma lysates. 
The opposite effect was shown in co-culture experiments with MVMp-infected 
glioma GL261 cells. The results of these experiments clearly revealed a strong 
activation of DCs by infected GL261 cells compared with untreated DCs. Most 
likely, the DCs were activated by apoptotic bodies or specific virus-induced proteins 
in case of the infected glioma GL261 cells, since the melanoma B78/H1 cells did not 
show apoptotic features of death (no significant caspase-3 activation or DNA 
fragmentation) upon MVM infection. 
 
Given that peripheral DCs do not represent the physiological environment for 
GL261 tumor cells, additional experiments using microglia derived from newborn 
brain tissues were performed. It is known, that microglia are considered as resident 
macrophages of the brain and display antigen-presenting, phagocytic capacities, and 
are able to secret cytokines and chemokines.  
It was previously shown, that the MVMp virus, even at high concentration did 
not replicate in microglia. (Abschuetz A., 2006). PV MVMp infection of microglia 
alone did not induce a robust immune response in microglia. Current data from the 
research group of Dr. A. Régnier-Vigouroux revealed that PV infection of microglial 
cells was not sufficient to induce TNF production, nor did PV alone induce the 
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expression of iNOS and the release of NO, a first line of reaction in terms of 
activation of these cells. (Abschuetz A., 2006). Neither were glioma GL261 cells 
alone able to activate microglia efficiently. We could also show, that MOCK-infected 
glioma GL261 cells did not stimulate microglia. The direct co-culture of microglia 
with untreated and uninfected GL261 cells was not conducted, as an overgrowth of 
the tumor cells in this system was to be expected. Therefore, glioma cells were 
arrested in cell cycle to prevent further proliferation. Additonal data showed that 
microglia in co-culture with irradiated glioma GL261 cells did not reveal a different 
pattern of IL-1β expression at the RNA level compared to untreated microglia (H. 
Hong, diploma thesis, 2005). Glioma GL261 cells were also lysed by freeze/thaw 
(F/T) cycles, which led to necrotic lysis of cells. F/T lysed glioma GL261 cells did 
not induce significant secretion of TNF, nor did they have a measurable effect on IL-
6 production. This observation confirmed data in the literature, which states that F/T 
lysed tumor cells had only a poor effect on the activation of DCs in a comparable co-
culture set-up (Rad A.N. et. al. 2003). Taken together, the experimental data 
indicated that GL261 cells alone are unable to initiate a robust immune response in 
cultured microglia.  
Upon co-culture of microglia with MVMp-infected GL261 cells we detected 
release of TNF and IL-6 as well as a significant and specific upregulation of the same 
set of activation markers analyzed on myeloid and lymphoid DCs. These data 
strongly correlate with observation of H.Hong showing that in co-culture assays 
microglia up-regulated IL-1β expression at the mRNA level, as well as IFN-β 
expression. Furthermore, significant amounts of TNF could be detected by ELISA in 
the supernatants of co-cultured microglia, whereas GL261 cells did not secrete TNF 
in detectable amounts in any of the performed experiments. This provided evidence 
that murine primary microglia were specifically activated by PV MVMp infected 
tumor cells and that a tumor-specific immune response was induced. Therefore, PV 
MVMp-induced cell lysis of GL261 cells seems to be a crucial requirement to ensure 
efficient activation of microglia.  
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Thus, evidence was provided in support of the initial research hypothesis, that 
MVMp-infected tumor cells could specifically activate an immune response. The 
results were also consistent with the current view of microglia and their role as major 
immuno-competent cells in the brain (Aloisi F., 2001). They are able to discern a 
complex mass of various signals and they belong to the most diligent cytokine 
secreting cells in the brain. Microglia act as antigen-presenting cells and could 
therefore also initiate to a certain degree of T cell mediated immune responses in the 
brain.  
 
An obvious question to address was to investigate the molecular pathways 
involved in the activation of DCs and microglia. A specific aim of this thesis work 
was to analyze the role of TLR signaling and the downstream NFk-B signaling 
pathway that might be involved in the activation of DCs and microglia. 
DCs are the most efficient inducers of all immune responses. While 
plasmocytoid DCs and myeloid DCs share common functional features related to 
antigen uptake, processing and presentation, each type expresses unique sets of 
receptors that enables them to specifically recognize and respond to different 
pathogens (Colonna et al., 2004; Larsson et al., 2004; Iwasaki and Medzhitov, 2004). 
For example, all DCs and cells of the innate immune system express evolutionally 
preserved pattern recognition receptors, toll-like receptors. Viral pathogens can be 
sensed by TLR3 (double stranded RNA), TLR7 or TLR8 (single-stranded RNA), 
bacterial lipopolysaccharide and some viral proteins by TLR4, bacterial CpG 
sequences in DNA by TLR9 and flagellin by TLR5. TLR2 has a broad recognition 
profile that includes Gram-positive peptidoglycans and di- and triacetylated 
lipopeptides as well as selected viruses (Iwasaki and Medzhitov, 2004). Recently 
identified in human, TLR11 is activated by uropathogenic bacteria and Toxoplasma 
gondii in mice (Zhang et al., 2004; Yarovinsky et al., 2005), while no equivalent of 
TLR11 was found in other species. Plasmocytoid DCs express TLR7 and TLR9 that 
are pivotal in recognition of viruses and bacteria while myeloid DCs express TLR2, 
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TLR4, and TLR3 and monocytes express a broad profile of TLRs including TLR2, 3, 
4, and 5 (Hornung et al., 2002). Microglia were shown to be activated by different 
PAMPs as well (Tran C.T. et al., 1998; Ebert S. et al., 2005). However, not only 
microbial and viral compounds but also tumour-derived and most probably host-
derived components might play a role in the activation of microglia. 
In view of the stimulatory capacity for DCs and microglia of MVMp-infected 
glioma GL261 cell lysates we were interested to know if this stimulation was 
associated with increased expression of one or more TLRs. Unfortunately, analysis of 
APC-specific TLRs expression was not possible in co-cultures since the glioma 
GL261 cells also express TLRs. Therefore, the TLR expression profile on the mRNA 
level in DCs infected with MVMp alone was studied. Expression of TLR 2, 3, 4 and 
9 on myeloid DCs and TLR 2, 6 and 9 on lymphoid DCs was increased upon PV 
MVMp infection. Unfortunately, the limited amount of DCs in the experiments did 
not allow for analysis of TLR signal transduction pathways in cellular extracts from 
these cells. Therefore, heterologous expression of different TLRs in a tissue culture 
cell line was established to study activation following contact with MVMp–infected 
glioma or melanoma tumor cells or with virus alone as a control. The experiments 
were conducted with cell lines stably transfected with TLR2, TLR2/TLR6, TLR3, 
TLR4, TLR4/MD2/CD14 and TLR9. These TLRs were chosen as the most promising 
candidates. MD2 and CD14 are accessory molecules, which could further increase 
the efficiency of LPS recognition (Akira S. and K. Takeda, 2004). As it was shown, 
all investigated TLRs, except TLR3, were not activated either by MVMp-mediated 
tumor cell lysates, or by virus alone. Only TLR3 showed significant activation in 
response to MVMp-mediated tumor cell lysates. The level of activation was 
significantly higher towards glioma GL261 cell lysates compared to melanoma 
B78/H1 cell lysates, which confirm the DC activation data overall.   
 
It was extensively discussed that live glioma GL261 cells did not induce any 
efficient activation of DCs and microglia, nor did F/T lysed GL261 cells induced a 
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strong immune response. This provided evidence that PV infection and PV MVMp-
induced lysis of glioma GL261 cells was required to mediate a robust activation of 
APC. Thus, the mode of cell lysis might play an important role. During the lysis of 
the glioma cells by the virus, cellular compounds are released, which would not be 
set free by F/T cycles. These yet unknown cellular molecules might be recognized by 
receptors displayed on the surface of APC and stimulate these target cells.  
Further research on the molecular mechanisms of PV-mediated cell killing is 
required. Cell lysis upon PV infection of tumor cells can either be accomplished by 
necrosis, by apoptosis or autophagy formation and seems to be dependent from the 
cellular system, in which the experiments are conducted. For instance, Möhler et al. 
showed that the rat PV H1 is cytotoxic to human hepatoma cells. In their 
experiments, two of the three hepatoma cells lines presented over 50% apoptotic cells 
at days 3-6 post infection as detected by flow cytometry analysis (Moehler M., et al. 
2001). Another study by Ran et al. suggested that NAD might play a role in the 
regulation between apoptosis and necrosis. Inhibition of NAD consuming enzymes 
interfered with PV induced NAD depletion, resulting in an increased number of 
infected cells lysed with apoptotic features (Ran Z., et. al., 1999). 
Möhler and colleagues published additional evidence describing and 
characterizing PV induced cell killing in a human melanoma cell line (give the name 
of the melanoma cell line), which was highly susceptible to rat PV H1 infection. 
Assuming that HSPs can be detected in cells in stress situations, they analysed the 
constitutive and inducible form of HSP70 after H1 infection in this melanoma cell 
line. Interestingly, they found that intracellular levels of inducible HSP72 decreased 
continuously from day 2 post infection, whereas the HSP72 levels were elevated in 
the cell culture medium. A release of HSPs post infection was therefore observed 
(Moehler M., et al. 2003).  
 
Taking together all these in vitro results demonstrate significant activation of 
DCs and microglia upon co-culture with MVMp-infected GL261 glioma cells. This 
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activation might lead to an initial innate and subsequently tumor specific adaptive 
immune response.  
 
 5.3. MVMp-mediated tumor cell lysates stimulate a specific antitumor 
immune response. 
 
So far, all the experiments conducted in this study were in vitro approaches. 
The final aim of this work was to show the generation of a specific immune response 
in vivo. So far all the promising results concerning the activation of APC were 
obtained in the glioma model, the all futher experiments were conducted in the same 
model. As a matter of fact, the complexity of the physiological environment in the 
CNS is surely far beyond any in vitro approach. Seligman and Shear induced the 
“glioma 261” in 1939 by chemical carcinogen implantation into brains of mice 
(Seligman A.M., Shear M.J. 1939). Since they were established, Gl261 cells are used 
for both intracranial (Ausman J.I. et al. 1970; Ehtesham M. et al. 2002; Saito R. et al. 
2004) and s.c. (Miyatake S. et al. 1997; Schueneman A.J. et al. 2003) induction of 
tumors. It is an interesting intracranial model, because it recapitulates many of the 
histopathological and biological features of human high-grade glioma including both 
necrosis and invasion of the brain adjacent to the tumor (Newcomb E.W. et al. 2004). 
In our study it was shown that glioma GL261 cells injected s.c. induce tumor 
growth. As it was clearly shown, the oncolytic effect of MVMp was not complete in 
immune deficient RAG2-/- mice. The growth of tumor was much more aggressive and 
the size of tumor was significantly larger in the RAG2-/- animals compared to normal 
immunocompetent C57BL/6 mice. Eighty percent of RAG2-/- mice developed 
significant tumor burden 21 days post injection even in the case of infection with 
high titer of virus (MOI 30). This clearly showed undoubtedly the role of an adaptive 
immune response in complete rejection of s.c. glioma GL261 tumor cell 
transplantation. 
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Additionally, ELISpot assays showed a specific recognition of tumor cells by 
host cells obtained from the spleen. The recognition and the repsective specific 
immune response were significantly higher in the group of animals, which received 
MVMp-infected glioma GL261 cells s.c.. Which specific cell subset contributed to 
this effect remains however undetermined. From the literature it is not clear which 
cells, CD4+ or CD8+, play the major role in the antitumoral immune response (Segal 
B. M. et al. 2002, Lumniczky K. et al. 2002, Horton H.M. et al. 1999, Yang S.Y. et 
al. 2004). In a therapeutic vaccination approach against intracranial GL261-derived 
tumors depletion of either CD4+ or CD8+ lymphocytes equally prevented the 
antitumor effect of the vaccine (Lumniczky K. et al. 2002).  
On the contrary to the above-mentioned results other authors showed that the 
antitumor effect in experimental glioma models is rather CD8+ T cell–dependent. 
Functional analyses demonstrated that CD8+ cells seem to play the major role in the 
antitumoral response in glioma models. Histological data may support this 
hypothesis. A strong infiltration of rat brain tumors with CD4 and especially CD8 
cells could be observed when human embryonic neural stem cells engineered to 
release IL-12 were implanted intratumorally (Yang S.Y. et al. 2004). It is known, that 
IL-12 is a critical cytokine involved in the transition from the innate to the adaptive 
immune response. One of the hallmarks of the biological functions of IL-12 is its 
ability to regulate the balance between Th1 and Th2 responses of T cells. Th1 cells 
secrete IFN-γ and IL-2, whereas Th2 response is manifested by IL-4, IL-5, IL-6, IL-
10 and IL-13 secretion. One promotes cell-mediated immunity, whereas the other 
facilitates humoral immunity (Paul W.E. et. al., 1994). IL-12 favors Th1 responses 
promoting the differentiation of naïve T cells into Th1-cells, which are capable to 
produce large amounts of IFN-γ. Furthermore, IL-12 acts as a co-stimulus, which is 
necessary for maximum production of IFN-γ by differentiated Th1 cells responding 
to specific antigen. IL-12 also stimulates the development of IFN-γ secreting Th1 
cells from resting memory T cell populations by interacting with an antigen to which 
the T cells have been previously exposed (DeKruyff R.H. et. al., 1995). Similarly to 
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many other cytokines, IL-12 can impart functions contradicting each other. For 
example, IL-12 was also shown to support Th2 responses. Thus, the role of IL-12 
appears to depend on the cytokine micro-environment and on the state of maturation 
of T-cells. Besides its role in T cell activation, IL-12 also induces secretion of other 
cytokines, including anti-inflammatory cytokines such as IL-10, which might be 
involved in negatively regulating its own effects (Tripp C. S. et al., 1993).  For these 
reasons, it would be interesting to analyze whether APC co-cultured with PV MVMp 
infected GL261 cells could induce the release of IL-12.  
Another possibility to analyze the activation of a specific immune response 
furthermore would be the investigation of the TLR expression patterns on APC prior 
to and after stimulation with MVMp-induced tumor cell lysates. Doyle et al. 
examined the up-regulation of TLR3 and TLR4 after stimulating macrophages with 
TLR specific ligands (Doyle S.E., et al., 2003). TLR3 as well as TLR4 induced the 
expression of IFN-β. IFN-β in turn is believed to activate secondary antiviral gene 
induction by autocrine and paracrine pathways. 
 
As a summary, PV MVMp infection and lysis of tumor cells could encompass 
two beneficial effects. On the one hand, upon completion of the PV life cycle in 
glioma cells there will be a drastic increase in the release of newly generated viral 
particles. Newly produced viral particles could lead to re-infection and thus enhance 
the cytotoxic effect in gliomas. On the other hand, lysis of glioma cells could elevate 
the immunogenicity of the tumor as lysed tumor cell debris might be a target for 
APCs like microglia. Upon culture of single TLR expressing stable cell lines with 
MVMp-mediated tumor cell lysates, the cell line stably expressing TLR3 had an eight 
fold higher activation of NF-κB reporter gene expression compared to control. This 
finding called for a role of TLR3 mediated signaling in the activation NF-kB and 
downstream target genes such as pro- and inflammatory cytokines. Activated 
microglia could then in turn activate invading T cells and promote either a Th1 or a 
Th2 response. 
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So far, no effective therapy is available to treat glioma and all conventional 
attempts have failed to cure this disease. In this study, PV was discussed as a 
promising candidate as an alternative strategy to treat cancer.  
Vaccination strategies against cancer aim at priming immune cells against 
tumor antigens. Many problems have to be faced and overcome, such as the usually 
low immunogenicity of tumors, the immuno-suppressive features in the tumor 
environment, and possible side-effects associated with vaccination therapies, for 
instance possible autoimmune reactions. PVs could enhance the immunogenicity of 
tumors by releasing tumor antigens in the process of cell lysis. Therefore, the use of 
PV in regard to tumor vaccination strategies seems promising and future research in 
this area might soon include clinical trials.  
 
List of references 
  
 
List of References. 
 
1. Abad, J.D., Wrzensinski, C., Overwijk, W., De Witte, M.A., Jorritsma, 
A., Hsu, C., Gattinoni, L., Cohen, C.J., Paulos, C.M., Palmer, D.C., Haanen, J.B., 
Schumacher, T.N., Rosenberg, S.A., Restifo, N.P., Morgan, R.A. (2008) T-cell 
receptor gene therapy of established tumors in a murine melanoma model. J 
Immunother, 31(1), 1-6. 
2. Abschuetz, A., Kehl, T., Geibig, R., Leuchs, B., Rommelaere, J., 
Régnier-Vigouroux, A. (2006) Oncolytic murine autonomous parvovirus, a candidate 
vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse 
glial cells. Cell Tissue Res, 325(3), 423-36. 
3. Adams, J.M. (2003) Ways of dying: multiple pathways to apoptosis. 
Genes Dev, 17(20), 2481-95.  
4. Agbandje-McKenna, M., Llamas-Saiz, A.L. (1998) Functional 
implications of the structure of the murine parvovirus, minute virus of mice. 
Structure, 6(11), 1369-81.  
5. Aghi, M., Chiocca. E.A. (2006) Gene therapy for glioblastoma. 
Neurosurg Focus, 20(4), E18. 
6. Akira, S., Takeda K., et al. 2001. "Toll-like receptors: critical proteins 
linking innate and acquired immunity." Nat Immunol, 2(8): 675-80.  
7. Akira, S., Takeda, K. (2004) Toll-like receptor signalling. Nat Rev 
Immunol, 4(7), 499-511.  
8. Alexopoulou, L., Holt, A.C. (2001) Recognition of double-stranded 
RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 413(6857), 732-8. 
9. Aloisi, F. (2001) Immune function of microglia. Glia, 36(2), 165-79.  
10. Anouja, F., Wattiez, R. (1997) The cytotoxicity of the parvovirus minute 
virus of mice nonstructural protein NS1 is related to changes in the synthesis and 
phosphorylation of cell proteins. J Virol, 71(6), 4671-8.  
List of References 
 116
11. Aoki, H. (2001) Dendritic cells pulsed with tumor extract-cationic 
liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain 
tumor. Cancer Immunol. Immunother. 50, 463-468.  
12. Aoki, T., Hashimoto, N., Matsutani, M. (2007) Management of 
glioblastoma. Expert Opin Pharmacother, 8(18), 3133-46. 
13. Ausman, J.I., Shapiro, W.R., Rall, D.P. (1970) Studies on the 
chemotherapy of experimental brain tumors: development of an experimental model. 
Cancer Res., 30(9), 2394-400.   
14. Badie, B., Schartner, J. (2001) Role of microglia in glioma biology.” 
Microsc Res Tech. 54(2), 106-13.  
15. Balch, C., Buzaid, A., Soong, S., Atkins, M., Cascinelli, N., Coit, D., 
Fleming, I., Gershenwald, J., Houghton, A., Kirkwood, J., McMasters, K., Mihm, M., 
Morton, D., Reintgen, D., Ross, M., Sober, A., Thompson, J., Thompson, J. (2001) 
Final version of the American Joint Committee on Cancer staging system for 
cutaneous melanoma. J Clin Oncol, 19(16), 3635-48.  
16. Banchereau, J., Paczesny, S., Blanco, P., Bennett, L., Pascual, V., Fay, 
J., Palucka, A.K. (2003) Dendritic cells: controllers of the immune system and a new 
promise for immunotherapy, Ann. NY Acad. Sci., 987,180–187. 
17. Bansal, K., Engelhard, H.H. (2000) Gene therapy for brain tumors. Curr. 
Oncol Rep,  2, 463-472.  
18. Bauer, S., Kirschning, C.J., Häcker, H., Redecke, V., Hausmann, S., 
Akira, S., Wagner, H., Lipford, G.B. (2001) Human TLR9 confers responsiveness to 
bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA, 
98, 9237–9242. 
19. Blechacz, B., Russell, S.J. (2004) Parvovirus vectors: use and 
optimisation in cancer gene therapy. Expert Rev Mol Med, 6(16), 1-24.  
20. Brandes, A.A. (2003) State-of-the-art treatment of high-grade brain 
tumours. Semin Oncol, 30, 4-9. 
List of References 
 117
21. Breyer, R. (2000) Disruption of intracerebral progression of C6 rat 
glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J  
Neurosurg, 92, 140-149. 
22. Buckner, J.C., Brown, P.D., O'Neill, B.P., Meyer, F.B., Wetmore, C.J., 
Uhm, J.H. (2007) Central nervous system tumors. Mayo Clin Proc, 82(10), 1271-86 
23. Cassinotti, P., Schultze, D., Wieczorek, K., Schonenberger, R.,  Siegl, G. 
(1994) Parvovirus B19 infection antibody: how reliable are serological results? Clin  
Diagn Virol, 2, 87-94.  
24. Castro, M.G. (2003) Current and future strategies for the treatment of 
malignant brain tumors. Pharmacology & Therapeutics, 98, 71-108.  
25. Cavaliere, R., Wen, P.Y., Schiff, D. (2007) Novel therapies for 
malignant gliomas. Neurol Clin, 25(4), 1141-71. 
26. Chomarat, P., Banchereau, J. (2000) IL-6 switches the differentiation of 
monocytes from dendritic cells to macrophages. Nat Immunol, 1(6), 510-4.  
27. Colonna, M., Trinchieri, G., Liu, Y. (2004) Plasmacytoid dendritic cells 
in immunity. Nat Immunol., 5(12), 1219-26.  
28. Cornelis, J.J., Salome, N., (2004) Vectors based on autonomous 
parvoviruses: novel tools to treat cancer? J Gene Med, 6 Suppl 1, 193-202.  
29. Cotmore, S.F., Nuesch, J.P., Tattersall, P. (1993) Asymmetric resolution 
of a parvovirus palindrome in vitro. Virol., 67, 1579-1589.  
30. Cotmore, S.F., Tattersall, P. (2005) Encapsidation of minute virus of 
mice DNA: aspects of the translocation mechanism revealed by the structure of 
partially packaged genomes. Virol., 336(1), 100-12.  
31. Dai, C., Holland, E.C. (2001) Glioma models. Biochim. Biophys. Acta, 
1551, 19-27. 
List of References 
 118
32. de Groot, J.F., Gilbert, M.R. (2007) New molecular targets in malignant 
gliomas. Curr Opin Neurol., 20(6), 712-8. 
33. DeKruyff, R.H., Fang, Y. (1995) IL-12 inhibits IL-4 synthesis in keyhole 
limpet hemocyanin-primed CD4+ T cells through an effect on antigen-presenting 
cells. J Immunol, 154(6), 2578-87.  
34. Deleu, L. (1998) Opposite transcriptional effects of cyclic AMP-
responsive elements in confluent or p27KIP-overexpressing cells versus serum-
starved or growing cells. Mol. Cell Biol., 18, 409-419.  
35. Doyle, S.E., R. O'Connell, (2003) Toll-like receptor 3 mediates a more 
potent antiviral response than Toll-like receptor 4. J Immunol, 170(7), 3565-71.  
36. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, 
K., Jackson, V., Hamada, H., Pardoll, D., Mulligan, R.C. (1993) Vaccination with 
irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-
stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. 
Proc. Natl. Acad. Sci. USA, 90, 3539-3543. 
37. Dupressoir, T., Vanacker, J.M., Cornelis, J.J., Duponchel, N., 
Rommelaere, J. (1989) Inhibition by parvovirus H-1 of the formation of tumors in 
nude mice and colonies in vitro by transformed human mammary epithelial cells. 
Cancer Res., 49, 3203-3208. 
38. Ebert, S., Gerber, J. (2005). Dose-dependent activation of microglial 
cells by Toll-like receptor agonists alone and in combination. J Neuroimmunol, 
159(1-2), 87-96.  
39. Ehtesham, M., Samoto, K., Kabos, P., Acosta, F.L., Gutierrez, M.A., 
Black, K.L., Yu, J.S. (2002) Treatment of intracranial glioma with in situ interferon-
gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther., 9(11), 925-
34. 
40. Eichwald, V., Daeffler, L., Klein, M., Rommelaere, J., Salome, N. 
(2002) The NS2 proteins of parvovirus minute virus of mice are required for efficient 
nuclear egress of progeny virions in mouse cells. J. Virol., 76, 10307-10319. 
List of References 
 119
41. El Andaloussi, A., Han, Y., Lesniak, M.S. (2006) Prolongation of 
survival following depletion of CD4+CD25+ regulatory T cells in mice with 
experimental brain tumors. J Neurosurg., 105(3), 430-7. 
42. El Shikh, M.E., El Sayed, R.M., Wu, Y., Szakal, A.K., Tew, J.G. (2007) 
TLR4 on follicular dendritic cells: an activation pathway that promotes accessory 
activity. J Immunol., 179(7), 4444-50. 
43. Emsley, J., White, H.E. (1994) Structure of pentameric human serum 
amyloid P component. Nature, 367(6461), 338-45.  
44.  Errington, F., White, C.L., Twigger, K.R., Rose, A., Scott, K., Steele, 
L., Ilett, L.J., Prestwich, R., Pandha, H.S., Coffey, M., Selby, P., Vile, R., Harrington, 
K.J., Melcher, A.A. (2008) Inflammatory tumour cell killing by oncolytic reovirus for 
the treatment of melanoma. Gene Ther  
45. Fischer, U., Meese, E. (2007) Glioblastoma multiforme: the role of DSB 
repair between genotype and phenotype. 26(56),7809-15.  
46. Forsyth, P.A., Wong, H. (1999) Gelatinase-A (MMP-2), gelatinase-B 
(MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved 
in different aspects of the pathophysiology of malignant gliomas. Br J Cancer, 79(11-
12), 1828-35. 
47. Fortis, C., Foppoli, M., Gianotti, L., Galli, L., Citterio, G., Consogno, G., 
Gentilini, O., Braga, M.  (1996) Increased interleukin-10 serum levels in patients with 
solid tumours. Cancer Lett., 104(1), 1-5. 
48. Geletneky, K., Herrero, Y. Calle M., Rommelaere, J., Schlehofer, J.R. 
(2005) Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a 
brief review. J Vet Med B Infect Dis Vet Public Health, 52(7-8), 327-30. 
49. Georgelas. A., Schibler. K. (2000) Characterization of myeloid and 
lymphoid subsets in dendritic cells derived from cord blood and adult blood.  
Experimental Hematology, 28(12), 1499-1499. 
List of References 
 120
50. Gerstenblith, M.R., Goldstein, A.M., Tucker, M.A., Fraser, M.C. (2007) 
Genetic testing for melanoma predisposition: current challenges. Cancer Nurs., 30(6), 
452-9; quiz 462-3. 
51. Glick, R.P., Lichtor, T., Cohen, E.P. (2000) Cytokine immunogene 
therapy. Neurosurg Focus., 15, 9(6). 
52. Green, D.R. (1998) Apoptosis. Death deceiver. Nature., 396(6712), 629-
30.  
53. Green, D.R., Amarante-Mendes, G.P. (1998) 
54. Guetta, E., Graziani, Y., Talm J. (1986) Supression of Ehrlich ascities 
tumors in mice by minute virus of mice. Journal of National Cancer Institute, 76, 
1177-80. 
55.  Haag, A., Wayss, K., Rommelaere, J., Cornelis, J.J. (2000) 
Experimentally induced infection with autonomous parvoviruses, minute virus of 
mice and H-1, in the African multimammate mouse (Mastomys coucha). Comp Med., 
50(6), 613-21. 
56. Harrison, D.E., Lerner, C.P. (1991) Most primitive hematopoietic stem 
cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood., 78(5), 
1237-40.  
57. Hellman, P., Eriksson, H. (2007) Early activation markers of human 
peripheral dendritic cells. Hum Immunol., 68(5), 324-33. 
58. Herrero, Y.C.M., Cornelis, J.J., (2004) Parvovirus H-1 infection of 
human glioma cells leads to complete viral replication and efficient cell killing. Int J 
Cancer, 109(1), 76-84.  
59. Hertzog, P.J., O'Neill, L.A. (2003). The interferon in TLR signaling: 
more than just antiviral. Trends Immunol, 24(10),534-9.  
60. Hiasa, A., Hirayama, M., Nishikawa, H., Kitano, S., Nukaya, I., Yu, 
S.S., Mineno, J., Kato. I., Shiku, H. (2008) Long-term phenotypic, functional and 
genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced 
to CD8+ T cells. Gene Ther.,15(9), 695-9. 
List of References 
 121
61. Holland, E.C. (2001) Gliomagenesis: genetic alterations and mouse 
models. Nat Rev Genet, 2(2), 120-9.  
62. Homsi, J., Kashani-Sabet, M., Messina, J., Daud, A. (2005) Cutaneous 
melanoma: prognostic factors. Cancer Control, 12(4), 223-9. 
63. Horton, H.M., Parker, S.E., Wloch, M.K., Norman, J.A. (1999) DNA 
vaccines for cancer therapy. Expert Opin Investig Drugs., 8(12), 2017-2026. 
64. Ishikawa, E. (2004). Autologous natural killer cell therapy for human 
recurrent malignant glioma.  Anticancer Res., 24, 1861-1871. 
65. Itoh, Y., Ueda, H., Suzuki, E. (1995) Overexpression of bcl-2, apoptosis 
suppressing gene: Prolonged viable culture period of hybridoma and enhanced 
antibody production. Biotechnol Bioeng., 48(2), 118-22. 
66. Iwasaki, A., Medzhitov. R. (2004) Toll-like receptor control of the 
adaptive immune responses. Nat Immunol, 5(10), 987-95.  
67. Karsunky, H., Merad, M., Cozzio, A., Weissman, I.L., Manz, M.G. 
(2003) Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and 
myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med., 198, 305-
313. 
68. Karsunky, H., Merad, M., Mende, I., Manz, M.G., Engleman E.G., 
Weissman, I.L. (2005) Developmental origin of interferon-alpha-producing dendritic 
cells from hematopoietic precursors. Exp Hematol., 33(2), 173-81. 
69. Kilham, L., Olivier, L.J. (1959) A latent virus of rats isolated in tissue 
culture. Virology, 7,428-437.  
70. King, G.D., Curtin, J.F., Candolfi, M., Kroeger, K., Lowenstein, P.R., 
Castro, M.G. (2005) Gene therapy and targeted toxins for glioma. Curr Gene Ther., 
5(6), 535-57. 
71. Kohler, C., Orrenius, S., Zhivotovsky, B. (2002) Evaluation of caspase 
activity in apoptotic cells. J Immunol Method, 265, 97-110.  
72. Kopf, M., Baumann, H. (1994). Impaired immune and acute-phase 
responses in interleukin-6-deficient mice. Nature, 368(6469), 339-42.  
List of References 
 122
73. Lang, S.I., Boelz, S., Stroh-Dege, A.Y., Rommelaere, J., Dinsart, C., 
Cornelis, J.J. (2005) The infectivity and lytic activity of minute virus of mice wild-
type and derived vector particles are strikingly different.” 
74. Lang, S.I., Giese, N.A., Rommelaere, J., Dinsart, C., Cornelis, J.J. (2006)  
Humoral immune responses against minute virus of mice vectors. J Gene Med., 8(9), 
1141-50 
75. Lans, T.E., Van Horssen, R., Eggermont, A.M., Ten Hagen, T.L. (2004) 
Involvement of endothelial monocyte activating polypeptide II in tumor necrosis 
factor-alpha-based anti-cancer therapy. Anticancer Res., 24(4), 2243-8.  
76. Lassman, A.B., Holland, E.C. (2007) Incorporating molecular tools into 
clinical trials and treatment for gliomas? Curr Opin Neurol., 20(6), 708-11. 
77. Le Cesne, A., Dupressoir, T. (1993) Intra-lesional administration of a 
live virus, parvovirus H-1 (PHV-1) in cancer patients: feasibility study. Proc Ann 
Meet Am Soc Clin Oncol, 12, 297. 
78. Leadbetter, E.A., Rifkin, I.R. (2002) Chromatin-IgG complexes activate 
B cells by dual engagement of IgM and Toll-like receptors. Nature, 416(6881), 603-
7.  
79. Levering, W.H., Sutherland, D.R., Keeneyet M. (2004) Hematopietic 
stem and progenitor cells: enumeration, phenotypic characterisation, and clinical 
applications, Transfus Med Hematother, 31, 341–352. 
80.  Louis, D.N. (2006) Molecular pathology of malignant gliomas. Annu 
Rev Pathol., 1, 97-117. 
81. Lucas, R. (2006) Global Burden of Disease of Solar Ultraviolet 
Radiation, Environmental Burden of Disease Series. News release, World Health 
Organization, July 25, No. 13.  
82. Lumniczky, K., Desaknai, S., Mangel, L., Szende, B., Hamada, H., 
Hidvegi, E.J., Safrany, G. (2002) Local tumor irradiation augments the antitumor 
effect of cytokine-producing autologous cancer cell vaccines in a murine glioma 
model. Cancer Gene Ther., 9(1), 44-52. 
List of References 
 123
83. Mach, N., Gillessen, S., Wilson, S.B., Sheehan, C., Mihm, M., Dranoff, 
G. (2000) Differences in dendritic cells stimulated in vivo by tumors engineered to 
secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer 
Res,  60, 3239-46. 
84. Maher, E.A., Furnari, F.B. (2001) Malignant glioma: genetics and 
biology of a grave matter. Genes Dev, 15(11), 1311-33.  
85. Markert, J.M., Parker, J.N., Buchsbaum, D.J., Grizzle, W.E., Gillespie, 
G.Y., Whitley, R.J. (2006) Oncolytic HSV-1 for the treatment of brain tumours. 
13(3), 66-71. 
86. Medzhitov, R., Janeway, C.A. (1997) Innate immunity: impact on the 
adaptive immune response. Curr Opin Immunol, 9(1), 4-9.  
87. Mellman, Steinman R.M. (2001) Dendritic cells: specialized and 
regulated antigen processing machines. Cell, 106, 255–258. 
88. Miller, C.L., Pintel, D.J. (2001) The NS2 protein generated by the 
parvovirus minute virus of mice is degraded by the proteasome in a manner 
independent of ubiquitin chain elongation or activation. Virology, 285, 346-355. 
89. Mitchell, D.A., Fecci, P.E., Sampson, J.H. (2003) Adoptive 
immunotherapy for malignant glioma. Cancer J., 9(3), 157-66. 
90. Miyatake, S., Martuza, R.L., Rabkin, S.D. (1997) Defective herpes 
simplex virus vectors expressing thymidine kinase for the treatment of malignant 
glioma. Cancer Gene Ther., 4(4), 222-8. 
91. Moehler, M., Blechacz, B. (2001) Effective infection, apoptotic cell 
killing and gene transfer of human hepatoma cells but not primary hepatocytes by 
parvovirus H1 and derived vectors. Cancer Gene Ther., 8(3), 158-67.  
92. Moehler, M., Zeidler, M. (2003) Oncolytic parvovirus H1 induces 
release of heat-shock protein HSP72 in susceptible human tumor cells but may not 
affect primary immune cells. Cancer Gene Ther, 10(6), 477-80.  
List of References 
 124
93. Mohanam, S., Go, Y. (1999) Elevated levels of urokinase-type 
plasminogen activator and its receptor during tumor growth in vivo. Int J Oncol, 
14(1), 169-74.  
94. Morgan, W.R., Ward, D.C. (1986) Three splicing patterns are used to 
excise the small intron common to all minute virus of mice RNAs. J. Virol., 60, 
1170-1174.  
95. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and 
survival: application to proliferation and cytotoxicity assays. J Immunol Methods., 
65(1-2), 55-63. 
96. Muller, U., Steinhoff, U. (1994) Functional role of type I and type II 
interferons in antiviral defense. Science, 264(5167), 1918-21.  
97. Naeger, L.K., Cater, J., Pintel, D.J. (1990) The small nonstructural 
protein (NS2) of the parvovirus minute virus of mice is required for efficient DNA 
replication and infectious virus production in a cell-type-specific manner. J. Virol., 
64, 6166-6175. 
98. Nakauchi, H. (1998) Hematopietic stem cells: are they CD34-positive or 
CD34-negative? Nat Med, 4, 1009–1010. 
99. Nestle, F.O., Banchereau, J., Hart, D. (2001) Dendritic cells: On the 
move from bench to bedside. Nat Med., 7(7), 761-5. 
100. Newcomb, E.W., Lymberis, S.C., Lukyanov, Y., Shao, Y., Schnee, T., 
Devitt, M., Rosenstein, B.S., Zagzag, D., Formenti, S.C. (2006) Radiation sensitivity 
of GL261 murine glioma model and enhanced radiation response by flavopiridol. 
Cell Cycle., 93-9.  
101. Nguyen, K.B., Watford, W.T., (2002) Critical role for STAT4 activation 
by type 1 interferons in the interferon-gamma response to viral infection. Science, 
297(5589), 2063-6. 
102. Nuesch, J.P., Lachmann, S. (2005) Selective alterations of the host cell 
architecture upon infection with parvovirus minute virus of mice. Virology, 331(1), 
159-74.  
List of References 
 125
103. Nuesch, J.P., Lachmann, S., Corbau, R., Rommelaere, J. (2003) 
Regulation of minute virus of mice NS1 replicative functions by atypical PKClambda 
in vivo. J. Virol., 77, 433-442. 
104. Ohshima, T., Iwama, M. (1998) Induction of apoptosis in vitro and in 
vivo by H-1 parvovirus infection. J Gen Virol,  79 (12), 3067-71.  
105. Okada, H. (1999) Effective cytokine gene therapy against an intracranial 
glioma using a retrovirally-transduced IL-4 plus HSVtk tumor vaccine. Gene Ther., 
6, 219-226. 
106. Okada, H., Pollack, I.F. (2004) Cytokine gene therapy for malignant 
glioma. Expert Opin Biol Ther., 4(10), 1609-20. 
107. Op De Beeck, A., Caillet-Fauquet, P. (1997) The NS1 protein of the 
autonomous parvovirus minute virus of mice blocks cellular DNA replication: a 
consequence of lesions to the chromatin? J Virol, 71(7), 5323-9.  
108. Ozinsky, A., Underhill, D.M. (2000) The repertoire for pattern 
recognition of pathogens by the innate immune system is defined by cooperation 
between toll-like receptors. Proc Natl Acad Sci U S A, 97(25), 13766-71. 
109. Parney, I.F. (1997) Granulocyte-macrophage colony-stimulating factor 
and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige 
mouse-human glioblastoma multiforme model. Hum. Gene Ther., 8, 1073-1085. 
110. Pashine, A., Valiante, N.M., Ulmer, J.B. (2005) Targeting the innate immune 
response with improved vaccine adjuvants. Nature Medicine, 11, 63 -68. 
111. Paul, W.E., Seder R.A. (1994) Lymphocyte responses and cytokines. 
Cell, 76(2), 241-51.  
112. Perros, M., Deleu, L., Vanacker, J.M., Kherrouche, Z., Spruyt, N., Faisst, 
S., Rommelaere, J. (1995) Upstream CREs participate in the basal activity of minute 
virus of mice promoter P4 and in its stimulation in ras-transformed cells. J Virol., 
69(9), 5506-15. 
List of References 
 126
113. Rad, A.N., Pollara, G. (2003) The differential influence of allogeneic 
tumor cell death via DNA damage on dendritic cell maturation and antigen 
presentation. Cancer Res, 63(16), 5143-50.  
114. Ran, Z., Rayet, B., (1999) Parvovirus H-1-induced cell death: influence 
of intracellular NAD consumption on the regulation of necrosis and apoptosis. Virus 
Res, 65(2), 161-74.  
115. Randall, T.D., Weissman, I.L. (1997) Phenotypic and functional changes 
induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. 
Blood., 89(10), 3596-606. 
116. Rayet, B., Lopez-Guerrero, J.A., Rommelaere, J., Dinsart, C. (1998)  
Induction of programmed cell death by parvovirus H-1 in U937 cells: connection 
with the tumor necrosis alpha signaling pathway. J Virol., 72, 8893-8903. 
117. Re F,, Strominger J., 2004. 
118. Re, F., Strominger, J.L. (2004) Heterogeneity of TLR-induced responses 
in dendritic cells: from innate to adaptive immunity. Immunobiology., 209(1-2), 191-
8.  
119. Reimold, A.M. (2002) TNFalpha as therapeutic target: new drugs, more 
applications. Curr Drug Targets Inflamm Allergy., 1(4), 377-92.  
120. Rogge, L., D'Ambrosio, D. (1998) The role of Stat4 in species-specific 
regulation of Th cell development by type I IFNs. J Immunol, 161(12), 6567-74. 
121. Rommelaere, J., Cornelis, J.J. (1991) Antineoplastic activity of 
parvoviruses. J. Virol. Methods, 33, 233-251. 
122. Rommelaere, J., Cornelis, J.J. (2001) Aunomous Parvoviruses. In Krager 
(ed.) Replication-competent viruses for cancer therapy. P. Hernaiz Driver, S.D.  
Rabkin, Basel, Vol.22, 100-129.  
123. Saito, R., Bringas, J., Mirek, H., Berger, M.S., Bankiewicz, K.S. (2004) 
Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant 
sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant 
glioma. J. Neurosurg., 101(5), 826-31. 
List of References 
 127
124. Sawaya, R.E., Yamamoto, M. (1996) Expression and localization of 72 
kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp 
Metastasis, 14(1), 35-42.  
125. Schirrmacher V., Bai L., Umansky V., Yu L., Xing Y. and Qian Z., 
2000. “Newcastle disease virus activates macrophages for anti-tumor activity”. Int J 
Oncol, 16: 363-373. 
126. Schirrmacher, V. (2005) Clinical trials of antitumor vaccination with an 
autologous tumor cell vaccine modified by virus infection: improvement of patient 
survival based on improved antitumor immune memory. Cancer Immunol 
Immunother, 54, 587-598. 
127. Schueneman, A.J., Himmelfarb, E., Geng, L., Tan, J., Donnelly, E., 
Mendel, D., McMahon, G., Hallahan, D.E. (2003) SU11248 maintenance therapy 
prevents tumor regrowth after fractionated irradiation of murine tumor models. 
Cancer Res., 63(14), 4009-16. 
128. Schumann, R.R., Leong, S.R. (1990) Structure and function of 
lipopolysaccharide binding protein. Science, 249(4975), 1429-31.  
129. Segal, B.M., Glass, D.D., Shevach, E.M. (2002) Cutting Edge: IL-10-
producing CD4+ T cells mediate tumor rejection. J Immunol., 168(1), 1-4. 
130. Shah, A.C., Benos, D., Gillespie, G.Y., Markert, J.M. (2003) Oncolytic 
viruses: clinical applications as vectors for the treatment of malignant gliomas. J. 
Neurooncol., 65, 203-226.  
131. Shigematsu, H., Reizis, B., Iwasaki, H. (2004) Plasmacytoid dendritic 
cells activate lymphoid-specific genetic programs irrespective of their cellular origin. 
Immunity, 21, 43-53. 
132. Shimamura, T., Husain, S.R., Puri, R.K. (2006) The IL-4 and IL-13 
pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus., 20(4), 
E11. 
133. Shinkai, Y., Rathbun, G., Lam, K.P., Oltz, E.M., Stewart, V., 
Mendelsohn, M., Charron, J., Datta, M., Young, F., Stall, A.M. (1992) RAG-2-
List of References 
 128
deficient mice lack mature lymphocytes owing to inability to initiate V(D)J 
rearrangement. Cell., 68(5), 855-67.  
134. Slack, J.L., Schooley, K. (2000) Identification of two major sites in the 
type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-
inflammatory signaling pathways. J Biol Chem, 275(7), 4670-8.  
135.  Sonabend, A.M., Rolle, C.E., Lesniak, M.S. (2008) The role of 
regulatory T cells in malignant glioma. Anticancer Res., 28(2B), 1143-50.  
136. Sonabend, A.M., Ulasov, I.V., Han, Y., Lesniak, M.S. (2006) Oncolytic 
adenoviral therapy for glioblastoma multiforme. Neurosurg Focus., 20(4), 19. 
137. Stark, G.R., Kerr, I.M. (1998) How cells respond to interferons. Annu 
Rev Biochem, 67, 227-64.  
138. Steinman, R.M., Turley, S., Mellman I., Inaba, K. (2000) The induction 
of tolerance by dendritic cells that have captured apoptotic cells, J. Exp. Med., 191,  
411–416. 
139. Suikkanen, S., Saajarvi, K. (2002) Role of recycling endosomes and 
lysosomes in dynein-dependent entry of canine parvovirus. J Virol, 76(9), 4401-11.  
140. Szatmári, T., Lumniczky, K., Désaknai, S., Trajcevski, S., Hídvégi, E.J., 
Hamada, H., Sáfrány, G. (2006) Detailed characterization of the mouse glioma 261 
tumor model for experimental glioblastoma therapy. Cancer Science, 97, 546-553.  
141. Telerman, A., Tuynder, M., Dupressoir, T., Robaye, B., Sigaux, F., 
Shaulian, E., Oren, M., Rommelaere, J., Amson, R. (1993) A model for tumor 
suppression using H-1 parvovirus. Proc Natl Acad Sci U S A., 90(18), 8702-6. 
142. Todo T. (2008) Oncolytic virus therapy using genetically engineered 
herpes simplex viruses. Front Biosci., 13, 2060-4.  
143. Toolan, H.W. (1960) Experimental production of mongoloid hamsters. 
Science, 131, 1446-8.  
144. Toolan, H.W. (1967) Lack of oncogenic effect of the H-viruses for 
hamsters. Nature, 214(92), 1036. 
List of References 
 129
145. Tran, C. T., Wolz P. (1998) Differential expression of MHC class II 
molecules by microglia and neoplastic astroglia: relevance for the escape of 
astrocytoma cells from immune surveillance. Neuropathol Appl Neurobiol, 24(4), 
293-301.  
146. Tripp, C. S., Wolf S.F. (1993) Interleukin 12 and tumor necrosis factor 
alpha are costimulators of interferon gamma production by natural killer cells in 
severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a 
physiologic antagonist. Proc Natl Acad Sci U S A,  90(8), 3725-9.  
147. Tullis G.E., Burger L.R. (1993) The minor capsid protein VP1 of the 
autonomous parvovirus minute virus of mice is dispensable for encapsidation of 
progeny single-stranded DNA but is required for infectivity. J Virol, 67(1), 131-41.  
148. Ulevitch, R.J., Tobias, P.S. (1995) Receptor-dependent mechanisms of 
cell stimulation by bacterial endotoxin. Annu Rev Immunol, 13, 437-57. 
149. Vanacker J m 1995 
150. Varney, M.L., Olsen, K.J., Mosley, R.L., Bucana, C.D., Talmadge, J.E., 
Singh, R.K. (2002) Monocyte/macrophage recruitment, activation and differentiation 
modulate interleukin-8 production: a paracrine role of tumor-associated macrophages 
in tumor angiogenesis. In Vivo, 16(6), 471-7. 
151. Vilhardt, F. (2005) Microglia: phagocyte and glia cell. Int J Biochem 
Cell Biol, 37(1), 17-21.  
152. Wetzel, K., Struyf, S., Van Damme, J., Kayser, T., Vecchi, A., Sozzani, 
S., Rommelaere, J., Cornelis, J.J., Dinsart, C. (2007) MCP-3 (CCL7) delivered by 
parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through 
activation of T lymphocytes and NK cells. Int J Cancer., 120(6), 1364-71. 
153. Wildner, O. (2001) Oncolytic viruses as therapeutic agents. Ann Med., 
33(5), 291-304. 
154. Willwand, K., Hirt, B. (1991) The minute virus of mice capsid 
specifically recognizes the 3' hairpin structure of the viral replicative-form DNA: 
List of References 
 130
mapping of the binding site by hydroxyl radical footprinting. J. Virol., 65, 4629-
4635. 
155. Willwand, K., Hirt, B. (1991) The minute virus of mice capsid 
specifically recognizes the 3' hairpin structure of the viral replicative-form DNA: 
mapping of the binding site by hydroxyl radical footprinting. J. Virol. 65, 4629-4635. 
156. Wollmann, G., Tattersall, P. (2005) Targeting human glioblastoma cells: 
comparison of nine viruses with oncolytic potential. J Virol, 79(10), 6005-22. 
157. Yang, S.Y., Xue, L. (2004) Human neuronal apoptosis secondary to 
traumatic brain injury and the regulative role of apoptosis-related genes. Chin J 
Traumatol., 7(3), 159-64. 
158. Yarovinsky, F., Zhang, D., Andersen, J.F., Bannenberg, G.L., Serhan, 
C.N., Hayden, M.S., Hieny, S., Sutterwala, F.S., Flavell, R.A., Ghosh, S., Sher, A. 
(2005) TLR11 activation of dendritic cells by a protozoan profilin-like protein. 
Science., 308(5728), 1626-9.  
159. Yonemitsu, Y., Ueda, Y., Kinoh, H., Hasegawa, M. (2008) 
Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer 
therapeutic regimen. Front Biosci., 13, 1892-8. 
160. Zhivotosky, B., Orrenius, S. (2001) Assessment of apoptosis and 
necrosis by DNA fragmentation and morphological criteria. Curr Protoc Cell Biol., 
Chapter 18, Unit 18.3. 
 
 
Appendix  
 
 
TransLucent Reporter Control Vector Sequence, Catalog #: LR0000 
 
 
 
The cis-acting enhancer element sequence resides between the NheI and 
BglII restriction sites, upstream of the TATA box promoter, which drives 
expression of the firefly luciferase reporter gene upon transcription factor 
binding. Unique restriction sites are listed on the map. The length of the 
enhancer element differs for each Reporter Vector, therefore the positions 
indicated on the vector map should be adjusted accordingly. All of the Vectors 
contain the Panomics signature sequence. These vectors are intended for 
research use only and should not be used commercially. 
 
 
Vector contains minimal TA promoter immediately upstream of luciferase 
gene (Photinus pyralis). 
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ggtaccgagctcttacgcgtgctagcccgggctcgagatctgggtatataatggaagcttggcattccg
gtactgttggtaaagccaccatggaagacgccaaaaacataaagaaaggcccggcgccattctatccgctggaag
atggaaccgctggagagcaactgcataaggctatgaagagatacgccctggttcctggaacaattgcttttacagat
gcacatatcgaggtggacatcacttacgctgagtacttcgaaatgtccgttcggttggcagaagctatgaaacgata
tgggctgaatacaaatcacagaatcgtcgtatgcagtgaaaactctcttcaattctttatgccggtgttgggcgcgtta
tttatcggagttgcagttgcgcccgcgaacgacatttataatgaacgtgaattgctcaacagtatgggcatttcgcag
cctaccgtggtgttcgtttccaaaaaggggttgcaaaaaattttgaacgtgcaaaaaaagctcccaatcatccaaaa
aattattatcatggattctaaaacggattaccagggatttcagtcgatgtacacgttcgtcacatctcatctacctcccg
gttttaatgaatacgattttgtgccagagtccttcgatagggacaagacaattgcactgatcatgaactcctctggatct
actggtctgcctaaaggtgtcgctctgcctcatagaactgcctgcgtgagattctcgcatgccagagatcctatttttg
gcaatcaaatcattccggatactgcgattttaagtgttgttccattccatcacggttttggaatgtttactacactcggat
atttgatatgtggatttcgagtcgtcttaatgtatagatttgaagaagagctgtttctgaggagccttcaggattacaag
attcaaagtgcgctgctggtgccaaccctattctccttcttcgccaaaagcactctgattgacaaatacgatttatctaa
tttacacgaaattgcttctggtggcgctcccctctctaaggaagtcggggaagcggttgccaagaggttccatctgc
caggtatcaggcaaggatatgggctcactgagactacatcagctattctgattacacccgagggggatgataaacc
gggcgcggtcggtaaagttgttccattttttgaagcgaaggttgtggatctggataccgggaaaacgctgggcgtta
atcaaagaggcgaactgtgtgtgagaggtcctatgattatgtccggttatgtaaacaatccggaagcgaccaacgc
cttgattgacaaggatggatggctacattctggagacatagcttactgggacgaagacgaacacttcttcatcgttga
ccgcctgaagtctctgattaagtacaaaggctatcaggtggctcccgctgaattggaatccatcttgctccaacaccc
caacatcttcgacgcaggtgtcgcaggtcttcccgacgatgacgccggtgaacttcccgccgccgttgttgttttgg
agcacggaaagacgatgacggaaaaagagatcgtggattacgtcgccagtcaagtaacaaccgcgaaaaagttg
cgcggaggagttgtgtttgtggacgaagtaccgaaaggtcttaccggaaaactcgacgcaagaaaaatcagaga
gatcctcataaaggccaagaagggcggaaagatcgccgtgtaattctagagtcggggcggccggccgcttcgag
cagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaatgctttatttgtgaaa
tttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagttaacaacaacaattgcattcattttatgtttc
aggttcagggggaggtgtgggaggttttttaaagcaagtaaaacctctacaaatgtggtaaaatcgataaggatccg
tcgaccccgccaaccagatgatctgttctcccgccaaccagatgatctgttctcgatgcccttgagagccttcaacc
cagtcagctccttccggtgggcgcggggcatgactatcgtcgccgcacttatgactgtcttctttatcatgcaactcgt
aggacaggtgccggcagcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgag
cggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgag
NheI Restriction Site 
BglII Restriction Site 
 
Response elements are inserted directly 
 between these two restriction sites. 
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caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccct
gacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtt
tccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcg
ggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgt
gtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagac
acgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagt
tcttgaagtggtggcctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttacctt
cggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagc
agattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaa
aactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagtttt
aaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcga
tctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggc
cccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccgga
agggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagt
aagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggt
atggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttag
ctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataat
tctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatg
cggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctca
tcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactc
gtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgcc
gcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatca
gggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccc
cgaaaagtgccacctgacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtga
ccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccc
cgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatt
agggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaa
tagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatt
tcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaatttcc
cattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctattacgccagcccaagc
taccatgataagtaagtaatattaaggtacgggaggtacttggagcggccgcaataaaatatctttattttcattacatc
tgtgtgttggttttttgtgtgaatcgatagtactaacatacgctctccatcaaaacaaaacgaaacaaaacaaactagc
aaaataggctgtccccagtgcaagtgcaggtgccagaacatttctctatcgata 
 
 
 
 
Acknowledgment 
  
 
 
Acknowledgments 
 
The following dissertation was done within the Research Division of Tumour 
Virology and INSERM U701 at the German Cancer Research Centre, Heidelberg. I 
would like to thank Prof. Dr. Jean Rommelaere for the opportunity to complete my 
PhD thesis in his department.  
I’m very grateful to Prof. Dr. Rainer Zawatzky, Prof. Dr. Stefan Wölfl, Dr. rer. 
nat. Ute Koch and Dr. rer. nat. Celina Cziepluch for the supervision of the project, 
scientific discussions, insightful reading of parts of this work and for being a referee 
of this PhD thesis.  
I would like to thank Prof. Dr. Lutz Gissmann and Dr. Anne Regnier-
Vigouroux, for their friendly takeover as a co-referee.  
I would like to express my thankfulness to the very supportive colleagues in 
the INSERM U701, with whom I had the privilege to work together with. I am very 
grateful to other members of our institute who were always ready to answer the most 
complicated questions and share their experience. 
I’m very thankful to all my friends, for their encouragement, their love and the 
comfort, which they gave to me during these years.  
I thank my loving parents and sister. I’m very much indebted for their yearlong 
faithful friendship, love, care and help in any situation of my studies.  
 
 
 
 
 
 
